| Package | hl7.fhir.uv.ebm |
| Type | ImplementationGuide |
| Id | Id |
| FHIR Version | R6 |
| Source | http://hl7.org/fhir/uv/ebm/https://build.fhir.org/ig/HL7/ebm/index.html |
| Url | http://hl7.org/fhir/uv/ebm/ImplementationGuide/hl7.fhir.uv.ebm |
| Version | 2.0.0-ballot |
| Status | draft |
| Date | 2024-12-16T14:35:45+00:00 |
| Name | EBMIG |
| Title | Evidence Based Medicine on FHIR Implementation Guide |
| Experimental | False |
| Realm | uv |
| Authority | hl7 |
No resources found
No resources found
Note: links and images are rebased to the (stated) source
Generated Narrative: ImplementationGuide hl7.fhir.uv.ebm
The official URL for this implementation guide is:
http://hl7.org/fhir/uv/ebm/ImplementationGuide/hl7.fhir.uv.ebm
FHIR{
"resourceType" : "ImplementationGuide",
"id" : "hl7.fhir.uv.ebm",
"text" : {
"status" : "generated",
"div" : "<div xmlns=\"http://www.w3.org/1999/xhtml\"><p class=\"res-header-id\"><b>Generated Narrative: ImplementationGuide hl7.fhir.uv.ebm</b></p><a name=\"hl7.fhir.uv.ebm\"> </a><a name=\"hchl7.fhir.uv.ebm\"> </a><a name=\"hl7.fhir.uv.ebm-en-US\"> </a><h2>EBMIG</h2><p>The official URL for this implementation guide is: </p><pre>http://hl7.org/fhir/uv/ebm/ImplementationGuide/hl7.fhir.uv.ebm</pre></div>"
},
"extension" : [
{
"url" : "http://hl7.org/fhir/StructureDefinition/structuredefinition-wg",
"valueCode" : "cds"
}
],
"url" : "http://hl7.org/fhir/uv/ebm/ImplementationGuide/hl7.fhir.uv.ebm",
"identifier" : [
{
"system" : "urn:ietf:rfc:3986",
"value" : "urn:oid:2.16.840.1.113883.4.642.40.44"
}
],
"version" : "2.0.0-ballot",
"name" : "EBMIG",
"title" : "Evidence Based Medicine on FHIR Implementation Guide",
"status" : "draft",
"date" : "2024-12-16T14:35:45+00:00",
"publisher" : "HL7 International / Clinical Decision Support",
"contact" : [
{
"name" : "HL7 International / Clinical Decision Support",
"telecom" : [
{
"system" : "url",
"value" : "http://www.hl7.org/Special/committees/dss"
}
]
}
],
"jurisdiction" : [
{
"coding" : [
{
"system" : "http://unstats.un.org/unsd/methods/m49/m49.htm",
"code" : "001",
"display" : "World"
}
]
}
],
"packageId" : "hl7.fhir.uv.ebm",
"license" : "CC0-1.0",
"fhirVersion" : [
"6.0.0-ballot2"
],
"dependsOn" : [
{
"id" : "hl7_fhir_uv_extensions_r5",
"uri" : "http://hl7.org/fhir/extensions/ImplementationGuide/hl7.fhir.uv.extensions",
"packageId" : "hl7.fhir.uv.extensions.r5",
"version" : "5.1.0"
},
{
"id" : "hl7_terminology_r5",
"uri" : "http://terminology.hl7.org/ImplementationGuide/hl7.terminology",
"packageId" : "hl7.terminology.r5",
"version" : "6.1.0"
}
],
"definition" : {
"extension" : [
{
"url" : "http://hl7.org/fhir/tools/StructureDefinition/ig-internal-dependency",
"valueCode" : "hl7.fhir.uv.tools.r5#0.3.0"
}
],
"resource" : [
{
"extension" : [
{
"url" : "http://hl7.org/fhir/tools/StructureDefinition/resource-information",
"valueString" : "Citation"
}
],
"reference" : {
"reference" : "Citation/267246"
},
"name" : "11232013 Rosiglitazone monotherapy is effective in patients with type 2 diabetes.",
"description" : "This Citation Resource is referenced in an example for the EBMonFHIR Implementation Guide.",
"isExample" : true,
"profile" : [
"http://hl7.org/fhir/uv/ebm/StructureDefinition/journal-article-citation"
]
},
{
"extension" : [
{
"url" : "http://hl7.org/fhir/tools/StructureDefinition/resource-information",
"valueString" : "Evidence"
}
],
"reference" : {
"reference" : "Evidence/55"
},
"name" : "14-day mortality remdesivir vs placebo meta-analysis (ACTT-1, Wang et al, WHO SOLIDARITY)",
"description" : "COVID-19 pneumonia remdesivir vs. placebo 14-day mortality (779 events among 6,744 participants, 3 randomized trials)\nRisk ratio 0.85 (95% CI 0.74 to 0.96) in fixed-effect analysis\nRisk ratio 0.81 (95% CI 0.60 to 1.08) in random-effects analysis",
"isExample" : true
},
{
"extension" : [
{
"url" : "http://hl7.org/fhir/tools/StructureDefinition/resource-information",
"valueString" : "Citation"
}
],
"reference" : {
"reference" : "Citation/179628"
},
"name" : "14706014 Chemohormonal therapy as primary treatment for metastatic prostate cancer: a randomized study of estramustine phosphate plus luteinizing hormone-releasing hormone agonist versus flutamide plus luteinizing hormone-releasing hormone agonist.",
"description" : "This Citation Resource is referenced in an example for the EBMonFHIR Implementation Guide.",
"isExample" : true,
"profile" : [
"http://hl7.org/fhir/uv/ebm/StructureDefinition/journal-article-citation"
]
},
{
"extension" : [
{
"url" : "http://hl7.org/fhir/tools/StructureDefinition/resource-information",
"valueString" : "Citation"
}
],
"reference" : {
"reference" : "Citation/267247"
},
"name" : "15832493 Spotlight on rosiglitazone in the management of type 2 diabetes mellitus.",
"description" : "This Citation Resource is referenced in an example for the EBMonFHIR Implementation Guide.",
"isExample" : true,
"profile" : [
"http://hl7.org/fhir/uv/ebm/StructureDefinition/journal-article-citation"
]
},
{
"extension" : [
{
"url" : "http://hl7.org/fhir/tools/StructureDefinition/resource-information",
"valueString" : "Citation"
}
],
"reference" : {
"reference" : "Citation/267496"
},
"name" : "15855602 Defining and reporting hypoglycemia in diabetes: a report from the American Diabetes Association Workgroup on Hypoglycemia.",
"description" : "This Citation Resource is referenced in an example for the EBMonFHIR Implementation Guide.",
"isExample" : true,
"profile" : [
"http://hl7.org/fhir/uv/ebm/StructureDefinition/journal-article-citation"
]
},
{
"extension" : [
{
"url" : "http://hl7.org/fhir/tools/StructureDefinition/resource-information",
"valueString" : "DeviceDefinition"
}
],
"reference" : {
"reference" : "DeviceDefinition/179899"
},
"name" : "179899",
"description" : "This is an example describing the Boots Finger Pulse Oximeter for use in an example of Group.characteristic.determinedByReference and does not contain substantial detail as the focus is not the expression of device definition details.",
"isExample" : true
},
{
"extension" : [
{
"url" : "http://hl7.org/fhir/tools/StructureDefinition/resource-information",
"valueString" : "Citation"
}
],
"reference" : {
"reference" : "Citation/179602"
},
"name" : "18160893 Wonder woman. Like my childhood heroine, Mrs. Betty also had amazing powers.",
"description" : "This Citation Resource is referenced in an example for the EBMonFHIR Implementation Guide.",
"isExample" : true,
"profile" : [
"http://hl7.org/fhir/uv/ebm/StructureDefinition/journal-article-citation"
]
},
{
"extension" : [
{
"url" : "http://hl7.org/fhir/tools/StructureDefinition/resource-information",
"valueString" : "Citation"
}
],
"reference" : {
"reference" : "Citation/179637"
},
"name" : "18508207 A Phase 3 placebo-controlled, double-blind, multi-site trial of the alpha-2-adrenergic agonist, lofexidine, for opioid withdrawal.",
"description" : "This Citation Resource is referenced in an example for the EBMonFHIR Implementation Guide.",
"isExample" : true,
"profile" : [
"http://hl7.org/fhir/uv/ebm/StructureDefinition/journal-article-citation"
]
},
{
"extension" : [
{
"url" : "http://hl7.org/fhir/tools/StructureDefinition/resource-information",
"valueString" : "Citation"
}
],
"reference" : {
"reference" : "Citation/179631"
},
"name" : "19029421 Phase III trial of androgen ablation with or without three cycles of systemic chemotherapy for advanced prostate cancer.",
"description" : "This Citation Resource is referenced in an example for the EBMonFHIR Implementation Guide.",
"isExample" : true,
"profile" : [
"http://hl7.org/fhir/uv/ebm/StructureDefinition/journal-article-citation"
]
},
{
"extension" : [
{
"url" : "http://hl7.org/fhir/tools/StructureDefinition/resource-information",
"valueString" : "Citation"
}
],
"reference" : {
"reference" : "Citation/179627"
},
"name" : "19091394 Endocrine treatment, with or without radiotherapy, in locally advanced prostate cancer (SPCG-7/SFUO-3): an open randomised phase III trial.",
"description" : "This Citation Resource is referenced in an example for the EBMonFHIR Implementation Guide.",
"isExample" : true,
"profile" : [
"http://hl7.org/fhir/uv/ebm/StructureDefinition/journal-article-citation"
]
},
{
"extension" : [
{
"url" : "http://hl7.org/fhir/tools/StructureDefinition/resource-information",
"valueString" : "Citation"
}
],
"reference" : {
"reference" : "Citation/179603"
},
"name" : "19967827 Wonder woman was Argentine and her real name was Evita.",
"description" : "This Citation Resource is referenced in an example for the EBMonFHIR Implementation Guide.",
"isExample" : true,
"profile" : [
"http://hl7.org/fhir/uv/ebm/StructureDefinition/journal-article-citation"
]
},
{
"extension" : [
{
"url" : "http://hl7.org/fhir/tools/StructureDefinition/resource-information",
"valueString" : "Citation"
}
],
"reference" : {
"reference" : "Citation/179626"
},
"name" : "22056152 Combined androgen deprivation therapy and radiation therapy for locally advanced prostate cancer: a randomised, phase 3 trial.",
"description" : "This Citation Resource is referenced in an example for the EBMonFHIR Implementation Guide.",
"isExample" : true,
"profile" : [
"http://hl7.org/fhir/uv/ebm/StructureDefinition/journal-article-citation"
]
},
{
"extension" : [
{
"url" : "http://hl7.org/fhir/tools/StructureDefinition/resource-information",
"valueString" : "Citation"
}
],
"reference" : {
"reference" : "Citation/179625"
},
"name" : "22502942 Addition of radiotherapy to long-term androgen deprivation in locally advanced prostate cancer: an open randomised phase 3 trial.",
"description" : "This Citation Resource is referenced in an example for the EBMonFHIR Implementation Guide.",
"isExample" : true,
"profile" : [
"http://hl7.org/fhir/uv/ebm/StructureDefinition/journal-article-citation"
]
},
{
"extension" : [
{
"url" : "http://hl7.org/fhir/tools/StructureDefinition/resource-information",
"valueString" : "Citation"
}
],
"reference" : {
"reference" : "Citation/179615"
},
"name" : "23306100 Androgen-deprivation therapy alone or with docetaxel in non-castrate metastatic prostate cancer (GETUG-AFU 15): a randomised, open-label, phase 3 trial.",
"description" : "This Citation Resource is referenced in an example for the EBMonFHIR Implementation Guide.",
"isExample" : true,
"profile" : [
"http://hl7.org/fhir/uv/ebm/StructureDefinition/journal-article-citation"
]
},
{
"extension" : [
{
"url" : "http://hl7.org/fhir/tools/StructureDefinition/resource-information",
"valueString" : "Citation"
}
],
"reference" : {
"reference" : "Citation/179623"
},
"name" : "23452809 Long-term follow-up of a phase II trial of chemotherapy plus hormone therapy for biochemical relapse after definitive local therapy for prostate cancer.",
"description" : "This Citation Resource is referenced in an example for the EBMonFHIR Implementation Guide.",
"isExample" : true,
"profile" : [
"http://hl7.org/fhir/uv/ebm/StructureDefinition/journal-article-citation"
]
},
{
"extension" : [
{
"url" : "http://hl7.org/fhir/tools/StructureDefinition/resource-information",
"valueString" : "Citation"
}
],
"reference" : {
"reference" : "Citation/267501"
},
"name" : "23589542 Hypoglycemia and diabetes: a report of a workgroup of the American Diabetes Association and the Endocrine Society.",
"description" : "This Citation Resource is referenced in an example for the EBMonFHIR Implementation Guide.",
"isExample" : true,
"profile" : [
"http://hl7.org/fhir/uv/ebm/StructureDefinition/journal-article-citation"
]
},
{
"extension" : [
{
"url" : "http://hl7.org/fhir/tools/StructureDefinition/resource-information",
"valueString" : "Citation"
}
],
"reference" : {
"reference" : "Citation/179629"
},
"name" : "23604530 A phase II trial of androgen deprivation therapy (ADT) plus chemotherapy as initial treatment for local failures or advanced prostate cancer.",
"description" : "This Citation Resource is referenced in an example for the EBMonFHIR Implementation Guide.",
"isExample" : true,
"profile" : [
"http://hl7.org/fhir/uv/ebm/StructureDefinition/journal-article-citation"
]
},
{
"extension" : [
{
"url" : "http://hl7.org/fhir/tools/StructureDefinition/resource-information",
"valueString" : "Citation"
}
],
"reference" : {
"reference" : "Citation/179624"
},
"name" : "24598155 Long-term results of a phase II study with neoadjuvant docetaxel chemotherapy and complete androgen blockade in locally advanced and high-risk prostate cancer.",
"description" : "This Citation Resource is referenced in an example for the EBMonFHIR Implementation Guide.",
"isExample" : true,
"profile" : [
"http://hl7.org/fhir/uv/ebm/StructureDefinition/journal-article-citation"
]
},
{
"extension" : [
{
"url" : "http://hl7.org/fhir/tools/StructureDefinition/resource-information",
"valueString" : "Citation"
}
],
"reference" : {
"reference" : "Citation/179617"
},
"name" : "25301760 Survival with Newly Diagnosed Metastatic Prostate Cancer in the \"Docetaxel Era\": Data from 917 Patients in the Control Arm of the STAMPEDE Trial (MRC PR08, CRUK/06/019).",
"description" : "This Citation Resource is referenced in an example for the EBMonFHIR Implementation Guide.",
"isExample" : true,
"profile" : [
"http://hl7.org/fhir/uv/ebm/StructureDefinition/journal-article-citation"
]
},
{
"extension" : [
{
"url" : "http://hl7.org/fhir/tools/StructureDefinition/resource-information",
"valueString" : "Citation"
}
],
"reference" : {
"reference" : "Citation/179622"
},
"name" : "26002607 Should docetaxel be standard of care for patients with metastatic hormone-sensitive prostate cancer? Pro and contra.",
"description" : "This Citation Resource is referenced in an example for the EBMonFHIR Implementation Guide.",
"isExample" : true,
"profile" : [
"http://hl7.org/fhir/uv/ebm/StructureDefinition/journal-article-citation"
]
},
{
"extension" : [
{
"url" : "http://hl7.org/fhir/tools/StructureDefinition/resource-information",
"valueString" : "Citation"
}
],
"reference" : {
"reference" : "Citation/179621"
},
"name" : "26028518 Androgen deprivation therapy plus docetaxel and estramustine versus androgen deprivation therapy alone for high-risk localised prostate cancer (GETUG 12): a phase 3 randomised controlled trial.",
"description" : "This Citation Resource is referenced in an example for the EBMonFHIR Implementation Guide.",
"isExample" : true,
"profile" : [
"http://hl7.org/fhir/uv/ebm/StructureDefinition/journal-article-citation"
]
},
{
"extension" : [
{
"url" : "http://hl7.org/fhir/tools/StructureDefinition/resource-information",
"valueString" : "Citation"
}
],
"reference" : {
"reference" : "Citation/179630"
},
"name" : "26092557 Feasibility study of a randomized controlled trial comparing docetaxel chemotherapy and androgen deprivation therapy with sequential prostatic biopsies from patients with advanced non-castration-resistant prostate cancer.",
"description" : "This Citation Resource is referenced in an example for the EBMonFHIR Implementation Guide.",
"isExample" : true,
"profile" : [
"http://hl7.org/fhir/uv/ebm/StructureDefinition/journal-article-citation"
]
},
{
"extension" : [
{
"url" : "http://hl7.org/fhir/tools/StructureDefinition/resource-information",
"valueString" : "Citation"
}
],
"reference" : {
"reference" : "Citation/179616"
},
"name" : "26244877 Chemohormonal Therapy in Metastatic Hormone-Sensitive Prostate Cancer.",
"description" : "This Citation Resource is referenced in an example for the EBMonFHIR Implementation Guide.",
"isExample" : true,
"profile" : [
"http://hl7.org/fhir/uv/ebm/StructureDefinition/journal-article-citation"
]
},
{
"extension" : [
{
"url" : "http://hl7.org/fhir/tools/StructureDefinition/resource-information",
"valueString" : "Citation"
}
],
"reference" : {
"reference" : "Citation/267500"
},
"name" : "26502880 A novel nasal powder formulation of glucagon: toxicology studies in animal models.",
"description" : "This Citation Resource is referenced in an example for the EBMonFHIR Implementation Guide.",
"isExample" : true,
"profile" : [
"http://hl7.org/fhir/uv/ebm/StructureDefinition/journal-article-citation"
]
},
{
"extension" : [
{
"url" : "http://hl7.org/fhir/tools/StructureDefinition/resource-information",
"valueString" : "Citation"
}
],
"reference" : {
"reference" : "Citation/267499"
},
"name" : "26681725 Intranasal Glucagon for Treatment of Insulin-Induced Hypoglycemia in Adults With Type 1 Diabetes: A Randomized Crossover Noninferiority Study.",
"description" : "This Citation Resource is referenced in an example for the EBMonFHIR Implementation Guide.",
"isExample" : true,
"profile" : [
"http://hl7.org/fhir/uv/ebm/StructureDefinition/journal-article-citation"
]
},
{
"extension" : [
{
"url" : "http://hl7.org/fhir/tools/StructureDefinition/resource-information",
"valueString" : "Citation"
}
],
"reference" : {
"reference" : "Citation/267498"
},
"name" : "26859072 Emotional Distress in the Partners of Type 1 Diabetes Adults: Worries About Hypoglycemia and Other Key Concerns.",
"description" : "This Citation Resource is referenced in an example for the EBMonFHIR Implementation Guide.",
"isExample" : true,
"profile" : [
"http://hl7.org/fhir/uv/ebm/StructureDefinition/journal-article-citation"
]
},
{
"extension" : [
{
"url" : "http://hl7.org/fhir/tools/StructureDefinition/resource-information",
"valueString" : "Citation"
}
],
"reference" : {
"reference" : "Citation/33089"
},
"name" : "27222544 Metabolic Surgery in the Treatment Algorithm for Type 2 Diabetes: A Joint Statement by International Diabetes Organizations.",
"description" : "This Citation Resource is referenced in an example for the EBMonFHIR Implementation Guide.",
"isExample" : true,
"profile" : [
"http://hl7.org/fhir/uv/ebm/StructureDefinition/journal-article-citation"
]
},
{
"extension" : [
{
"url" : "http://hl7.org/fhir/tools/StructureDefinition/resource-information",
"valueString" : "Citation"
}
],
"reference" : {
"reference" : "Citation/179613"
},
"name" : "27308831 Efficacy and Safety of Combined Androgen Deprivation Therapy (ADT) and Docetaxel Compared with ADT Alone for Metastatic Hormone-Naive Prostate Cancer: A Systematic Review and Meta-Analysis.",
"description" : "This Citation Resource is referenced in an example for the EBMonFHIR Implementation Guide.",
"isExample" : true,
"profile" : [
"http://hl7.org/fhir/uv/ebm/StructureDefinition/journal-article-citation"
]
},
{
"extension" : [
{
"url" : "http://hl7.org/fhir/tools/StructureDefinition/resource-information",
"valueString" : "Citation"
}
],
"reference" : {
"reference" : "Citation/267497"
},
"name" : "27979893 6. Glycemic Targets.",
"description" : "This Citation Resource is referenced in an example for the EBMonFHIR Implementation Guide.",
"isExample" : true,
"profile" : [
"http://hl7.org/fhir/uv/ebm/StructureDefinition/journal-article-citation"
]
},
{
"extension" : [
{
"url" : "http://hl7.org/fhir/tools/StructureDefinition/resource-information",
"valueString" : "Citation"
}
],
"reference" : {
"reference" : "Citation/179601"
},
"name" : "29114761 Web Exclusives. Annals Story Slam - How Wonder Woman Became My Alter Ego.",
"description" : "This Citation Resource is referenced in an example for the EBMonFHIR Implementation Guide.",
"isExample" : true,
"profile" : [
"http://hl7.org/fhir/uv/ebm/StructureDefinition/journal-article-citation"
]
},
{
"extension" : [
{
"url" : "http://hl7.org/fhir/tools/StructureDefinition/resource-information",
"valueString" : "Citation"
}
],
"reference" : {
"reference" : "Citation/179600"
},
"name" : "29114762 Web Exclusives. Annals Story Slam - Wonder Woman Is a Cartoon Character.",
"description" : "This Citation Resource is referenced in an example for the EBMonFHIR Implementation Guide.",
"isExample" : true,
"profile" : [
"http://hl7.org/fhir/uv/ebm/StructureDefinition/journal-article-citation"
]
},
{
"extension" : [
{
"url" : "http://hl7.org/fhir/tools/StructureDefinition/resource-information",
"valueString" : "Citation"
}
],
"reference" : {
"reference" : "Citation/179599"
},
"name" : "29202628 \"I Kinda Feel Like Wonder Woman\": An Interpretative Phenomenological Analysis of Pole Fitness and Positive Body Image.",
"description" : "This Citation Resource is referenced in an example for the EBMonFHIR Implementation Guide.",
"isExample" : true,
"profile" : [
"http://hl7.org/fhir/uv/ebm/StructureDefinition/journal-article-citation"
]
},
{
"extension" : [
{
"url" : "http://hl7.org/fhir/tools/StructureDefinition/resource-information",
"valueString" : "Citation"
}
],
"reference" : {
"reference" : "Citation/179598"
},
"name" : "29357271 Using Hawkeye from the Avengers to communicate on the eye.",
"description" : "This Citation Resource is referenced in an example for the EBMonFHIR Implementation Guide.",
"isExample" : true,
"profile" : [
"http://hl7.org/fhir/uv/ebm/StructureDefinition/journal-article-citation"
]
},
{
"extension" : [
{
"url" : "http://hl7.org/fhir/tools/StructureDefinition/resource-information",
"valueString" : "Citation"
}
],
"reference" : {
"reference" : "Citation/179597"
},
"name" : "29694275 A regressive formula of perversity: Wertham and the women of comics.",
"description" : "This Citation Resource is referenced in an example for the EBMonFHIR Implementation Guide.",
"isExample" : true,
"profile" : [
"http://hl7.org/fhir/uv/ebm/StructureDefinition/journal-article-citation"
]
},
{
"extension" : [
{
"url" : "http://hl7.org/fhir/tools/StructureDefinition/resource-information",
"valueString" : "Citation"
}
],
"reference" : {
"reference" : "Citation/179596"
},
"name" : "29694302 Introduction: \"Suffering Sappho!\": Lesbian content and queer female characters in comics.",
"description" : "This Citation Resource is referenced in an example for the EBMonFHIR Implementation Guide.",
"isExample" : true,
"profile" : [
"http://hl7.org/fhir/uv/ebm/StructureDefinition/journal-article-citation"
]
},
{
"extension" : [
{
"url" : "http://hl7.org/fhir/tools/StructureDefinition/resource-information",
"valueString" : "Citation"
}
],
"reference" : {
"reference" : "Citation/179595"
},
"name" : "30467172 Finding my inner Wonder Woman.",
"description" : "This Citation Resource is referenced in an example for the EBMonFHIR Implementation Guide.",
"isExample" : true,
"profile" : [
"http://hl7.org/fhir/uv/ebm/StructureDefinition/journal-article-citation"
]
},
{
"extension" : [
{
"url" : "http://hl7.org/fhir/tools/StructureDefinition/resource-information",
"valueString" : "Citation"
}
],
"reference" : {
"reference" : "Citation/179594"
},
"name" : "34871555 What Can Wonder Woman Teach Radiologists?",
"description" : "This Citation Resource is referenced in an example for the EBMonFHIR Implementation Guide.",
"isExample" : true,
"profile" : [
"http://hl7.org/fhir/uv/ebm/StructureDefinition/journal-article-citation"
]
},
{
"extension" : [
{
"url" : "http://hl7.org/fhir/tools/StructureDefinition/resource-information",
"valueString" : "Citation"
}
],
"reference" : {
"reference" : "Citation/33399"
},
"name" : "35243488 Bariatric surgery and cardiovascular disease: a systematic review and meta-analysis.",
"description" : "This Citation Resource is referenced in an example for the EBMonFHIR Implementation Guide.",
"isExample" : true,
"profile" : [
"http://hl7.org/fhir/uv/ebm/StructureDefinition/journal-article-citation"
]
},
{
"extension" : [
{
"url" : "http://hl7.org/fhir/tools/StructureDefinition/resource-information",
"valueString" : "Citation"
}
],
"reference" : {
"reference" : "Citation/179605"
},
"name" : "36491989 Another Georgia Wonder Woman: She Does More Astounding Tricks Than Did Lula Hurst.",
"description" : "This Citation Resource is referenced in an example for the EBMonFHIR Implementation Guide.",
"isExample" : true,
"profile" : [
"http://hl7.org/fhir/uv/ebm/StructureDefinition/journal-article-citation"
]
},
{
"extension" : [
{
"url" : "http://hl7.org/fhir/tools/StructureDefinition/resource-information",
"valueString" : "Citation"
}
],
"reference" : {
"reference" : "Citation/264329"
},
"name" : "37024129 Benefits and harms of drug treatment for type 2 diabetes: systematic review and network meta-analysis of randomised controlled trials.",
"description" : "This Citation Resource is referenced in an example for the EBMonFHIR Implementation Guide.",
"isExample" : true,
"profile" : [
"http://hl7.org/fhir/uv/ebm/StructureDefinition/journal-article-citation"
]
},
{
"extension" : [
{
"url" : "http://hl7.org/fhir/tools/StructureDefinition/resource-information",
"valueString" : "Citation"
}
],
"reference" : {
"reference" : "Citation/179604"
},
"name" : "6907780 Career guide: to change what needs changing...doesn't take Wonder Woman.",
"description" : "This Citation Resource is referenced in an example for the EBMonFHIR Implementation Guide.",
"isExample" : true,
"profile" : [
"http://hl7.org/fhir/uv/ebm/StructureDefinition/journal-article-citation"
]
},
{
"extension" : [
{
"url" : "http://hl7.org/fhir/tools/StructureDefinition/resource-information",
"valueString" : "ResearchStudy"
}
],
"reference" : {
"reference" : "ResearchStudy/267245"
},
"name" : "A Study of Nasal Glucagon (LY900018) in Japanese Participants With Diabetes Mellitus - M11 Example",
"description" : "This ResearchStudy Resource was derived from data in the ClinicalTrials.gov record then modified for use to support an M11 Report.",
"isExample" : true,
"profile" : [
"http://hl7.org/fhir/uv/ebm/StructureDefinition/m11-research-study"
]
},
{
"extension" : [
{
"url" : "http://hl7.org/fhir/tools/StructureDefinition/resource-information",
"valueString" : "StructureDefinition:resource"
}
],
"reference" : {
"reference" : "StructureDefinition/adaptation"
},
"name" : "Adaptation",
"description" : "Profile of ArtifactAssessment for Evidence Based Medicine IG. The Adaptation Profile is used for assessments of a knowledge artifact that are used to create a new knowledge artifact through acceptance, rejection or modification of the assessed artifact.",
"isExample" : false
},
{
"extension" : [
{
"url" : "http://hl7.org/fhir/tools/StructureDefinition/resource-information",
"valueString" : "Evidence"
}
],
"reference" : {
"reference" : "Evidence/179683"
},
"name" : "ADAS-Cog(11) EndpointAnalysisPlan from PHUSE Lilly Redacted Protocol - EBMonFHIR IG Version",
"description" : "An example of an EndpointAnalysisPlan Profile which uses intended='true' and include-if extensions within Evidence.statistic.modelCharacteristic elements.",
"isExample" : true,
"profile" : [
"http://hl7.org/fhir/uv/ebm/StructureDefinition/endpoint-analysis-plan"
]
},
{
"extension" : [
{
"url" : "http://hl7.org/fhir/tools/StructureDefinition/resource-information",
"valueString" : "Group"
}
],
"reference" : {
"reference" : "Group/265093"
},
"name" : "Adults with type 2 diabetes",
"description" : "An example of CohortDefinition used to support a SystematicReviewEligibilityCriteria example.",
"isExample" : true,
"profile" : [
"http://hl7.org/fhir/uv/ebm/StructureDefinition/cohort-definition"
]
},
{
"extension" : [
{
"url" : "http://hl7.org/fhir/tools/StructureDefinition/resource-information",
"valueString" : "Group"
}
],
"reference" : {
"reference" : "Group/236947"
},
"name" : "Adults with type 2 diabetes and CVD and CKD",
"description" : "This Group Resource is referenced in an example for the EBMonFHIR Implementation Guide.",
"isExample" : true
},
{
"extension" : [
{
"url" : "http://hl7.org/fhir/tools/StructureDefinition/resource-information",
"valueString" : "Citation"
}
],
"reference" : {
"reference" : "Citation/7636"
},
"name" : "Anticoagulation for COVID-19 Combined RCTs in NEJM",
"description" : "The peer-reviewed report for combination of 3 adaptive RCTs",
"isExample" : true
},
{
"extension" : [
{
"url" : "http://hl7.org/fhir/tools/StructureDefinition/resource-information",
"valueString" : "StructureDefinition:extension"
}
],
"reference" : {
"reference" : "StructureDefinition/artifact-assessment-compared"
},
"name" : "ArtifactAssessmentCompared",
"description" : "The artifact being compared to the referenced artifact.",
"isExample" : false
},
{
"extension" : [
{
"url" : "http://hl7.org/fhir/tools/StructureDefinition/resource-information",
"valueString" : "StructureDefinition:extension"
}
],
"reference" : {
"reference" : "StructureDefinition/artifact-assessment-date-as-rating"
},
"name" : "ArtifactAssessmentDateAsRating",
"description" : "A date or dateTime value as the classifier or rating value.",
"isExample" : false
},
{
"extension" : [
{
"url" : "http://hl7.org/fhir/tools/StructureDefinition/resource-information",
"valueString" : "Composition"
}
],
"reference" : {
"reference" : "Composition/235365"
},
"name" : "Baseline Measure Report: Association of Bariatric Surgery vs Medical Obesity Treatment With Long-term Medical Complications and Obesity-Related Comorbidities (2018 Norwegian Cohort)",
"description" : "This example of a BaselineMeasureReport Profile shows a report from a single observational study with 2 baseline measures.",
"isExample" : true,
"profile" : [
"http://hl7.org/fhir/uv/ebm/StructureDefinition/baseline-measure-report"
]
},
{
"extension" : [
{
"url" : "http://hl7.org/fhir/tools/StructureDefinition/resource-information",
"valueString" : "StructureDefinition:resource"
}
],
"reference" : {
"reference" : "StructureDefinition/baseline-measure-evidence"
},
"name" : "BaselineMeasureEvidence",
"description" : "Profile of Evidence for Evidence Based Medicine IG. The BaselineMeasureEvidence Profile is used for evidence with a measured variable (with the role of outcome for this Evidence) that is considered an independent variable with respect to the outcome of an exposure or intervention in a study.",
"isExample" : false
},
{
"extension" : [
{
"url" : "http://hl7.org/fhir/tools/StructureDefinition/resource-information",
"valueString" : "Evidence"
}
],
"reference" : {
"reference" : "Evidence/179451"
},
"name" : "BaselineMeasureEvidence: Age in 2018 Norwegian Cohort Medical Group",
"description" : "Age in Medical Group (n = 956) mean 45.7 years, SD 13.5 years",
"isExample" : true,
"profile" : [
"http://hl7.org/fhir/uv/ebm/StructureDefinition/baseline-measure-evidence"
]
},
{
"extension" : [
{
"url" : "http://hl7.org/fhir/tools/StructureDefinition/resource-information",
"valueString" : "Evidence"
}
],
"reference" : {
"reference" : "Evidence/179452"
},
"name" : "BaselineMeasureEvidence: Age in 2018 Norwegian Cohort Surgical Group",
"description" : "Age in Surgical Group (n = 932) mean 41.2 years, SD 10.5 years",
"isExample" : true,
"profile" : [
"http://hl7.org/fhir/uv/ebm/StructureDefinition/baseline-measure-evidence"
]
},
{
"extension" : [
{
"url" : "http://hl7.org/fhir/tools/StructureDefinition/resource-information",
"valueString" : "Evidence"
}
],
"reference" : {
"reference" : "Evidence/179458"
},
"name" : "BaselineMeasureEvidence: BMI in 2018 Norwegian Cohort Medical Group",
"description" : "BMI in Medical Group (n = 956) mean 42.9 kg/m2, SD 5.7 kg/m2",
"isExample" : true,
"profile" : [
"http://hl7.org/fhir/uv/ebm/StructureDefinition/baseline-measure-evidence"
]
},
{
"extension" : [
{
"url" : "http://hl7.org/fhir/tools/StructureDefinition/resource-information",
"valueString" : "Evidence"
}
],
"reference" : {
"reference" : "Evidence/179457"
},
"name" : "BaselineMeasureEvidence: BMI in 2018 Norwegian Cohort Surgical Group",
"description" : "BMI in Surgical Group (n = 932) mean 45.4 kg/m2, SD 6.2 kg/m2",
"isExample" : true,
"profile" : [
"http://hl7.org/fhir/uv/ebm/StructureDefinition/baseline-measure-evidence"
]
},
{
"extension" : [
{
"url" : "http://hl7.org/fhir/tools/StructureDefinition/resource-information",
"valueString" : "StructureDefinition:resource"
}
],
"reference" : {
"reference" : "StructureDefinition/baseline-measure-report"
},
"name" : "BaselineMeasureReport",
"description" : "Profile of Composition for Evidence Based Medicine IG. The BaselineMeasureReport Profile is used for an evidence report including the findings for any number of baseline measures in a research study.",
"isExample" : false
},
{
"extension" : [
{
"url" : "http://hl7.org/fhir/tools/StructureDefinition/resource-information",
"valueString" : "ResearchStudy"
}
],
"reference" : {
"reference" : "ResearchStudy/264321"
},
"name" : "Benefits and harms of drug treatment for type 2 diabetes: systematic review and network meta-analysis of randomised controlled trials",
"description" : "**Objective** To compare the benefits and harms of drug treatments for adults with type 2 diabetes, adding non-steroidal mineralocorticoid receptor antagonists (including finerenone) and tirzepatide (a dual glucose dependent insulinotropic polypeptide (GIP)/glucagon-like peptide-1 (GLP-1) receptor agonist) to previously existing treatment options.\n**Design** Systematic review and network meta-analysis.\n**Data sources** Ovid Medline, Embase, and Cochrane Central up to 14 October 2022.\n**Eligibility criteria for selecting studies** Eligible randomised controlled trials compared drugs of interest in adults with type 2 diabetes. Eligible trials had a follow-up of 24 weeks or longer. Trials systematically comparing combinations of more than one drug treatment class with no drug, subgroup analyses of randomised controlled trials, and non-English language studies were deemed ineligible. Certainty of evidence was assessed following the GRADE (grading of recommendations, assessment, development and evaluation) approach.\n**Results** The analysis identified 816 trials with 471 038 patients, together evaluating 13 different drug classes; all subsequent estimates refer to the comparison with standard treatments. Sodium glucose cotransporter-2 (SGLT-2) inhibitors (odds ratio 0.88, 95% confidence interval 0.83 to 0.94; high certainty) and GLP-1 receptor agonists (0.88, 0.82 to 0.93; high certainty) reduce all cause death; non-steroidal mineralocorticoid receptor antagonists, so far tested only with finerenone in patients with chronic kidney disease, probably reduce mortality (0.89, 0.79 to 1.00; moderate certainty); other drugs may not. The study confirmed the benefits of SGLT-2 inhibitors and GLP-1 receptor agonists in reducing cardiovascular death, non-fatal myocardial infarction, admission to hospital for heart failure, and end stage kidney disease. Finerenone probably reduces admissions to hospital for heart failure and end stage kidney disease, and possibly cardiovascular death. Only GLP-1 receptor agonists reduce non-fatal stroke; SGLT-2 inhibitors are superior to other drugs in reducing end stage kidney disease. GLP-1 receptor agonists and probably SGLT-2 inhibitors and tirzepatide improve quality of life. Reported harms were largely specific to drug class (eg, genital infections with SGLT-2 inhibitors, severe gastrointestinal adverse events with tirzepatide and GLP-1 receptor agonists, hyperkalaemia leading to admission to hospital with finerenone). Tirzepatide probably results in the largest reduction in body weight (mean difference −8.57 kg; moderate certainty). Basal insulin (mean difference 2.15 kg; moderate certainty) and thiazolidinediones (mean difference 2.81 kg; moderate certainty) probably result in the largest increases in body weight. Absolute benefits of SGLT-2 inhibitors, GLP-1 receptor agonists, and finerenone vary in people with type 2 diabetes, depending on baseline risks for cardiovascular and kidney outcomes (https://matchit.magicevidence.org/230125dist-diabetes).\n**Conclusions** This network meta-analysis extends knowledge beyond confirming the substantial benefits with the use of SGLT-2 inhibitors and GLP-1 receptor agonists in reducing adverse cardiovascular and kidney outcomes and death by adding information on finerenone and tirzepatide. These findings highlight the need for continuous assessment of scientific progress to introduce cutting edge updates in clinical practice guidelines for people with type 2 diabetes.",
"isExample" : true,
"profile" : [
"http://hl7.org/fhir/uv/ebm/StructureDefinition/systematic-review"
]
},
{
"extension" : [
{
"url" : "http://hl7.org/fhir/tools/StructureDefinition/resource-information",
"valueString" : "StructureDefinition:resource"
}
],
"reference" : {
"reference" : "StructureDefinition/book-citation"
},
"name" : "BookCitation",
"description" : "Profile of Citation for Evidence Based Medicine IG. The BookCitation Profile is used for citations of a book.",
"isExample" : false
},
{
"extension" : [
{
"url" : "http://hl7.org/fhir/tools/StructureDefinition/resource-information",
"valueString" : "Citation"
}
],
"reference" : {
"reference" : "Citation/121719"
},
"name" : "BookCitation: Crossing the Quality Chasm: A New Health System for the 21st Century",
"description" : "An example to map the BookCitation Profile",
"isExample" : true,
"profile" : [
"http://hl7.org/fhir/uv/ebm/StructureDefinition/book-citation"
]
},
{
"extension" : [
{
"url" : "http://hl7.org/fhir/tools/StructureDefinition/resource-information",
"valueString" : "StructureDefinition:resource"
}
],
"reference" : {
"reference" : "StructureDefinition/book-part-citation"
},
"name" : "BookPartCitation",
"description" : "Profile of Citation for Evidence Based Medicine IG. The BookPartCitation Profile is used for citations of a part of a book.",
"isExample" : false
},
{
"extension" : [
{
"url" : "http://hl7.org/fhir/tools/StructureDefinition/resource-information",
"valueString" : "Citation"
}
],
"reference" : {
"reference" : "Citation/139859"
},
"name" : "BookPartCitation: Chapter 3 of Crossing the Quality Chasm: A New Health System for the 21st Century",
"description" : "This Citation Resource is referenced in an example for the EBMonFHIR Implementation Guide.",
"isExample" : true,
"profile" : [
"http://hl7.org/fhir/uv/ebm/StructureDefinition/book-part-citation"
]
},
{
"extension" : [
{
"url" : "http://hl7.org/fhir/tools/StructureDefinition/resource-information",
"valueString" : "Citation"
}
],
"reference" : {
"reference" : "Citation/139860"
},
"name" : "BookPartCitation: Chapter 3 of Crossing the Quality Chasm: A New Health System for the 21st Century - without baseCitation",
"description" : "An example to map the BookCitation Profile",
"isExample" : true,
"profile" : [
"http://hl7.org/fhir/uv/ebm/StructureDefinition/book-part-citation"
]
},
{
"extension" : [
{
"url" : "http://hl7.org/fhir/tools/StructureDefinition/resource-information",
"valueString" : "ArtifactAssessment"
}
],
"reference" : {
"reference" : "ArtifactAssessment/179693"
},
"name" : "Certainty of Evidence Rating of 14-day mortality remdesivir vs placebo meta-analysis (ACTT-1, Wang et al, WHO SOLIDARITY)",
"description" : "This example of a CertaintyOfEvidence Profile shows a recursive pattern of component elements with type/classifier paired values for different aspects of rating the certainty of evidence.",
"isExample" : true,
"profile" : [
"http://hl7.org/fhir/uv/ebm/StructureDefinition/certainty-of-evidence"
]
},
{
"extension" : [
{
"url" : "http://hl7.org/fhir/tools/StructureDefinition/resource-information",
"valueString" : "StructureDefinition:resource"
}
],
"reference" : {
"reference" : "StructureDefinition/certainty-of-evidence"
},
"name" : "CertaintyOfEvidence",
"description" : "Profile of ArtifactAssessment for Evidence Based Medicine IG. The CertaintyOfEvidence Profile is used for expression of the certainty (also called quality or confidence in the estimates) of an Evidence artifact.",
"isExample" : false
},
{
"extension" : [
{
"url" : "http://hl7.org/fhir/tools/StructureDefinition/resource-information",
"valueString" : "StructureDefinition:extension"
}
],
"reference" : {
"reference" : "StructureDefinition/characteristic-timing"
},
"name" : "CharacteristicTiming",
"description" : "Timing in which the characteristic is determined or action is taken.",
"isExample" : false
},
{
"extension" : [
{
"url" : "http://hl7.org/fhir/tools/StructureDefinition/resource-information",
"valueString" : "Evidence"
}
],
"reference" : {
"reference" : "Evidence/179690"
},
"name" : "CIBIC+ EndpointAnalysisPlan from PHUSE Lilly Redacted Protocol - EBMonFHIR IG Version",
"description" : "An example of an EndpointAnalysisPlan Profile which uses intended='true' and include-if extensions within Evidence.statistic.modelCharacteristic elements.",
"isExample" : true,
"profile" : [
"http://hl7.org/fhir/uv/ebm/StructureDefinition/endpoint-analysis-plan"
]
},
{
"extension" : [
{
"url" : "http://hl7.org/fhir/tools/StructureDefinition/resource-information",
"valueString" : "Citation"
}
],
"reference" : {
"reference" : "Citation/247416"
},
"name" : "Citation for Composition: ComparativeEvidenceReport: Association of Bariatric Surgery vs Medical Obesity Treatment With Long-term Medical Complications and Obesity-Related Comorbidities (2018 Norwegian Cohort)",
"description" : "A citation of a Resource on the FEvIR Platform",
"isExample" : true,
"profile" : [
"http://hl7.org/fhir/uv/ebm/StructureDefinition/database-entry-citation"
]
},
{
"extension" : [
{
"url" : "http://hl7.org/fhir/tools/StructureDefinition/resource-information",
"valueString" : "Citation"
}
],
"reference" : {
"reference" : "Citation/58"
},
"name" : "Citation for FEvIR Evidence 55: 14-day mortality remdesivir vs placebo meta-analysis (ACTT-1, Wang et al, WHO SOLIDARITY)",
"description" : "This Citation Resource is referenced in an example for the EBMonFHIR Implementation Guide.",
"isExample" : true
},
{
"extension" : [
{
"url" : "http://hl7.org/fhir/tools/StructureDefinition/resource-information",
"valueString" : "Citation"
}
],
"reference" : {
"reference" : "Citation/7638"
},
"name" : "Citation for FEvIR Evidence 7637: Critically appraised summary of primary outcome of multi-platform RCT of anticoagulation for non-critically ill COVID-19",
"description" : "A Evidence Resource to demonstrate complex evidence reporting",
"isExample" : true
},
{
"extension" : [
{
"url" : "http://hl7.org/fhir/tools/StructureDefinition/resource-information",
"valueString" : "StructureDefinition:resource"
}
],
"reference" : {
"reference" : "StructureDefinition/classification"
},
"name" : "Classification",
"description" : "Profile of ArtifactAssessment for Evidence Based Medicine IG. The Classification Profile is used for classifier tags that may be created independently from Resource creators and may be used for search indexes.",
"isExample" : false
},
{
"extension" : [
{
"url" : "http://hl7.org/fhir/tools/StructureDefinition/resource-information",
"valueString" : "ArtifactAssessment"
}
],
"reference" : {
"reference" : "ArtifactAssessment/179448"
},
"name" : "Classification: Study Design for Association of Bariatric Surgery with Complications and Comorbidities JAMA 2018 Norwegian Cohort",
"description" : "This Classification Profile example is used to represent the study design classifiers (as CodeableConcept datatype values) in support of a ComparativeEvidenceReport Profile.",
"isExample" : true,
"profile" : [
"http://hl7.org/fhir/uv/ebm/StructureDefinition/classification"
]
},
{
"extension" : [
{
"url" : "http://hl7.org/fhir/tools/StructureDefinition/resource-information",
"valueString" : "StructureDefinition:resource"
}
],
"reference" : {
"reference" : "StructureDefinition/cohort-definition"
},
"name" : "CohortDefinition",
"description" : "Profile of Group for Evidence Based Medicine IG. The CohortDefinition Profile is used to provide a definitional representation of a Group. The type element is required. (Alternatively, the ConceptualCohortDefinition Profile uses membership = conceptual and allows avoiding the required use of type.)",
"isExample" : false
},
{
"extension" : [
{
"url" : "http://hl7.org/fhir/tools/StructureDefinition/resource-information",
"valueString" : "StructureDefinition:resource"
}
],
"reference" : {
"reference" : "StructureDefinition/comment"
},
"name" : "Comment",
"description" : "Profile of ArtifactAssessment for Evidence Based Medicine IG. The Comment Profile is used for comments about a Resource that may be created independently from Resource creators.",
"isExample" : false
},
{
"extension" : [
{
"url" : "http://hl7.org/fhir/tools/StructureDefinition/resource-information",
"valueString" : "ArtifactAssessment"
}
],
"reference" : {
"reference" : "ArtifactAssessment/179694"
},
"name" : "Comment on Guideline: ADA 2021 Standards of Medical Care 8. Obesity Management for the Treatment of Type 2 Diabetes by Joanne Dehnbostel 2023-11-28T15:19:01.266Z",
"description" : "This example of a Comment Profile shows a comment about another Resource (Guideline Profile) in which the commenter is not the author of the Resource commented upon.",
"isExample" : true,
"profile" : [
"http://hl7.org/fhir/uv/ebm/StructureDefinition/comment"
]
},
{
"extension" : [
{
"url" : "http://hl7.org/fhir/tools/StructureDefinition/resource-information",
"valueString" : "StructureDefinition:resource"
}
],
"reference" : {
"reference" : "StructureDefinition/comparative-baseline-measure-evidence"
},
"name" : "ComparativeBaselineMeasureEvidence",
"description" : "Profile of Evidence for Evidence Based Medicine IG. The ComparativeBaselineMeasureEvidence Profile is used for comparative evidence with a measured variable (with the role of outcome for this Evidence) that is considered an independent variable with respect to the outcome of an exposure or intervention in a study.",
"isExample" : false
},
{
"extension" : [
{
"url" : "http://hl7.org/fhir/tools/StructureDefinition/resource-information",
"valueString" : "Evidence"
}
],
"reference" : {
"reference" : "Evidence/179455"
},
"name" : "ComparativeBaselineMeasureEvidence: Age in 2018 Norwegian Cohort Surgical Group vs. Medical Group",
"description" : "Mean age 41.2 in Surgical Group vs. 45.7 in Medical Group (p < 0.001)",
"isExample" : true,
"profile" : [
"http://hl7.org/fhir/uv/ebm/StructureDefinition/comparative-baseline-measure-evidence"
]
},
{
"extension" : [
{
"url" : "http://hl7.org/fhir/tools/StructureDefinition/resource-information",
"valueString" : "Evidence"
}
],
"reference" : {
"reference" : "Evidence/179456"
},
"name" : "ComparativeBaselineMeasureEvidence: BMI in 2018 Norwegian Cohort Surgical Group vs. Medical Group",
"description" : "Mean BMI 45.4 in Surgical Group vs. 42.9 in Medical Group (p < 0.001)",
"isExample" : true,
"profile" : [
"http://hl7.org/fhir/uv/ebm/StructureDefinition/comparative-baseline-measure-evidence"
]
},
{
"extension" : [
{
"url" : "http://hl7.org/fhir/tools/StructureDefinition/resource-information",
"valueString" : "StructureDefinition:resource"
}
],
"reference" : {
"reference" : "StructureDefinition/comparative-evidence"
},
"name" : "ComparativeEvidence",
"description" : "Profile of Evidence for Evidence Based Medicine IG. The ComparativeEvidence Profile is used for evidence with a measured variable that is considered the outcome of an exposure or intervention, and an exposure variable with two or more categories that are being compared.",
"isExample" : false
},
{
"extension" : [
{
"url" : "http://hl7.org/fhir/tools/StructureDefinition/resource-information",
"valueString" : "Evidence"
}
],
"reference" : {
"reference" : "Evidence/49328"
},
"name" : "ComparativeEvidence: All-cause mortality effect of bariatric surgery in 2022 meta-analysis",
"description" : "effect estimate for bariatric surgery on all-cause mortality pooled hazard ratio (HR) 0.55 (95% confidence interval 0.49 to 0.62; P < 0.001 vs. controls) in meta-analysis of 21 cohort studies with 133,524 patients after bariatric surgery and 263,478 obese controls",
"isExample" : true,
"profile" : [
"http://hl7.org/fhir/uv/ebm/StructureDefinition/comparative-evidence"
]
},
{
"extension" : [
{
"url" : "http://hl7.org/fhir/tools/StructureDefinition/resource-information",
"valueString" : "Evidence"
}
],
"reference" : {
"reference" : "Evidence/32144"
},
"name" : "ComparativeEvidence: Bariatric Surgery effect for ADA triple outcome at 5 years (Diabetes Surgery Study)",
"description" : "Of 120 participants who were initially randomized, 98 (82%) completed 5 years of follow-up. At 5 years, 13 participants (23%) in the gastric bypass group and 2 (4%) in the lifestyle-intensive medical management group had achieved the composite triple end point (difference, 19%; 95% CI, 4%-34%; P\t=\t.01).",
"isExample" : true,
"profile" : [
"http://hl7.org/fhir/uv/ebm/StructureDefinition/comparative-evidence"
]
},
{
"extension" : [
{
"url" : "http://hl7.org/fhir/tools/StructureDefinition/resource-information",
"valueString" : "Evidence"
}
],
"reference" : {
"reference" : "Evidence/104157"
},
"name" : "ComparativeEvidence: Bypass surgery effects on Additional GI surgical procedure in JAMA 2018 Norwegian cohort study",
"description" : "Surgical patients had a greater risk for undergoing at least 1 additional gastrointestinal surgical procedure (AR, 31.3% vs 15.5%; RD, 15.8% [95% CI, 13.1%-18.5%]; RR, 2.0 [95% CI, 1.7-2.4]).",
"isExample" : true,
"profile" : [
"http://hl7.org/fhir/uv/ebm/StructureDefinition/comparative-evidence"
]
},
{
"extension" : [
{
"url" : "http://hl7.org/fhir/tools/StructureDefinition/resource-information",
"valueString" : "Evidence"
}
],
"reference" : {
"reference" : "Evidence/104098"
},
"name" : "ComparativeEvidence: Bypass surgery effects on Myocardial infarction or stroke in Swedish Obese Subjects (SOS) study",
"description" : "Bariatric surgery was associated with a reduced number of cardiovascular deaths (28 events among 2010 patients in the surgery group vs 49 events among 2037 patients in the control group; adjusted hazard ratio [HR], 0.47; 95% CI, 0.29-0.76; P = .002). The number of total first time (fatal or nonfatal) cardiovascular events (myocardial infarction or stroke, whichever came first) was lower in the surgery group (199 events among 2010 patients) than in the control group (234 events among 2037 patients; adjusted HR, 0.67; 95% CI, 0.54-0.83; P < .001). -- Extrapolated from this data the outcome of Nonfatal myocardial infarction or stroke occurred in 188 out of 2037 patients in the control group and 171 out of 2010 patients in the surgery group, and the adjusted HR for total events is assumed to apply (adjusted HR 0.67, 95% CI 0.54 to 0.83)",
"isExample" : true,
"profile" : [
"http://hl7.org/fhir/uv/ebm/StructureDefinition/comparative-evidence"
]
},
{
"extension" : [
{
"url" : "http://hl7.org/fhir/tools/StructureDefinition/resource-information",
"valueString" : "Evidence"
}
],
"reference" : {
"reference" : "Evidence/104155"
},
"name" : "ComparativeEvidence: Bypass surgery effects on New onset depression in JAMA 2018 Norwegian cohort study",
"description" : "greater risk of new-onset depression: AR, 8.9% vs 6.5%; RD, 2.4% [95% CI, 1.3%-3.5%], RR, 1.5 [95% CI, 1.4-1.7]",
"isExample" : true,
"profile" : [
"http://hl7.org/fhir/uv/ebm/StructureDefinition/comparative-evidence"
]
},
{
"extension" : [
{
"url" : "http://hl7.org/fhir/tools/StructureDefinition/resource-information",
"valueString" : "Evidence"
}
],
"reference" : {
"reference" : "Evidence/104121"
},
"name" : "ComparativeEvidence: Bypass surgery effects on Remission of diabetes in JAMA 2018 Norwegian cohort study",
"description" : "greater likelihood of diabetes remission: AR, 57.5% vs 14.8%; RD, 42.7% [95% CI, 35.8%-49.7%], RR, 3.9 [95% CI, 2.8-5.4]",
"isExample" : true,
"profile" : [
"http://hl7.org/fhir/uv/ebm/StructureDefinition/comparative-evidence"
]
},
{
"extension" : [
{
"url" : "http://hl7.org/fhir/tools/StructureDefinition/resource-information",
"valueString" : "Evidence"
}
],
"reference" : {
"reference" : "Evidence/104156"
},
"name" : "ComparativeEvidence: Bypass surgery effects on Treatment with opioids in JAMA 2018 Norwegian cohort study",
"description" : "greater risk of treatment with opioids: AR, 19.4% vs 15.8%, RD, 3.6% [95% CI, 2.3%-4.9%], RR, 1.3 [95% CI, 1.2-1.4]",
"isExample" : true,
"profile" : [
"http://hl7.org/fhir/uv/ebm/StructureDefinition/comparative-evidence"
]
},
{
"extension" : [
{
"url" : "http://hl7.org/fhir/tools/StructureDefinition/resource-information",
"valueString" : "Evidence"
}
],
"reference" : {
"reference" : "Evidence/47740"
},
"name" : "ComparativeEvidence: Mean difference in HbA1c between Surgery and Medical/Lifestyle groups in Courcoulas 2014",
"description" : "Mean HbA1c at 12 months in Courcoulas 2014 was 6.6 % in Surgery group (n = 41) and 7.0% in Medical/Lifestyle group (n = 17), mean difference -0.40% (95% CI -0.89% to 0.09%)",
"isExample" : true,
"profile" : [
"http://hl7.org/fhir/uv/ebm/StructureDefinition/comparative-evidence"
]
},
{
"extension" : [
{
"url" : "http://hl7.org/fhir/tools/StructureDefinition/resource-information",
"valueString" : "Evidence"
}
],
"reference" : {
"reference" : "Evidence/47768"
},
"name" : "ComparativeEvidence: Mean difference in HbA1c between Surgery and Medical/Lifestyle groups in Courcoulas 2015",
"description" : "Mean HbA1c at 36 months in Courcoulas 2015 was 7.1% in Surgery group (n = 38) and 7.2% in Medical/Lifestyle group (n = 14), mean difference -0.10% (95% CI -0.35% to 0.15%)",
"isExample" : true,
"profile" : [
"http://hl7.org/fhir/uv/ebm/StructureDefinition/comparative-evidence"
]
},
{
"extension" : [
{
"url" : "http://hl7.org/fhir/tools/StructureDefinition/resource-information",
"valueString" : "Evidence"
}
],
"reference" : {
"reference" : "Evidence/47759"
},
"name" : "ComparativeEvidence: Mean difference in HbA1c between Surgery and Medical/Lifestyle groups in Cummings 2016",
"description" : "Mean HbA1c at 12 months in Cummings 2016 was 6.4% in Surgery group (n = 15) and 6.9% in Medical/Lifestyle group (n = 17), mean difference -0.50% (95% CI -1.52% to 0.52%)",
"isExample" : true,
"profile" : [
"http://hl7.org/fhir/uv/ebm/StructureDefinition/comparative-evidence"
]
},
{
"extension" : [
{
"url" : "http://hl7.org/fhir/tools/StructureDefinition/resource-information",
"valueString" : "Evidence"
}
],
"reference" : {
"reference" : "Evidence/47748"
},
"name" : "ComparativeEvidence: Mean difference in HbA1c between Surgery and Medical/Lifestyle groups in Ding 2015",
"description" : "Mean HbA1c at 12 months in Ding 2015 was 7.17 % in Surgery group (n = 18) and 7.15% in Medical/Lifestyle group (n = 22), mean difference 0.02% (95% CI -0.16% to 0.20%)",
"isExample" : true,
"profile" : [
"http://hl7.org/fhir/uv/ebm/StructureDefinition/comparative-evidence"
]
},
{
"extension" : [
{
"url" : "http://hl7.org/fhir/tools/StructureDefinition/resource-information",
"valueString" : "Evidence"
}
],
"reference" : {
"reference" : "Evidence/47760"
},
"name" : "ComparativeEvidence: Mean difference in HbA1c between Surgery and Medical/Lifestyle groups in Dixon 2008",
"description" : "Mean HbA1c at 24 months in Dixon 2008 was 6% in Surgery group (n = 30) and 7.2% in Medical/Lifestyle group (n = 30), mean difference -1.20% (95% CI -1.78% to -0.62%)",
"isExample" : true,
"profile" : [
"http://hl7.org/fhir/uv/ebm/StructureDefinition/comparative-evidence"
]
},
{
"extension" : [
{
"url" : "http://hl7.org/fhir/tools/StructureDefinition/resource-information",
"valueString" : "Evidence"
}
],
"reference" : {
"reference" : "Evidence/47749"
},
"name" : "ComparativeEvidence: Mean difference in HbA1c between Surgery and Medical/Lifestyle groups in Halperin 2014",
"description" : "Mean HbA1c at 12 months in Halperin 2014 was 6.2 % in Surgery group (n = 19) and 8.8% in Medical/Lifestyle group (n = 19), mean difference -2.60% (95% CI -3.37% to -1.83%)",
"isExample" : true,
"profile" : [
"http://hl7.org/fhir/uv/ebm/StructureDefinition/comparative-evidence"
]
},
{
"extension" : [
{
"url" : "http://hl7.org/fhir/tools/StructureDefinition/resource-information",
"valueString" : "Evidence"
}
],
"reference" : {
"reference" : "Evidence/47751"
},
"name" : "ComparativeEvidence: Mean difference in HbA1c between Surgery and Medical/Lifestyle groups in Ikramuddin 2013",
"description" : "Mean HbA1c at 12 months in Ikramuddin 2013 was 6.3 % in Surgery group (n = 57) and 7.8% in Medical/Lifestyle group (n = 19), mean difference -1.50% (95% CI -1.95% to -1.05%)",
"isExample" : true,
"profile" : [
"http://hl7.org/fhir/uv/ebm/StructureDefinition/comparative-evidence"
]
},
{
"extension" : [
{
"url" : "http://hl7.org/fhir/tools/StructureDefinition/resource-information",
"valueString" : "Evidence"
}
],
"reference" : {
"reference" : "Evidence/47762"
},
"name" : "ComparativeEvidence: Mean difference in HbA1c between Surgery and Medical/Lifestyle groups in Ikramuddin 2015",
"description" : "Mean HbA1c at 24 months in Ikramuddin 2015 was 6.5% in Surgery group (n = 56) and 8.4% in Medical/Lifestyle group (n = 54), mean difference -1.90% (95% CI -2.78% to -1.02%)",
"isExample" : true,
"profile" : [
"http://hl7.org/fhir/uv/ebm/StructureDefinition/comparative-evidence"
]
},
{
"extension" : [
{
"url" : "http://hl7.org/fhir/tools/StructureDefinition/resource-information",
"valueString" : "Evidence"
}
],
"reference" : {
"reference" : "Evidence/47752"
},
"name" : "ComparativeEvidence: Mean difference in HbA1c between Surgery and Medical/Lifestyle groups in Liang 2013",
"description" : "Mean HbA1c at 12 months in Liang 2013 was 6 % in Surgery group (n = 31) and 7.6% in Medical/Lifestyle group (n = 70), mean difference -1.60% (95% CI -1.94% to -1.26%)",
"isExample" : true,
"profile" : [
"http://hl7.org/fhir/uv/ebm/StructureDefinition/comparative-evidence"
]
},
{
"extension" : [
{
"url" : "http://hl7.org/fhir/tools/StructureDefinition/resource-information",
"valueString" : "Evidence"
}
],
"reference" : {
"reference" : "Evidence/47665"
},
"name" : "ComparativeEvidence: Mean difference in HbA1c between Surgery and Medical/Lifestyle groups in Mingrone 2012 (DIBASY) trial",
"description" : "Mean HbA1c at 24 months in Mingrone 2012 was 5.65% in Surgery group (n = 20) and 7.69% in Medical/Lifestyle group (n = 20), mean difference -2.04% (95% CI -2.53% to -1.55%)",
"isExample" : true,
"profile" : [
"http://hl7.org/fhir/uv/ebm/StructureDefinition/comparative-evidence"
]
},
{
"extension" : [
{
"url" : "http://hl7.org/fhir/tools/StructureDefinition/resource-information",
"valueString" : "Evidence"
}
],
"reference" : {
"reference" : "Evidence/47695"
},
"name" : "ComparativeEvidence: Mean difference in HbA1c between Surgery and Medical/Lifestyle groups in Mingrone 2015 (DIBASY) trial",
"description" : "Mean HbA1c at 60 months in Mingrone 2015 was 6.55% in Surgery group (n = 38) and 6.9% in Medical/Lifestyle group (n = 15), mean difference -0.35% (95% CI -0.69% to -0.01%)",
"isExample" : true,
"profile" : [
"http://hl7.org/fhir/uv/ebm/StructureDefinition/comparative-evidence"
]
},
{
"extension" : [
{
"url" : "http://hl7.org/fhir/tools/StructureDefinition/resource-information",
"valueString" : "Evidence"
}
],
"reference" : {
"reference" : "Evidence/47738"
},
"name" : "ComparativeEvidence: Mean difference in HbA1c between Surgery and Medical/Lifestyle groups in Parikh 2014",
"description" : "Mean HbA1c at 6 months in Parikh 2014 was 6.2 % in Surgery group (n = 20) and 7.8% in Medical/Lifestyle group (n = 24), mean difference -1.60% (95% CI -2.39% to -0.81%)",
"isExample" : true,
"profile" : [
"http://hl7.org/fhir/uv/ebm/StructureDefinition/comparative-evidence"
]
},
{
"extension" : [
{
"url" : "http://hl7.org/fhir/tools/StructureDefinition/resource-information",
"valueString" : "Evidence"
}
],
"reference" : {
"reference" : "Evidence/47758"
},
"name" : "ComparativeEvidence: Mean difference in HbA1c between Surgery and Medical/Lifestyle groups in Schauer 2012 (STAMPEDE) trial",
"description" : "Mean HbA1c at 12 months in Schauer 2012 was 6.5% in Surgery group (n = 99) and 7.5% in Medical/Lifestyle group (n = 41), mean difference -1.00% (95% CI -1.58% to -0.42%)",
"isExample" : true,
"profile" : [
"http://hl7.org/fhir/uv/ebm/StructureDefinition/comparative-evidence"
]
},
{
"extension" : [
{
"url" : "http://hl7.org/fhir/tools/StructureDefinition/resource-information",
"valueString" : "Evidence"
}
],
"reference" : {
"reference" : "Evidence/47771"
},
"name" : "ComparativeEvidence: Mean difference in HbA1c between Surgery and Medical/Lifestyle groups in Schauer 2014 (STAMPEDE) trial",
"description" : "Mean HbA1c at 36 months in Schauer 2014 was 6.85% in Surgery group (n = 97) and 8.4% in Medical/Lifestyle group (n = 40), mean difference -1.55% (95% CI -2.28% to -0.82%)",
"isExample" : true,
"profile" : [
"http://hl7.org/fhir/uv/ebm/StructureDefinition/comparative-evidence"
]
},
{
"extension" : [
{
"url" : "http://hl7.org/fhir/tools/StructureDefinition/resource-information",
"valueString" : "Evidence"
}
],
"reference" : {
"reference" : "Evidence/47766"
},
"name" : "ComparativeEvidence: Mean difference in HbA1c between Surgery and Medical/Lifestyle groups in Wentworth 2014",
"description" : "Mean HbA1c at 24 months in Wentworth 2014 was 6.1% in Surgery group (n = 23) and 7.3% in Medical/Lifestyle group (n = 25), mean difference -1.20% (95% CI -1.84% to -0.56%)",
"isExample" : true,
"profile" : [
"http://hl7.org/fhir/uv/ebm/StructureDefinition/comparative-evidence"
]
},
{
"extension" : [
{
"url" : "http://hl7.org/fhir/tools/StructureDefinition/resource-information",
"valueString" : "Evidence"
}
],
"reference" : {
"reference" : "Evidence/33244"
},
"name" : "ComparativeEvidence: Mean difference in HbA1c effect of bariatric surgery in 2016 meta-analysis",
"description" : "effect estimate for differences in mean HbA1c at study end point between Surgery and Medical/Lifestyle groups -1.14% (95% CI -1.57% to -0.71%) in meta-analysis of 15 trials with 1,067 participants",
"isExample" : true,
"profile" : [
"http://hl7.org/fhir/uv/ebm/StructureDefinition/comparative-evidence"
]
},
{
"extension" : [
{
"url" : "http://hl7.org/fhir/tools/StructureDefinition/resource-information",
"valueString" : "StructureDefinition:resource"
}
],
"reference" : {
"reference" : "StructureDefinition/comparative-evidence-report"
},
"name" : "ComparativeEvidenceReport",
"description" : "Profile of Composition for Evidence Based Medicine IG. The ComparativeEvidenceReport Profile is used for an evidence report including the study group, exposure, comparator, and findings for any number of outcomes comparing the exposure to the comparator in the study group.",
"isExample" : false
},
{
"extension" : [
{
"url" : "http://hl7.org/fhir/tools/StructureDefinition/resource-information",
"valueString" : "Composition"
}
],
"reference" : {
"reference" : "Composition/178426"
},
"name" : "ComparativeEvidenceReport: Association of Bariatric Surgery vs Medical Obesity Treatment With Long-term Medical Complications and Obesity-Related Comorbidities (2018 Norwegian Cohort)",
"description" : "This example of a ComparativeEvidenceReport Profile shows a report from a single observational study with 2 baseline measures, 2 participant flow measures, and 4 outcome measures.",
"isExample" : true,
"profile" : [
"http://hl7.org/fhir/uv/ebm/StructureDefinition/comparative-evidence-report"
]
},
{
"extension" : [
{
"url" : "http://hl7.org/fhir/tools/StructureDefinition/resource-information",
"valueString" : "StructureDefinition:resource"
}
],
"reference" : {
"reference" : "StructureDefinition/comparative-evidence-report-subject"
},
"name" : "ComparativeEvidenceReportSubject",
"description" : "Profile of Group for Evidence Based Medicine IG. The EvidenceReportSubject Profile is used to define the subject of an EvidenceReport.",
"isExample" : false
},
{
"extension" : [
{
"url" : "http://hl7.org/fhir/tools/StructureDefinition/resource-information",
"valueString" : "Group"
}
],
"reference" : {
"reference" : "Group/179633"
},
"name" : "ComparativeEvidenceReportSubject: Association of Bariatric Surgery vs Medical Obesity Treatment With Long-term Medical Complications and Obesity-Related Comorbidities (2018 Norwegian Cohort)",
"description" : "This example of a ComparativeEvidenceReportSubject Profile expresses the conceptual group of PICO elements using the 'all of'' code in the combinationMethod element. Each of the characteristics described in this example are defined by reference to another Resource so the characteristic.code element has a value of text:'Defined by Reference' and uses a valueReference element. Three of the characteristics are defined by reference to a Group Resource and the last characteristic (Outcomes) is defined by reference to a List Resource. This example demonstrates the use of the 'conceptual' code for the membership element. In this case the Group Resource is being used for the conceptual grouping of characteristics and is not a group of people or physical objects.",
"isExample" : true,
"profile" : [
"http://hl7.org/fhir/uv/ebm/StructureDefinition/comparative-evidence-report-subject"
]
},
{
"extension" : [
{
"url" : "http://hl7.org/fhir/tools/StructureDefinition/resource-information",
"valueString" : "StructureDefinition:resource"
}
],
"reference" : {
"reference" : "StructureDefinition/comparative-evidence-synthesis-report"
},
"name" : "ComparativeEvidenceSynthesisReport",
"description" : "Profile of Composition for Evidence Based Medicine IG. The ComparativeEvidenceSynthesisReport Profile is used for an evidence report including the intended population, intended exposure, intended comparator, and findings for any number of outcomes comparing the exposure to the comparator with observed study group, observed exposure group, and observed comparator group unique for each outcome.",
"isExample" : false
},
{
"extension" : [
{
"url" : "http://hl7.org/fhir/tools/StructureDefinition/resource-information",
"valueString" : "StructureDefinition:resource"
}
],
"reference" : {
"reference" : "StructureDefinition/comparative-participant-flow-evidence"
},
"name" : "ComparativeParticipantFlowEvidence",
"description" : "Profile of Evidence for Evidence Based Medicine IG. The ComparativeParticipantFlowEvidence Profile is used for comparisons of counts of completion and reasons for non-completion of participation in a research study.",
"isExample" : false
},
{
"extension" : [
{
"url" : "http://hl7.org/fhir/tools/StructureDefinition/resource-information",
"valueString" : "Evidence"
}
],
"reference" : {
"reference" : "Evidence/179635"
},
"name" : "ComparativeParticipantFlowEvidence: Dropout due to stopping intervention Lofexidine vs. Placebo in opioid detoxification trial",
"description" : "Dropout due to stopping intervention 18/33 with Lofexidine vs. 12/35 with Placebo in opioid detoxification trial",
"isExample" : true,
"profile" : [
"http://hl7.org/fhir/uv/ebm/StructureDefinition/comparative-participant-flow-evidence"
]
},
{
"extension" : [
{
"url" : "http://hl7.org/fhir/tools/StructureDefinition/resource-information",
"valueString" : "StructureDefinition:resource"
}
],
"reference" : {
"reference" : "StructureDefinition/comparator-definition"
},
"name" : "ComparatorDefinition",
"description" : "Profile of Group for Evidence Based Medicine IG. The ComparatorDefinition Profile is used to express the criteria defining a reference group for comparison.",
"isExample" : false
},
{
"extension" : [
{
"url" : "http://hl7.org/fhir/tools/StructureDefinition/resource-information",
"valueString" : "Group"
}
],
"reference" : {
"reference" : "Group/236776"
},
"name" : "ComparatorDefinition: Glucagon-Like Peptide-1 (GLP-1) receptor agonists",
"description" : "This Group Resource is referenced in an example for the EBMonFHIR Implementation Guide.",
"isExample" : true,
"profile" : [
"http://hl7.org/fhir/uv/ebm/StructureDefinition/exposure-definition"
]
},
{
"extension" : [
{
"url" : "http://hl7.org/fhir/tools/StructureDefinition/resource-information",
"valueString" : "Group"
}
],
"reference" : {
"reference" : "Group/172424"
},
"name" : "ComparatorDefinition: NOT Bariatric Surgery (RYGB, VSG, LAGB, BPD)",
"description" : "Absence of any of 4 bariatric surgery procedures (Roux-en-Y Gastric Bypass, Vertical Sleeve Gastrectomy, Laparoscopic Adjustable Gastric banding, Biliopancreatic Diversion)",
"isExample" : true,
"profile" : [
"http://hl7.org/fhir/uv/ebm/StructureDefinition/comparator-definition"
]
},
{
"extension" : [
{
"url" : "http://hl7.org/fhir/tools/StructureDefinition/resource-information",
"valueString" : "Group"
}
],
"reference" : {
"reference" : "Group/179785"
},
"name" : "ComparatorDefinition: Usual-care pharmacologic thromboprophylaxis",
"description" : "Description: usual-care pharmacologic thromboprophylaxis\nNote: Thromboprophylaxis was provided at a dose and duration determined by the treating clinician according to local practice.\nNote: Usual-care pharmacological thromboprophylaxis included both intermediate-intensity (in 27%) and prophylactic-intensity dosing (in 72%). Subgroup analyses may be informative to determine if there is a difference related to the intensity used in the control arm of the trial.",
"isExample" : true,
"profile" : [
"http://hl7.org/fhir/uv/ebm/StructureDefinition/comparator-definition"
]
},
{
"extension" : [
{
"url" : "http://hl7.org/fhir/tools/StructureDefinition/resource-information",
"valueString" : "StructureDefinition:resource"
}
],
"reference" : {
"reference" : "StructureDefinition/comparator-group"
},
"name" : "ComparatorGroup",
"description" : "Profile of Group for Evidence Based Medicine IG. The ComparatorGroup Profile is used to represent a group (definitional or enumerated) used as a comparator in a ComparativeEvidence.",
"isExample" : false
},
{
"extension" : [
{
"url" : "http://hl7.org/fhir/tools/StructureDefinition/resource-information",
"valueString" : "Group"
}
],
"reference" : {
"reference" : "Group/172939"
},
"name" : "ComparatorGroup: JAMA 2018 Norwegian cohort study Control cohort",
"description" : "Example of an ComparatorGroup Profile with an enumerated group (quantity = 956) meeting 2 characteristics defined by Group Resources (Member of a StudyGroup Profile, excluding a Procedure defined by an ExposureDefinition Profile)",
"isExample" : true,
"profile" : [
"http://hl7.org/fhir/uv/ebm/StructureDefinition/comparator-group"
]
},
{
"extension" : [
{
"url" : "http://hl7.org/fhir/tools/StructureDefinition/resource-information",
"valueString" : "Group"
}
],
"reference" : {
"reference" : "Group/172460"
},
"name" : "ComparatorGroup: Obese patients ≥ 18 years old without bariatric surgery",
"description" : "This example of a ComparatorGroup Profile expresses the definition of a group by the combination of meeting both (all of) two characteristics by using the 'all-of' code in the combinationMethod element. Each of the two characteristics in this example are defined by reference to another Group Resource, so the characteristic.code element has a value of text:'Defined by Reference' and uses a valueReference element.",
"isExample" : true,
"profile" : [
"http://hl7.org/fhir/uv/ebm/StructureDefinition/comparator-group"
]
},
{
"extension" : [
{
"url" : "http://hl7.org/fhir/tools/StructureDefinition/resource-information",
"valueString" : "StructureDefinition:resource"
}
],
"reference" : {
"reference" : "StructureDefinition/comparator-only-evidence"
},
"name" : "ComparatorOnlyEvidence",
"description" : "Profile of Evidence for Evidence Based Medicine IG. The ComparatorOnlyEvidence Profile is used for evidence with a measured variable that is considered the outcome of an exposure or intervention, and a population that has an exposure with a categorical value that is the reference category for the exposure in a ComparativeEvidence Profile. The ComparatorOnlyEvidence describes the evidence for the comparator group.",
"isExample" : false
},
{
"extension" : [
{
"url" : "http://hl7.org/fhir/tools/StructureDefinition/resource-information",
"valueString" : "Evidence"
}
],
"reference" : {
"reference" : "Evidence/104385"
},
"name" : "ComparatorOnlyEvidence: Additional GI surgical procedure without bariatric surgery (Control Group) in JAMA 2018 Norwegian cohort study",
"description" : "Risk of additional GI surgical procedure in control group was 15.5%.",
"isExample" : true,
"profile" : [
"http://hl7.org/fhir/uv/ebm/StructureDefinition/comparator-only-evidence"
]
},
{
"extension" : [
{
"url" : "http://hl7.org/fhir/tools/StructureDefinition/resource-information",
"valueString" : "Evidence"
}
],
"reference" : {
"reference" : "Evidence/104384"
},
"name" : "ComparatorOnlyEvidence: All-cause mortality without bariatric surgery in 2022 meta-analysis",
"description" : "estimate for all-cause mortality without bariatric surgery 4.75% based on median control event rate in 26 cohort studies with post-bariatric surgery patients and obese controls",
"isExample" : true,
"profile" : [
"http://hl7.org/fhir/uv/ebm/StructureDefinition/comparator-only-evidence"
]
},
{
"extension" : [
{
"url" : "http://hl7.org/fhir/tools/StructureDefinition/resource-information",
"valueString" : "Evidence"
}
],
"reference" : {
"reference" : "Evidence/104397"
},
"name" : "ComparatorOnlyEvidence: Myocardial infarction or stroke without bariatric surgery (Control Group) in Swedish Obese Subjects (SOS) study",
"description" : "Bariatric surgery was associated with 49 cardiovascular deaths among 2037 patients in the control group. The number of total first time (fatal or nonfatal) cardiovascular events (myocardial infarction or stroke, whichever came first) in the control group was 234 events among 2037 patients. Extrapolated from this data the outcome of Nonfatal myocardial infarction or stroke occurred in 188 out of 2037 patients in the control group.",
"isExample" : true,
"profile" : [
"http://hl7.org/fhir/uv/ebm/StructureDefinition/comparator-only-evidence"
]
},
{
"extension" : [
{
"url" : "http://hl7.org/fhir/tools/StructureDefinition/resource-information",
"valueString" : "Evidence"
}
],
"reference" : {
"reference" : "Evidence/104395"
},
"name" : "ComparatorOnlyEvidence: New onset depression without bariatric surgery (Control Group) in JAMA 2018 Norwegian cohort study",
"description" : "Risk of New onset depression in control group was 6.5%.",
"isExample" : true,
"profile" : [
"http://hl7.org/fhir/uv/ebm/StructureDefinition/comparator-only-evidence"
]
},
{
"extension" : [
{
"url" : "http://hl7.org/fhir/tools/StructureDefinition/resource-information",
"valueString" : "Evidence"
}
],
"reference" : {
"reference" : "Evidence/104396"
},
"name" : "ComparatorOnlyEvidence: Remission of diabetes without bariatric surgery (Control Group) in JAMA 2018 Norwegian cohort study",
"description" : "Risk of Remission of diabetes in control group was 14.8%.",
"isExample" : true,
"profile" : [
"http://hl7.org/fhir/uv/ebm/StructureDefinition/comparator-only-evidence"
]
},
{
"extension" : [
{
"url" : "http://hl7.org/fhir/tools/StructureDefinition/resource-information",
"valueString" : "Evidence"
}
],
"reference" : {
"reference" : "Evidence/104394"
},
"name" : "ComparatorOnlyEvidence: Treatment with opioids without bariatric surgery (Control Group) in JAMA 2018 Norwegian cohort study",
"description" : "Risk of Treatment with opioids in control group was 15.8%.",
"isExample" : true,
"profile" : [
"http://hl7.org/fhir/uv/ebm/StructureDefinition/comparator-only-evidence"
]
},
{
"extension" : [
{
"url" : "http://hl7.org/fhir/tools/StructureDefinition/resource-information",
"valueString" : "StructureDefinition:resource"
}
],
"reference" : {
"reference" : "StructureDefinition/comparison"
},
"name" : "Comparison",
"description" : "Profile of ArtifactAssessment for Evidence Based Medicine IG. The Comparison Profile is used for assessments of similarities and differences between knowledge artifacts.",
"isExample" : false
},
{
"extension" : [
{
"url" : "http://hl7.org/fhir/tools/StructureDefinition/resource-information",
"valueString" : "ArtifactAssessment"
}
],
"reference" : {
"reference" : "ArtifactAssessment/179700"
},
"name" : "Comparison: Original and Adapted Recommendation: ADA Obesity Management Recommendation 8.16",
"description" : "This Comparison Profile shows a comparison of top-level elements between two Resources and classifies each element pairing as Same or Different based on whether the content is a match.",
"isExample" : true,
"profile" : [
"http://hl7.org/fhir/uv/ebm/StructureDefinition/comparison"
]
},
{
"extension" : [
{
"url" : "http://hl7.org/fhir/tools/StructureDefinition/resource-information",
"valueString" : "ArtifactAssessment"
}
],
"reference" : {
"reference" : "ArtifactAssessment/171898"
},
"name" : "Composite Rating of FOI 153881 for Project FOI 112280",
"description" : "This example of a CompositeRating Profile is a result from evaluating 2 or more Rating Profile instances about the same artifactReference and path, and reporting the agreed value in the summary element with a classifier value of SAME when all ratings were in agreement, and reporting MISMATCH in both elements when disagreements occurred.",
"isExample" : true,
"profile" : [
"http://hl7.org/fhir/uv/ebm/StructureDefinition/composite-rating"
]
},
{
"extension" : [
{
"url" : "http://hl7.org/fhir/tools/StructureDefinition/resource-information",
"valueString" : "StructureDefinition:resource"
}
],
"reference" : {
"reference" : "StructureDefinition/composite-rating"
},
"name" : "CompositeRating",
"description" : "Profile of ArtifactAssessment for Evidence Based Medicine IG. The CompositeRating Profile is used for a composite rating or classification of a Resource that may be created following ratings or classifications by two or more parties.",
"isExample" : false
},
{
"extension" : [
{
"url" : "http://hl7.org/fhir/tools/StructureDefinition/resource-information",
"valueString" : "Organization"
}
],
"reference" : {
"reference" : "Organization/118079"
},
"name" : "Computable_Publishing_LLC",
"description" : "Computable Publishing® augments digital publishing with machine-interpretable forms. Computable Publishing® offers publishers of any type (commercial, nonprofit, academic, government) the ability to extend their published works with computable (machine-interpretable) forms of expression, and users of any type support in using computable data to enhance, improve and achieve desired outcomes.",
"isExample" : true
},
{
"extension" : [
{
"url" : "http://hl7.org/fhir/tools/StructureDefinition/resource-information",
"valueString" : "StructureDefinition:resource"
}
],
"reference" : {
"reference" : "StructureDefinition/conceptual-cohort-definition"
},
"name" : "ConceptualCohortDefinition",
"description" : "Profile of Group for Evidence Based Medicine IG. The ConceptualCohortDefinition Profile is used to provide a conceptual representation of a Group. The membership = conceptual allows avoiding the required use of type.",
"isExample" : false
},
{
"extension" : [
{
"url" : "http://hl7.org/fhir/tools/StructureDefinition/resource-information",
"valueString" : "Group"
}
],
"reference" : {
"reference" : "Group/179902"
},
"name" : "ConceptualCohortDefinition: At least 2 risk factors for stroke",
"description" : "This example shows used of combinationMethod (at-least) and combinationThreshold (2) to express at least 2 of a set of characteristics.",
"isExample" : true,
"profile" : [
"http://hl7.org/fhir/uv/ebm/StructureDefinition/conceptual-cohort-definition"
]
},
{
"extension" : [
{
"url" : "http://hl7.org/fhir/tools/StructureDefinition/resource-information",
"valueString" : "Group"
}
],
"reference" : {
"reference" : "Group/179514"
},
"name" : "ConceptualCohortDefinition: BMI 27.5-32.4 in Asian Americans who do not achieve durable weight loss and improvement in comorbidities without surgery",
"description" : "BMI 27.5-32.4 in Asian Americans who do not achieve durable weight loss and improvement in comorbidities without surgery",
"isExample" : true,
"profile" : [
"http://hl7.org/fhir/uv/ebm/StructureDefinition/conceptual-cohort-definition"
]
},
{
"extension" : [
{
"url" : "http://hl7.org/fhir/tools/StructureDefinition/resource-information",
"valueString" : "Group"
}
],
"reference" : {
"reference" : "Group/179513"
},
"name" : "ConceptualCohortDefinition: BMI 30-34.9 in persons who do not achieve durable weight loss and improvement in comorbidities without surgery",
"description" : "BMI 30-34.9 in persons who do not achieve durable weight loss and improvement in comorbidities without surgery",
"isExample" : true,
"profile" : [
"http://hl7.org/fhir/uv/ebm/StructureDefinition/conceptual-cohort-definition"
]
},
{
"extension" : [
{
"url" : "http://hl7.org/fhir/tools/StructureDefinition/resource-information",
"valueString" : "Group"
}
],
"reference" : {
"reference" : "Group/179510"
},
"name" : "ConceptualCohortDefinition: BMI 32.5-37.4 in Asian Americans who do not achieve durable weight loss and improvement in comorbidities without surgery",
"description" : "BMI 32.5-37.4 in Asian Americans who do not achieve durable weight loss and improvement in comorbidities without surgery",
"isExample" : true,
"profile" : [
"http://hl7.org/fhir/uv/ebm/StructureDefinition/conceptual-cohort-definition"
]
},
{
"extension" : [
{
"url" : "http://hl7.org/fhir/tools/StructureDefinition/resource-information",
"valueString" : "Group"
}
],
"reference" : {
"reference" : "Group/179509"
},
"name" : "ConceptualCohortDefinition: BMI 35-39.9 in persons who do not achieve durable weight loss and improvement in comorbidities without surgery",
"description" : "BMI 35-39.9 in persons who do not achieve durable weight loss and improvement in comorbidities without surgery",
"isExample" : true,
"profile" : [
"http://hl7.org/fhir/uv/ebm/StructureDefinition/conceptual-cohort-definition"
]
},
{
"extension" : [
{
"url" : "http://hl7.org/fhir/tools/StructureDefinition/resource-information",
"valueString" : "Group"
}
],
"reference" : {
"reference" : "Group/179506"
},
"name" : "ConceptualCohortDefinition: BMI criteria for ADA surgery recommendation",
"description" : "Body Mass Index (BMI) ≥ 40.0 kg/m2 (BMI ≥ 37.5 kg/m2 in Asian Americans), or BMI ≥ 35.0 kg/m2 and ≤ 39.9 kg/m2 (BMI 32.5-37.4 kg/m2 in Asian Americans) who do not achieve durable weight loss and improvement in comorbidities (including hyperglycemia) with nonsurgical methods.",
"isExample" : true,
"profile" : [
"http://hl7.org/fhir/uv/ebm/StructureDefinition/conceptual-cohort-definition"
]
},
{
"extension" : [
{
"url" : "http://hl7.org/fhir/tools/StructureDefinition/resource-information",
"valueString" : "Group"
}
],
"reference" : {
"reference" : "Group/179376"
},
"name" : "ConceptualCohortDefinition: BMI ≥ 35 and at least 1 obesity-related comorbidity",
"description" : "BMI ≥ 35 and at least 1 obesity-related comorbidity",
"isExample" : true,
"profile" : [
"http://hl7.org/fhir/uv/ebm/StructureDefinition/conceptual-cohort-definition"
]
},
{
"extension" : [
{
"url" : "http://hl7.org/fhir/tools/StructureDefinition/resource-information",
"valueString" : "Group"
}
],
"reference" : {
"reference" : "Group/179508"
},
"name" : "ConceptualCohortDefinition: BMI ≥ 37.5 kg/m2 in Asian Americans",
"description" : "BMI ≥ 37.5 kg/m2 in Asian Americans",
"isExample" : true,
"profile" : [
"http://hl7.org/fhir/uv/ebm/StructureDefinition/conceptual-cohort-definition"
]
},
{
"extension" : [
{
"url" : "http://hl7.org/fhir/tools/StructureDefinition/resource-information",
"valueString" : "Group"
}
],
"reference" : {
"reference" : "Group/179897"
},
"name" : "ConceptualCohortDefinition: Estimated glomerular filtration rate 45-59",
"description" : "A characteristic of estimated glomerular filtration rate (eGFR) of 45-59 mL/min/1.73m2 is shown here. LOINC Code guidance states 'If transitioning to the new 2021 calculations, note there are separate equations for male and female patients that need to be implemented. The same LOINC code is applied regardless of which sex-based equation is used to generate the result. Laboratories need to build each male and female equation within their LIS and validate per their accreditation requirements.' and 'While LOINC does not have a specific code for reporting the exact equation used to calculate eGFR, it may be appropriate for labs to transmit this information as part of the information contained in the result comment field. The individual laboratory should determine whether it is better to include the equation, or the author(s) of the equation, to identify the method used to perform the eGFR calculation.' This example uses Group.characteristic.determinedByExpression to show where the exact equation may be reported.",
"isExample" : true,
"profile" : [
"http://hl7.org/fhir/uv/ebm/StructureDefinition/conceptual-cohort-definition"
]
},
{
"extension" : [
{
"url" : "http://hl7.org/fhir/tools/StructureDefinition/resource-information",
"valueString" : "Group"
}
],
"reference" : {
"reference" : "Group/179901"
},
"name" : "ConceptualCohortDefinition: Heart failure based on Phenotypes",
"description" : "This example shows how to express a Group defined by meeting either of two phenotype definitions for 'heart failure' where the phenotype definitions are found by URL in a system not using FHIR for phenotype expression. This demonstrates the Group.characteristic.valueUri element.",
"isExample" : true,
"profile" : [
"http://hl7.org/fhir/uv/ebm/StructureDefinition/conceptual-cohort-definition"
]
},
{
"extension" : [
{
"url" : "http://hl7.org/fhir/tools/StructureDefinition/resource-information",
"valueString" : "Group"
}
],
"reference" : {
"reference" : "Group/179512"
},
"name" : "ConceptualCohortDefinition: Lower BMI criteria for ADA surgery consideration",
"description" : "Body Mass Index (BMI) ≥ 30.0 kg/m2 and ≤ 34.9 kg/m2 (BMI 27.5-32.4 kg/m2 in Asian Americans) who do not achieve durable weight loss and improvement in comorbidities (including hyperglycemia) with nonsurgical methods.",
"isExample" : true,
"profile" : [
"http://hl7.org/fhir/uv/ebm/StructureDefinition/conceptual-cohort-definition"
]
},
{
"extension" : [
{
"url" : "http://hl7.org/fhir/tools/StructureDefinition/resource-information",
"valueString" : "Group"
}
],
{
"extension" : [
{
"url" : "http://hl7.org/fhir/tools/StructureDefinition/resource-information",
"valueString" : "Group"
}
],
"reference" : {
"reference" : "Group/291369"
},
"name" : "ExposureDefinition: Therapeutic-dose anticoagulation with heparin",
"description" : "This Group Resource is referenced in an example for the EBMonFHIR Implementation Guide.",
"isExample" : true,
"profile" : [
"http://hl7.org/fhir/uv/ebm/StructureDefinition/exposure-definition"
]
},
{
"extension" : [
{
"url" : "http://hl7.org/fhir/tools/StructureDefinition/resource-information",
"valueString" : "StructureDefinition:resource"
}
],
"reference" : {
"reference" : "StructureDefinition/exposure-group"
},
"name" : "ExposureGroup",
"description" : "Profile of Group for Evidence Based Medicine IG. The ExposureGroup Profile is used to represent a group (definitional or enumerated) used in a ComparativeEvidence.",
"isExample" : false
},
{
"extension" : [
{
"url" : "http://hl7.org/fhir/tools/StructureDefinition/resource-information",
"valueString" : "Group"
}
],
"reference" : {
"reference" : "Group/172934"
},
"name" : "ExposureGroup: JAMA 2018 Norwegian cohort study Surgery cohort",
"description" : "Example of an ExposureGroup Profile with an enumerated group (quantity = 932) meeting 2 characteristics defined by Group Resources (Member of a StudyGroup Profile, Procedure defined by an ExposureDefinition Profile)",
"isExample" : true,
"profile" : [
"http://hl7.org/fhir/uv/ebm/StructureDefinition/exposure-group"
]
},
{
"extension" : [
{
"url" : "http://hl7.org/fhir/tools/StructureDefinition/resource-information",
"valueString" : "EvidenceVariable"
}
],
"reference" : {
"reference" : "EvidenceVariable/179449"
},
"name" : "ExposureVariable: Age (as continuous variable)",
"description" : "This example expresses the variable 'Age' as a continuous variable with a simple definition using definition.concept.coding and is used with the BaselineMeasureEvidence Profile of Evidence in the Evidence.variableDefinition with variableRole='outcome'",
"isExample" : true,
"profile" : [
"http://hl7.org/fhir/uv/ebm/StructureDefinition/variable-definition"
]
},
{
"extension" : [
{
"url" : "http://hl7.org/fhir/tools/StructureDefinition/resource-information",
"valueString" : "EvidenceVariable"
}
],
"reference" : {
"reference" : "EvidenceVariable/179450"
},
"name" : "ExposureVariable: Body Mass Index (as continuous variable)",
"description" : "This example expresses the variable 'Body Mass Index' as a continuous variable with a simple definition using definition.concept.coding and is used with the BaselineMeasureEvidence Profile of Evidence in the Evidence.variableDefinition with variableRole='outcome'",
"isExample" : true,
"profile" : [
"http://hl7.org/fhir/uv/ebm/StructureDefinition/variable-definition"
]
},
{
"extension" : [
{
"url" : "http://hl7.org/fhir/tools/StructureDefinition/resource-information",
"valueString" : "EvidenceVariable"
}
],
"reference" : {
"reference" : "EvidenceVariable/179662"
},
"name" : "ExposureVariable: pht013093.v1.p1 Age at diagnosis",
"description" : "Subject age at diagnosis - datatype integer, encoded value",
"isExample" : true,
"profile" : [
"http://hl7.org/fhir/uv/ebm/StructureDefinition/variable-definition"
]
},
{
"extension" : [
{
"url" : "http://hl7.org/fhir/tools/StructureDefinition/resource-information",
"valueString" : "EvidenceVariable"
}
],
"reference" : {
"reference" : "EvidenceVariable/179661"
},
"name" : "ExposureVariable: pht013093.v1.p1 RACE",
"description" : "Self-reported race - datatype string",
"isExample" : true,
"profile" : [
"http://hl7.org/fhir/uv/ebm/StructureDefinition/variable-definition"
]
},
{
"extension" : [
{
"url" : "http://hl7.org/fhir/tools/StructureDefinition/resource-information",
"valueString" : "EvidenceVariable"
}
],
"reference" : {
"reference" : "EvidenceVariable/179658"
},
"name" : "ExposureVariable: pht013093.v1.p1 SEX",
"description" : "Self-reported sex - datatype CodeableConcept",
"isExample" : true,
"profile" : [
"http://hl7.org/fhir/uv/ebm/StructureDefinition/variable-definition"
]
},
{
"extension" : [
{
"url" : "http://hl7.org/fhir/tools/StructureDefinition/resource-information",
"valueString" : "EvidenceVariable"
}
],
"reference" : {
"reference" : "EvidenceVariable/179649"
},
"name" : "ExposureVariable: pht013093.v1.p1 SUBJECT_ID",
"description" : "Subject ID - datatype string",
"isExample" : true,
"profile" : [
"http://hl7.org/fhir/uv/ebm/StructureDefinition/variable-definition"
]
},
{
"extension" : [
{
"url" : "http://hl7.org/fhir/tools/StructureDefinition/resource-information",
"valueString" : "EvidenceVariable"
}
],
"reference" : {
"reference" : "EvidenceVariable/179680"
},
"name" : "ExposureVariable: pht013094.v1.p1 ANALYTE_TYPE",
"description" : "Analyte type of the sample - datatype string",
"isExample" : true,
"profile" : [
"http://hl7.org/fhir/uv/ebm/StructureDefinition/variable-definition"
]
},
{
"extension" : [
{
"url" : "http://hl7.org/fhir/tools/StructureDefinition/resource-information",
"valueString" : "EvidenceVariable"
}
],
"reference" : {
"reference" : "EvidenceVariable/179678"
},
"name" : "ExposureVariable: pht013094.v1.p1 BODY_SITE",
"description" : "Body site where sample was collected - datatype string",
"isExample" : true,
"profile" : [
"http://hl7.org/fhir/uv/ebm/StructureDefinition/variable-definition"
]
},
{
"extension" : [
{
"url" : "http://hl7.org/fhir/tools/StructureDefinition/resource-information",
"valueString" : "EvidenceVariable"
}
],
"reference" : {
"reference" : "EvidenceVariable/179682"
},
"name" : "ExposureVariable: pht013094.v1.p1 IS_TUMOR",
"description" : "The tumor status of the sample - datatype CodeableConcept",
"isExample" : true,
"profile" : [
"http://hl7.org/fhir/uv/ebm/StructureDefinition/variable-definition"
]
},
{
"extension" : [
{
"url" : "http://hl7.org/fhir/tools/StructureDefinition/resource-information",
"valueString" : "EvidenceVariable"
}
],
"reference" : {
"reference" : "EvidenceVariable/179677"
},
"name" : "ExposureVariable: pht013094.v1.p1 SAMPLE_ID",
"description" : "Sample ID - datatype string",
"isExample" : true,
"profile" : [
"http://hl7.org/fhir/uv/ebm/StructureDefinition/variable-definition"
]
},
{
"extension" : [
{
"url" : "http://hl7.org/fhir/tools/StructureDefinition/resource-information",
"valueString" : "EvidenceVariable"
}
],
"reference" : {
"reference" : "EvidenceVariable/179679"
},
"name" : "ExposureVariable: pht013094.v1.p1 SAMPLE_USE",
"description" : "Technology employed on the sample - datatype string",
"isExample" : true,
"profile" : [
"http://hl7.org/fhir/uv/ebm/StructureDefinition/variable-definition"
]
},
{
"extension" : [
{
"url" : "http://hl7.org/fhir/tools/StructureDefinition/resource-information",
"valueString" : "EvidenceVariable"
}
],
"reference" : {
"reference" : "EvidenceVariable/179681"
},
"name" : "ExposureVariable: pht013094.v1.p1 Source_Type",
"description" : "Source of sample - datatype string",
"isExample" : true,
"profile" : [
"http://hl7.org/fhir/uv/ebm/StructureDefinition/variable-definition"
]
},
{
"extension" : [
{
"url" : "http://hl7.org/fhir/tools/StructureDefinition/resource-information",
"valueString" : "Group"
}
],
"reference" : {
"reference" : "Group/236948"
},
"name" : "GLP-1 RA Group in Adults with type 2 diabetes",
"description" : "Glucagon-Like Peptide-1 (GLP-1) receptor agonists",
"isExample" : true,
"profile" : [
"http://hl7.org/fhir/uv/ebm/StructureDefinition/comparator-group"
]
},
{
"extension" : [
{
"url" : "http://hl7.org/fhir/tools/StructureDefinition/resource-information",
"valueString" : "StructureDefinition:resource"
}
],
"reference" : {
"reference" : "StructureDefinition/group-assignment"
},
"name" : "GroupAssignment",
"description" : "Profile of EvidenceVariable for Evidence Based Medicine IG. The GroupAssignment Profile is used to classify an EvidenceVariable as an exposure managed as a categorical variable. The variable definitions are found in the category element instead of the definition element.",
"isExample" : false
},
{
"extension" : [
{
"url" : "http://hl7.org/fhir/tools/StructureDefinition/resource-information",
"valueString" : "EvidenceVariable"
}
],
"reference" : {
"reference" : "EvidenceVariable/172427"
},
"name" : "GroupAssignment: Bariatric Surgery vs. no bariatric surgery",
"description" : "This example of a GroupAssignment Profile describes a 2-group study (so handling='dichotomous') and lists the 2 study arms in category.name elements. Because the definition of this EvidenceVariable Resource is fully expressed in the handling and category elements, the definition.concept element uses a CodeableConcept for 'Defined in handling and category elements'.",
"isExample" : true,
"profile" : [
"http://hl7.org/fhir/uv/ebm/StructureDefinition/group-assignment"
]
},
{
"extension" : [
{
"url" : "http://hl7.org/fhir/tools/StructureDefinition/resource-information",
"valueString" : "EvidenceVariable"
}
],
"reference" : {
"reference" : "EvidenceVariable/183637"
},
"name" : "GroupAssignment: ExposureDefinition: Bariatric Surgery (RYGB, VSG, LAGB, BPD) vs. ComparatorDefinition: NOT Bariatric Surgery (RYGB, VSG, LAGB, BPD)",
"description" : "This EvidenceVariable Resource (GroupAssignment Profile) describes a 2-group study (so handling='dichotomous') and lists the 2 study arms in category.name elements. Because the definition of this EvidenceVariable Resource is fully expressed in the handling and category elements, the definition.concept element uses a CodeableConcept for 'Defined in handling and category elements'.",
"isExample" : true,
"profile" : [
"http://hl7.org/fhir/uv/ebm/StructureDefinition/group-assignment"
]
},
{
"extension" : [
{
"url" : "http://hl7.org/fhir/tools/StructureDefinition/resource-information",
"valueString" : "EvidenceVariable"
}
],
"reference" : {
"reference" : "EvidenceVariable/239273"
},
"name" : "GroupAssignment: ExposureGroup: JAMA 2018 Norwegian cohort study Surgery cohort vs. ComparatorGroup: JAMA 2018 Norwegian cohort study Control cohort",
"description" : "This EvidenceVariable Resource (GroupAssignment Profile) describes a 2-group study (so handling='dichotomous') and lists the 2 study arms in category.name elements. Because the definition of this EvidenceVariable Resource is fully expressed in the handling and category elements, the definition.concept element uses a CodeableConcept for 'Defined in handling and category elements'.",
"isExample" : true,
"profile" : [
"http://hl7.org/fhir/uv/ebm/StructureDefinition/group-assignment"
]
},
{
"extension" : [
{
"url" : "http://hl7.org/fhir/tools/StructureDefinition/resource-information",
"valueString" : "EvidenceVariable"
}
],
"reference" : {
"reference" : "EvidenceVariable/179689"
},
"name" : "GroupAssignment: high dose xanomeline vs. low dose xanomeline vs. placebo",
"description" : "This example of a GroupAssignment Profile describes a 3-arm trial (so handling='polychotomous') and lists the 3 trial arms in category.name elements. Because the definition of this EvidenceVariable Resource is fully expressed in the handling and category elements, the definition.concept element uses a CodeableConcept for 'Defined in handling and category elements'.",
"isExample" : true,
"profile" : [
"http://hl7.org/fhir/uv/ebm/StructureDefinition/group-assignment"
]
},
{
"extension" : [
{
"url" : "http://hl7.org/fhir/tools/StructureDefinition/resource-information",
"valueString" : "EvidenceVariable"
}
],
"reference" : {
"reference" : "EvidenceVariable/172479"
},
"name" : "GroupAssignment: Roux-en-Y gastric bypass or Biliopancreatic Diversion vs. medical treatment",
"description" : "This example of a GroupAssignment Profile describes a 2-group study (so handling='dichotomous') and lists the 2 study arms in category.name elements. Because the definition of this EvidenceVariable Resource is fully expressed in the handling and category elements, the definition.concept element uses a CodeableConcept for 'Defined in handling and category elements'.",
"isExample" : true,
"profile" : [
"http://hl7.org/fhir/uv/ebm/StructureDefinition/group-assignment"
]
},
{
"extension" : [
{
"url" : "http://hl7.org/fhir/tools/StructureDefinition/resource-information",
"valueString" : "EvidenceVariable"
}
],
"reference" : {
"reference" : "EvidenceVariable/172481"
},
"name" : "GroupAssignment: Roux-en-Y gastric bypass surgery vs. Lifestyle-intensive medical management intervention alone",
"description" : "This example of a GroupAssignment Profile describes a 2-group study (so handling='dichotomous') and lists the 2 study arms in category.name elements. Because the definition of this EvidenceVariable Resource is fully expressed in the handling and category elements, the definition.concept element uses a CodeableConcept for 'Defined in handling and category elements'.",
"isExample" : true,
"profile" : [
"http://hl7.org/fhir/uv/ebm/StructureDefinition/group-assignment"
]
},
{
"extension" : [
{
"url" : "http://hl7.org/fhir/tools/StructureDefinition/resource-information",
"valueString" : "EvidenceVariable"
}
],
"reference" : {
"reference" : "EvidenceVariable/172478"
},
"name" : "GroupAssignment: Roux-en-Y gastric bypass vs. medical treatment",
"description" : "This example of a GroupAssignment Profile describes a 2-group study (so handling='dichotomous') and lists the 2 study arms in category.name elements. Because the definition of this EvidenceVariable Resource is fully expressed in the handling and category elements, the definition.concept element uses a CodeableConcept for 'Defined in handling and category elements'.",
"isExample" : true,
"profile" : [
"http://hl7.org/fhir/uv/ebm/StructureDefinition/group-assignment"
]
},
{
"extension" : [
{
"url" : "http://hl7.org/fhir/tools/StructureDefinition/resource-information",
"valueString" : "EvidenceVariable"
}
],
"reference" : {
"reference" : "EvidenceVariable/236950"
},
"name" : "GroupAssignment: SGLT2 inhibitors vs. GLP-1 RA",
"description" : "This EvidenceVariable Resource is referenced in an example for the EBMonFHIR Implementation Guide.",
"isExample" : true,
"profile" : [
"http://hl7.org/fhir/uv/ebm/StructureDefinition/group-assignment"
]
},
{
"extension" : [
{
"url" : "http://hl7.org/fhir/tools/StructureDefinition/resource-information",
"valueString" : "EvidenceVariable"
}
],
"reference" : {
"reference" : "EvidenceVariable/179784"
},
"name" : "GroupAssignment: Therapeutic-dose anticoagulation with heparin vs. Usual-care pharmacologic thromboprophylaxis",
"description" : "Therapeutic-dose anticoagulation with heparin vs. Usual-care pharmacologic thromboprophylaxis in multi-platform RCT of anticoagulation for non-critically ill patients with COVID-19",
"isExample" : true,
"profile" : [
"http://hl7.org/fhir/uv/ebm/StructureDefinition/group-assignment"
]
},
{
"extension" : [
{
"url" : "http://hl7.org/fhir/tools/StructureDefinition/resource-information",
"valueString" : "StructureDefinition:resource"
}
],
"reference" : {
"reference" : "StructureDefinition/group-r6"
},
"name" : "GroupR6",
"description" : "Profile of Group for Evidence Based Medicine IG. The GroupR6 Profile is used to add extensions to Group.",
"isExample" : false
},
{
"extension" : [
{
"url" : "http://hl7.org/fhir/tools/StructureDefinition/resource-information",
"valueString" : "StructureDefinition:resource"
}
],
"reference" : {
"reference" : "StructureDefinition/guideline"
},
"name" : "Guideline",
"description" : "Profile of Composition for Evidence Based Medicine IG. The Guideline Profile is used for the composition of a clinical practice guideline and may be tightly related to use of Recommendation Profile of Composition for related content.",
"isExample" : false
},
{
"extension" : [
{
"url" : "http://hl7.org/fhir/tools/StructureDefinition/resource-information",
"valueString" : "Composition"
}
],
"reference" : {
"reference" : "Composition/179465"
},
"name" : "Guideline: ADA 2021 Standards of Medical Care 8. Obesity Management for the Treatment of Type 2 Diabetes",
"description" : "Example of Guideline Profile of Composition Resource",
"isExample" : true,
"profile" : [
"http://hl7.org/fhir/uv/ebm/StructureDefinition/guideline"
]
},
{
"extension" : [
{
"url" : "http://hl7.org/fhir/tools/StructureDefinition/resource-information",
"valueString" : "Group"
}
],
"reference" : {
"reference" : "Group/236769"
},
"name" : "InterventionDefinition: Sodium-Glucose Transport Protein 2 (SGLT2) inhibitors",
"description" : "This Group Resource is referenced in an example for the EBMonFHIR Implementation Guide.",
"isExample" : true,
"profile" : [
"http://hl7.org/fhir/uv/ebm/StructureDefinition/exposure-definition"
]
},
{
"extension" : [
{
"url" : "http://hl7.org/fhir/tools/StructureDefinition/resource-information",
"valueString" : "StructureDefinition:resource"
}
],
"reference" : {
"reference" : "StructureDefinition/intervention-only-evidence"
},
"name" : "InterventionOnlyEvidence",
"description" : "Profile of Evidence for Evidence Based Medicine IG. The InterventionOnlyEvidence Profile is used for evidence with a measured variable that is considered the outcome of an exposure or intervention. The InterventionOnlyEvidence describes the evidence for the intervention group.",
"isExample" : false
},
{
"extension" : [
{
"url" : "http://hl7.org/fhir/tools/StructureDefinition/resource-information",
"valueString" : "Evidence"
}
],
"reference" : {
"reference" : "Evidence/104398"
},
"name" : "InterventionOnlyEvidence: Additional GI surgical procedure with bariatric surgery (Intervention Group) in JAMA 2018 Norwegian cohort study",
"description" : "Risk of additional GI surgical procedure in intervention group was 31.3%. 292 out of 932 observed with percentage of: 31.3%",
"isExample" : true,
"profile" : [
"http://hl7.org/fhir/uv/ebm/StructureDefinition/intervention-only-evidence"
]
},
{
"extension" : [
{
"url" : "http://hl7.org/fhir/tools/StructureDefinition/resource-information",
"valueString" : "Evidence"
}
],
"reference" : {
"reference" : "Evidence/104400"
},
"name" : "InterventionOnlyEvidence: New onset depression with bariatric surgery (Intervention Group) in JAMA 2018 Norwegian cohort study",
"description" : "Risk of New onset depression in intervention group was 8.9%.",
"isExample" : true,
"profile" : [
"http://hl7.org/fhir/uv/ebm/StructureDefinition/intervention-only-evidence"
]
},
{
"extension" : [
{
"url" : "http://hl7.org/fhir/tools/StructureDefinition/resource-information",
"valueString" : "Evidence"
}
],
"reference" : {
"reference" : "Evidence/104401"
},
"name" : "InterventionOnlyEvidence: Remission of diabetes with bariatric surgery (Intervention Group) in JAMA 2018 Norwegian cohort study",
"description" : "Risk of Remission of diabetes in intervention group was 57.5%.",
"isExample" : true,
"profile" : [
"http://hl7.org/fhir/uv/ebm/StructureDefinition/intervention-only-evidence"
]
},
{
"extension" : [
{
"url" : "http://hl7.org/fhir/tools/StructureDefinition/resource-information",
"valueString" : "Evidence"
}
],
"reference" : {
"reference" : "Evidence/104402"
},
"name" : "InterventionOnlyEvidence: Treatment with opioids with bariatric surgery (Intervention Group) in JAMA 2018 Norwegian cohort study",
"description" : "Risk of Treatment with opioids in intervention group was 19.4%.",
"isExample" : true,
"profile" : [
"http://hl7.org/fhir/uv/ebm/StructureDefinition/intervention-only-evidence"
]
},
{
"extension" : [
{
"url" : "http://hl7.org/fhir/tools/StructureDefinition/resource-information",
"valueString" : "EvidenceVariable"
}
],
"reference" : {
"reference" : "EvidenceVariable/159673"
},
"name" : "Investigator",
"description" : "For all ANOVA and ANCOVA models, data collected from investigators who enrolled fewer than 3 patients in any one treatment group will be combined prior to analysis. If this combination still results in a treatment group having fewer than 3 patients in any one treatment group, then this group of patients will be combined with the next fewest enrolling investigator. In the event that there is a tie for fewest-enrolling investigator, one of these will be chosen at random by a random-number generator.",
"isExample" : true
},
{
"extension" : [
{
"url" : "http://hl7.org/fhir/tools/StructureDefinition/resource-information",
"valueString" : "EvidenceVariable"
}
],
"reference" : {
"reference" : "EvidenceVariable/156673"
},
"name" : "Investigator-by-treatment interaction for ADAS-Cog(11) ANCOVA",
"description" : "The Investigator-by-treatment interaction variable is polychotomous (a category for each investigator) but the investigator names are unknown at the time of trial planning so the category element is not used to define the categories.",
"isExample" : true
},
{
"extension" : [
{
"url" : "http://hl7.org/fhir/tools/StructureDefinition/resource-information",
"valueString" : "ActivityDefinition"
}
],
"reference" : {
"reference" : "ActivityDefinition/213"
},
"name" : "IV remdesivir 200 mg then 100 mg/day for 9 days",
"description" : "This example uses the Dosage datatype to represent dosing for IV remdesivir.",
"isExample" : true,
"profile" : [
"http://hl7.org/fhir/uv/ebm/StructureDefinition/recommendation-action"
]
},
{
"extension" : [
{
"url" : "http://hl7.org/fhir/tools/StructureDefinition/resource-information",
"valueString" : "ArtifactAssessment"
}
],
"reference" : {
"reference" : "ArtifactAssessment/179698"
},
"name" : "Joanne Dehnbostel's Adaptation Report of Recommendation: ADA Obesity Management Recommendation 8.16",
"description" : "This example of an Adaptation Profile shows the specific content that was changed when adapting one Recommendation Profile instance to create a new Recommendation Profile instance, serving a role of 'track changes' for structured data.",
"isExample" : true,
"profile" : [
"http://hl7.org/fhir/uv/ebm/StructureDefinition/adaptation"
]
},
{
"extension" : [
{
"url" : "http://hl7.org/fhir/tools/StructureDefinition/resource-information",
"valueString" : "StructureDefinition:resource"
}
],
"reference" : {
"reference" : "StructureDefinition/journal-article-citation"
},
"name" : "JournalArticleCitation",
"description" : "Profile of Citation for Evidence Based Medicine IG. The JournalArticleCitation Profile is used for citations of an article published in a periodical venue classified as a journal.",
"isExample" : false
},
{
"extension" : [
{
"url" : "http://hl7.org/fhir/tools/StructureDefinition/resource-information",
"valueString" : "Citation"
}
],
"reference" : {
"reference" : "Citation/32137"
},
"name" : "JournalArticleCitation: ADA 2021 Standards of Medical Care 8. Obesity Management for the Treatment of Type 2 Diabetes",
"description" : "This Citation Resource is referenced in an example for the EBMonFHIR Implementation Guide.",
"isExample" : true,
"profile" : [
"http://hl7.org/fhir/uv/ebm/StructureDefinition/journal-article-citation"
]
},
{
"extension" : [
{
"url" : "http://hl7.org/fhir/tools/StructureDefinition/resource-information",
"valueString" : "Citation"
}
],
"reference" : {
"reference" : "Citation/104116"
},
"name" : "JournalArticleCitation: Association of Bariatric Surgery with Complications and Comorbidities JAMA 2018 Norwegian Cohort",
"description" : "This Citation Resource is referenced in an example for the EBMonFHIR Implementation Guide.",
"isExample" : true,
"profile" : [
"http://hl7.org/fhir/uv/ebm/StructureDefinition/journal-article-citation"
]
},
{
"extension" : [
{
"url" : "http://hl7.org/fhir/tools/StructureDefinition/resource-information",
"valueString" : "ArtifactAssessment"
}
],
"reference" : {
"reference" : "ArtifactAssessment/179469"
},
"name" : "Justification for Recommendation: ADA Obesity Management Recommendation 8.16",
"description" : "An example using the ArtifactAssessment Resource for representation of the many judgments and concepts used to justify a recommendation.",
"isExample" : true,
"profile" : [
"http://hl7.org/fhir/uv/ebm/StructureDefinition/recommendation-justification"
]
},
{
"extension" : [
{
"url" : "http://hl7.org/fhir/tools/StructureDefinition/resource-information",
"valueString" : "ArtifactAssessment"
}
],
"reference" : {
"reference" : "ArtifactAssessment/179515"
},
"name" : "Justification for Recommendation: ADA Obesity Management Recommendation 8.17",
"description" : "An example using the ArtifactAssessment Resource for representation of the many judgments and concepts used to justify a recommendation.",
"isExample" : true,
"profile" : [
"http://hl7.org/fhir/uv/ebm/StructureDefinition/recommendation-justification"
]
},
{
"extension" : [
{
"url" : "http://hl7.org/fhir/tools/StructureDefinition/resource-information",
"valueString" : "Group"
}
],
"reference" : {
"reference" : "Group/267506"
},
"name" : "M11 IGBJ Protocol Example Eligibility Criteria",
"description" : "**Inclusion Criteria** \nPatients are eligible for inclusion in the study only if they meet all of the following criteria at screening and/or enrollment: \n1.\tMeet either T1DM-specific eligibility criteria or T2DM-specific eligibility criteria\n.a.\tT1DM-specific criteria\n..i.\tDiagnosis of T1DM based on the World Health Organization (WHO) diagnostic criteria\n..ii.\thave been on the following daily insulin therapy for at least 1 year \n...1)\tmultiple daily injection of long-acting insulin analog (either insulin glargine [U-100 or U-300] or insulin degludec [U-100]) and rapid-acting insulin analog (insulin lispro, insulin aspart, or insulin glulisine), or \n...2)\tcontinuous subcutaneous insulin infusion (CSII) \n..iii.\tare between 18 and 64 years old at the time of informed consent\n..iv.\thave a body mass index of 18.5 to 30.0 kg/m2 at the time of screening \n.b.\tT2DM-specific criteria\n..i.\tDiagnosis of T2DM based on the World Health Organization (WHO) diagnostic criteria\n..ii.\thave received the following daily insulin therapy with or without oral anti-hyperglycemic medications (OAMs) for at least 1 year \n...1)\tinsulin: long-acting insulin analog (either insulin glargine [U-100 or U-300] or insulin degludec [U-100]) alone, or in combination with rapid-acting insulin analog (insulin lispro, insulin aspart, or insulin glulisine) or CSII \n...2)\tOAM: up to 3 of the following OAMs in accordance with local regulations: metformin, dipeptidyl peptidase-4 inhibitor, sodium glucose cotransporter 2 inhibitor, sulfonylurea (should not be more than half of maximum approved doses), glinides, alpha-glucosidase inhibitor, or thiazolidine \n..iii.\tare between 20 and 70 years old at the time of informed consent \n..iv.\thave a body mass index of 18.5 to 35.0 kg/m2 at the time of screening \n2.\thave a hemoglobin A1c value ≤10% at the time of screening \n3.\tagree to use an effective method of contraception, defined by study protocol\n4.\thave clinical laboratory test results within normal reference range (except for glycemic parameters) for the population or investigative site, or results with acceptable deviations that are judged to be not clinically significant by the investigator \n5.\thave venous access sufficient to allow for blood sampling and administration of insulin for IV administration as per the protocol \n6.\tare reliable and willing to make themselves available for the duration of the study and are willing to follow study procedures \n7.\tare able and willing to give signed informed consent.\n\n**Exclusion Criteria** \nPatients will be excluded from study enrollment if they meet any of the following criteria at screening and/or enrollment: \n1.\tare investigative site personnel directly affiliated with this study and their immediate families. Immediate family is defined as a spouse, biological or legal guardian, child, or sibling \n2.\tare Lilly employees \n3.\tare currently enrolled in a clinical trial involving an investigational product or any other type of medical research judged not to be scientifically or medically compatible with this study \n4.\thave participated, within the last 4 months, in a clinical trial involving an investigational product. If the previous investigational product has a long half-life, 4 months or 5 half-lives (whichever is longer) should have passed from the last dose of investigational product \n5.\thave previously completed or withdrawn from this study or any other study investigating LY900018, and have previously received LY900018 \n6.\thave known allergies or sensitivity to LY900018, glucagon, related compounds, or any components of the formulation, or history of significant atopy \n7.\thave an abnormality in the 12-lead ECG that, in the opinion of the investigator, increases the risks associated with participating in the study\n8.\tany significant changes in insulin regimen and/or unstable blood glucose control within the past 3 months prior to screening as assessed by the investigator \n9.\thave received a total daily dose of insulin >1.2 U/kg at the time of screening \n10.\thave poorly controlled hypertension (ie, supine systolic BP >165 mm Hg or supine diastolic BP >95 mm Hg) at screening, or a change in antihypertensive medications within 30 days prior to screening \n11.\thave a history of pheochromocytoma (ie, adrenal gland tumor) or insulinoma \n12.\thave a history of an episode of severe hypoglycemia (as defined by an episode that required third party assistance for treatment) in the 1 month prior to screening or have a history of loss of consciousness within the last 2 years induced other than by hypoglycemia \n13.\thave a history of epilepsy or seizure disorder \n14.\thave a history or presence of cardiovascular, respiratory, hepatic, renal, gastrointestinal, endocrine (apart from T1DM or T2DM), hematological, or neurological disorders capable of significantly altering the absorption, metabolism, or elimination of drugs; of constituting a risk when taking the investigational product; or of interfering with the interpretation of data \n15.\thave known or ongoing psychiatric disorders that, in the opinion of the investigator, may preclude the patient from following and completing the protocol \n16.\tregularly use known drugs of abuse and/or show positive findings on urinary drug screening \n17.\tshow evidence of human immunodeficiency virus (HIV) infection and/or positive HIV antibodies and/or antigen \n18.\tshow evidence of hepatitis C and/or positive hepatitis C antibody\n19.\t show evidence of hepatitis B and/or positive hepatitis B surface antigen \n20.\tshow evidence of syphilis and/or are positive for syphilis test \n21.\tare women who are lactating \n22.\tuse of daily systemic beta-blocker, indomethacin, warfarin, anticholinergic drugs \n23.\thave donated 400 mL or more blood in the last 12 weeks (males) or in the last 16 weeks (females), or any blood donation (including apheresis) within the last 4 weeks, or total volume of blood donation within 12 months is 1200 mL (males)/800 mL (females) or more at screening\n24.\thave an average weekly alcohol intake that exceeds 21 units per week (males up to age 65) and 14 units per week (males over 65 and females), or are unwilling to stop alcohol consumption from Day -2 to discharge from CRU in each period (1 unit = 12 oz or 360 mL of beer; 5 oz or 150 mL of wine; 1.5 oz or 45 mL of distilled spirits) \n25.\tin the opinion of the investigator or sponsor, are unsuitable for inclusion in the study \n26.\thave pre-proliferative and proliferative retinopathy or maculopathy requiring treatment or not clinically stable in the last 6 months, or patients with active changes in subjective eye symptoms as determined by the investigator if an eye exam has not been performed in the last 6 months. Note: If an eye examination has been performed no more than 6 months before screening, it will not have to be repeated; however, the investigator will need to confirm via interview that there is no change in subjective symptoms.",
"isExample" : true,
"profile" : [
"http://hl7.org/fhir/uv/ebm/StructureDefinition/study-eligibility-criteria"
]
},
{
"extension" : [
{
"url" : "http://hl7.org/fhir/tools/StructureDefinition/resource-information",
"valueString" : "Composition"
}
],
"reference" : {
"reference" : "Composition/256358"
},
"name" : "M11 IGBJ Protocol Example for EBMonFHIR IG",
"description" : "This is an example of how an M11 Report can be supported in FHIR Profiles, and is actively revised in the Vulcan UDP meetings and Connectathons.",
"isExample" : true,
"profile" : [
"http://hl7.org/fhir/uv/ebm/StructureDefinition/m11-report"
]
},
{
"extension" : [
{
"url" : "http://hl7.org/fhir/tools/StructureDefinition/resource-information",
"valueString" : "Composition"
}
],
"reference" : {
"reference" : "Composition/239266"
},
"name" : "M11 Report Template Instructions",
"description" : "This M11Report Profile of Composition includes the instructions in each section.text.div element for creating an M11Report instance.",
"isExample" : true,
"profile" : [
"http://hl7.org/fhir/uv/ebm/StructureDefinition/m11-report"
]
},
{
"extension" : [
{
"url" : "http://hl7.org/fhir/tools/StructureDefinition/resource-information",
"valueString" : "StructureDefinition:resource"
}
],
"reference" : {
"reference" : "StructureDefinition/m11-report"
},
"name" : "M11Report",
"description" : "Profile of Composition for Evidence Based Medicine IG. The M11Report Profile is used for the International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use (ICH) Clinical Electronic Structured Harmonised Protocol (CeSHarP) M11 Technical Specification.",
"isExample" : false
},
{
"extension" : [
{
"url" : "http://hl7.org/fhir/tools/StructureDefinition/resource-information",
"valueString" : "StructureDefinition:resource"
}
],
"reference" : {
"reference" : "StructureDefinition/m11-research-study"
},
"name" : "M11ResearchStudy",
"description" : "Profile of ResearchStudy for Evidence Based Medicine IG. The M11ResearchStudy Profile is used to add extensions for use with an M11 Report.",
"isExample" : false
},
{
"extension" : [
{
"url" : "http://hl7.org/fhir/tools/StructureDefinition/resource-information",
"valueString" : "Evidence"
}
],
"reference" : {
"reference" : "Evidence/236955"
},
"name" : "MAGIC-derived ComparatorOnlyEvidence: All-cause mortality in GLP-1 RA Group in Adults with type 2 diabetes",
"description" : "This Evidence Resource is referenced in an example for the EBMonFHIR Implementation Guide.",
"isExample" : true,
"profile" : [
"http://hl7.org/fhir/uv/ebm/StructureDefinition/comparator-only-evidence"
]
},
{
"extension" : [
{
"url" : "http://hl7.org/fhir/tools/StructureDefinition/resource-information",
"valueString" : "Evidence"
}
],
"reference" : {
"reference" : "Evidence/236988"
},
"name" : "MAGIC-derived ComparatorOnlyEvidence: Body weight in GLP-1 RA Group in Adults with type 2 diabetes",
"description" : "This Evidence Resource is referenced in an example for the EBMonFHIR Implementation Guide.",
"isExample" : true,
"profile" : [
"http://hl7.org/fhir/uv/ebm/StructureDefinition/comparator-only-evidence"
]
},
{
"extension" : [
{
"url" : "http://hl7.org/fhir/tools/StructureDefinition/resource-information",
"valueString" : "Evidence"
}
],
"reference" : {
"reference" : "Evidence/236958"
},
"name" : "MAGIC-derived ComparatorOnlyEvidence: Cardiovascular mortality in GLP-1 RA Group in Adults with type 2 diabetes",
"description" : "This Evidence Resource is referenced in an example for the EBMonFHIR Implementation Guide.",
"isExample" : true,
"profile" : [
"http://hl7.org/fhir/uv/ebm/StructureDefinition/comparator-only-evidence"
]
},
{
"extension" : [
{
"url" : "http://hl7.org/fhir/tools/StructureDefinition/resource-information",
"valueString" : "Evidence"
}
],
"reference" : {
"reference" : "Evidence/236973"
},
"name" : "MAGIC-derived ComparatorOnlyEvidence: Diabetic ketoacidosis in GLP-1 RA Group in Adults with type 2 diabetes",
"description" : "This Evidence Resource is referenced in an example for the EBMonFHIR Implementation Guide.",
"isExample" : true,
"profile" : [
"http://hl7.org/fhir/uv/ebm/StructureDefinition/comparator-only-evidence"
]
},
{
"extension" : [
{
"url" : "http://hl7.org/fhir/tools/StructureDefinition/resource-information",
"valueString" : "Evidence"
}
],
"reference" : {
"reference" : "Evidence/236967"
},
"name" : "MAGIC-derived ComparatorOnlyEvidence: End-stage kidney disease in GLP-1 RA Group in Adults with type 2 diabetes",
"description" : "This Evidence Resource is referenced in an example for the EBMonFHIR Implementation Guide.",
"isExample" : true,
"profile" : [
"http://hl7.org/fhir/uv/ebm/StructureDefinition/comparator-only-evidence"
]
},
{
"extension" : [
{
"url" : "http://hl7.org/fhir/tools/StructureDefinition/resource-information",
"valueString" : "Evidence"
}
],
"reference" : {
"reference" : "Evidence/236979"
},
"name" : "MAGIC-derived ComparatorOnlyEvidence: Genital infection in GLP-1 RA Group in Adults with type 2 diabetes",
"description" : "This Evidence Resource is referenced in an example for the EBMonFHIR Implementation Guide.",
"isExample" : true,
"profile" : [
"http://hl7.org/fhir/uv/ebm/StructureDefinition/comparator-only-evidence"
]
},
{
"extension" : [
{
"url" : "http://hl7.org/fhir/tools/StructureDefinition/resource-information",
"valueString" : "Evidence"
}
],
"reference" : {
"reference" : "Evidence/236985"
},
"name" : "MAGIC-derived ComparatorOnlyEvidence: Health-related quality of life in GLP-1 RA Group in Adults with type 2 diabetes",
"description" : "This Evidence Resource is referenced in an example for the EBMonFHIR Implementation Guide.",
"isExample" : true,
"profile" : [
"http://hl7.org/fhir/uv/ebm/StructureDefinition/comparator-only-evidence"
]
},
{
"extension" : [
{
"url" : "http://hl7.org/fhir/tools/StructureDefinition/resource-information",
"valueString" : "Evidence"
}
],
"reference" : {
"reference" : "Evidence/236970"
},
"name" : "MAGIC-derived ComparatorOnlyEvidence: Heart failure in GLP-1 RA Group in Adults with type 2 diabetes",
"description" : "This Evidence Resource is referenced in an example for the EBMonFHIR Implementation Guide.",
"isExample" : true,
"profile" : [
"http://hl7.org/fhir/uv/ebm/StructureDefinition/comparator-only-evidence"
]
},
{
"extension" : [
{
"url" : "http://hl7.org/fhir/tools/StructureDefinition/resource-information",
"valueString" : "Evidence"
}
],
"reference" : {
"reference" : "Evidence/236961"
},
"name" : "MAGIC-derived ComparatorOnlyEvidence: Nonfatal myocardial infarction in GLP-1 RA Group in Adults with type 2 diabetes",
"description" : "This Evidence Resource is referenced in an example for the EBMonFHIR Implementation Guide.",
"isExample" : true,
"profile" : [
"http://hl7.org/fhir/uv/ebm/StructureDefinition/comparator-only-evidence"
]
},
{
"extension" : [
{
"url" : "http://hl7.org/fhir/tools/StructureDefinition/resource-information",
"valueString" : "Evidence"
}
],
"reference" : {
"reference" : "Evidence/236964"
},
"name" : "MAGIC-derived ComparatorOnlyEvidence: Nonfatal stroke in GLP-1 RA Group in Adults with type 2 diabetes",
"description" : "This Evidence Resource is referenced in an example for the EBMonFHIR Implementation Guide.",
"isExample" : true,
"profile" : [
"http://hl7.org/fhir/uv/ebm/StructureDefinition/comparator-only-evidence"
]
},
{
"extension" : [
{
"url" : "http://hl7.org/fhir/tools/StructureDefinition/resource-information",
"valueString" : "Evidence"
}
],
"reference" : {
"reference" : "Evidence/236976"
},
"name" : "MAGIC-derived ComparatorOnlyEvidence: Serious hyperglycaemia in GLP-1 RA Group in Adults with type 2 diabetes",
"description" : "This Evidence Resource is referenced in an example for the EBMonFHIR Implementation Guide.",
"isExample" : true,
"profile" : [
"http://hl7.org/fhir/uv/ebm/StructureDefinition/comparator-only-evidence"
]
},
{
"extension" : [
{
"url" : "http://hl7.org/fhir/tools/StructureDefinition/resource-information",
"valueString" : "Evidence"
}
],
"reference" : {
"reference" : "Evidence/236982"
},
"name" : "MAGIC-derived ComparatorOnlyEvidence: Severe gastrointestinal events in GLP-1 RA Group in Adults with type 2 diabetes",
"description" : "This Evidence Resource is referenced in an example for the EBMonFHIR Implementation Guide.",
"isExample" : true,
"profile" : [
"http://hl7.org/fhir/uv/ebm/StructureDefinition/comparator-only-evidence"
]
},
{
"extension" : [
{
"url" : "http://hl7.org/fhir/tools/StructureDefinition/resource-information",
"valueString" : "Evidence"
}
],
"reference" : {
"reference" : "Evidence/236954"
},
"name" : "MAGIC-derived Evidence: All-cause mortality with SGLT2 inhibitors vs. GLP-1 RA in Adults with type 2 diabetes",
"description" : "This Evidence Resource is referenced in an example for the EBMonFHIR Implementation Guide.",
"isExample" : true,
"profile" : [
"http://hl7.org/fhir/uv/ebm/StructureDefinition/comparative-evidence"
]
},
{
"extension" : [
{
"url" : "http://hl7.org/fhir/tools/StructureDefinition/resource-information",
"valueString" : "Evidence"
}
],
"reference" : {
"reference" : "Evidence/236987"
},
"name" : "MAGIC-derived Evidence: Body weight with SGLT2 inhibitors vs. GLP-1 RA in Adults with type 2 diabetes",
"description" : "This Evidence Resource is referenced in an example for the EBMonFHIR Implementation Guide.",
"isExample" : true,
"profile" : [
"http://hl7.org/fhir/uv/ebm/StructureDefinition/comparative-evidence"
]
},
{
"extension" : [
{
"url" : "http://hl7.org/fhir/tools/StructureDefinition/resource-information",
"valueString" : "Evidence"
}
],
"reference" : {
"reference" : "Evidence/236957"
},
"name" : "MAGIC-derived Evidence: Cardiovascular mortality with SGLT2 inhibitors vs. GLP-1 RA in Adults with type 2 diabetes",
"description" : "This Evidence Resource is referenced in an example for the EBMonFHIR Implementation Guide.",
"isExample" : true,
"profile" : [
"http://hl7.org/fhir/uv/ebm/StructureDefinition/comparative-evidence"
]
},
{
"extension" : [
{
"url" : "http://hl7.org/fhir/tools/StructureDefinition/resource-information",
"valueString" : "Evidence"
}
],
"reference" : {
"reference" : "Evidence/236972"
},
"name" : "MAGIC-derived Evidence: Diabetic ketoacidosis with SGLT2 inhibitors vs. GLP-1 RA in Adults with type 2 diabetes",
"description" : "This Evidence Resource is referenced in an example for the EBMonFHIR Implementation Guide.",
"isExample" : true,
"profile" : [
"http://hl7.org/fhir/uv/ebm/StructureDefinition/comparative-evidence"
]
},
{
"extension" : [
{
"url" : "http://hl7.org/fhir/tools/StructureDefinition/resource-information",
"valueString" : "Evidence"
}
],
"reference" : {
"reference" : "Evidence/236966"
},
"name" : "MAGIC-derived Evidence: End-stage kidney disease with SGLT2 inhibitors vs. GLP-1 RA in Adults with type 2 diabetes",
"description" : "This Evidence Resource is referenced in an example for the EBMonFHIR Implementation Guide.",
"isExample" : true,
"profile" : [
"http://hl7.org/fhir/uv/ebm/StructureDefinition/comparative-evidence"
]
},
{
"extension" : [
{
"url" : "http://hl7.org/fhir/tools/StructureDefinition/resource-information",
"valueString" : "Evidence"
}
],
"reference" : {
"reference" : "Evidence/236978"
},
"name" : "MAGIC-derived Evidence: Genital infection with SGLT2 inhibitors vs. GLP-1 RA in Adults with type 2 diabetes",
"description" : "This Evidence Resource is referenced in an example for the EBMonFHIR Implementation Guide.",
"isExample" : true,
"profile" : [
"http://hl7.org/fhir/uv/ebm/StructureDefinition/comparative-evidence"
]
},
{
"extension" : [
{
"url" : "http://hl7.org/fhir/tools/StructureDefinition/resource-information",
"valueString" : "Evidence"
}
],
"reference" : {
"reference" : "Evidence/236984"
},
"name" : "MAGIC-derived Evidence: Health-related quality of life with SGLT2 inhibitors vs. GLP-1 RA in Adults with type 2 diabetes",
"description" : "This Evidence Resource is referenced in an example for the EBMonFHIR Implementation Guide.",
"isExample" : true,
"profile" : [
"http://hl7.org/fhir/uv/ebm/StructureDefinition/comparative-evidence"
]
},
{
"extension" : [
{
"url" : "http://hl7.org/fhir/tools/StructureDefinition/resource-information",
"valueString" : "Evidence"
}
],
"reference" : {
"reference" : "Evidence/236969"
},
"name" : "MAGIC-derived Evidence: Heart failure with SGLT2 inhibitors vs. GLP-1 RA in Adults with type 2 diabetes",
"description" : "This Evidence Resource is referenced in an example for the EBMonFHIR Implementation Guide.",
"isExample" : true,
"profile" : [
"http://hl7.org/fhir/uv/ebm/StructureDefinition/comparative-evidence"
]
},
{
"extension" : [
{
"url" : "http://hl7.org/fhir/tools/StructureDefinition/resource-information",
"valueString" : "Evidence"
}
],
"reference" : {
"reference" : "Evidence/236960"
},
"name" : "MAGIC-derived Evidence: Nonfatal myocardial infarction with SGLT2 inhibitors vs. GLP-1 RA in Adults with type 2 diabetes",
"description" : "This Evidence Resource is referenced in an example for the EBMonFHIR Implementation Guide.",
"isExample" : true,
"profile" : [
"http://hl7.org/fhir/uv/ebm/StructureDefinition/comparative-evidence"
]
},
{
"extension" : [
{
"url" : "http://hl7.org/fhir/tools/StructureDefinition/resource-information",
"valueString" : "Evidence"
}
],
"reference" : {
"reference" : "Evidence/236963"
},
"name" : "MAGIC-derived Evidence: Nonfatal stroke with SGLT2 inhibitors vs. GLP-1 RA in Adults with type 2 diabetes",
"description" : "This Evidence Resource is referenced in an example for the EBMonFHIR Implementation Guide.",
"isExample" : true,
"profile" : [
"http://hl7.org/fhir/uv/ebm/StructureDefinition/comparative-evidence"
]
},
{
"extension" : [
{
"url" : "http://hl7.org/fhir/tools/StructureDefinition/resource-information",
"valueString" : "Evidence"
}
],
"reference" : {
"reference" : "Evidence/236975"
},
"name" : "MAGIC-derived Evidence: Serious hyperglycaemia with SGLT2 inhibitors vs. GLP-1 RA in Adults with type 2 diabetes",
"description" : "This Evidence Resource is referenced in an example for the EBMonFHIR Implementation Guide.",
"isExample" : true,
"profile" : [
"http://hl7.org/fhir/uv/ebm/StructureDefinition/comparative-evidence"
]
},
{
"extension" : [
{
"url" : "http://hl7.org/fhir/tools/StructureDefinition/resource-information",
"valueString" : "Evidence"
}
],
"reference" : {
"reference" : "Evidence/236981"
},
"name" : "MAGIC-derived Evidence: Severe gastrointestinal events with SGLT2 inhibitors vs. GLP-1 RA in Adults with type 2 diabetes",
"description" : "This Evidence Resource is referenced in an example for the EBMonFHIR Implementation Guide.",
"isExample" : true,
"profile" : [
"http://hl7.org/fhir/uv/ebm/StructureDefinition/comparative-evidence"
]
},
{
"extension" : [
{
"url" : "http://hl7.org/fhir/tools/StructureDefinition/resource-information",
"valueString" : "Evidence"
}
],
"reference" : {
"reference" : "Evidence/293980"
},
"name" : "MAGIC-derived InterventionOnlyEvidence: All-cause mortality in SGLT2 inhibitors Group in Adults with type 2 diabetes",
"description" : "This Evidence Resource is referenced in an example for the EBMonFHIR Implementation Guide.",
"isExample" : true,
"profile" : [
"http://hl7.org/fhir/uv/ebm/StructureDefinition/intervention-only-evidence"
]
},
{
"extension" : [
{
"url" : "http://hl7.org/fhir/tools/StructureDefinition/resource-information",
"valueString" : "Evidence"
}
],
"reference" : {
"reference" : "Evidence/293991"
},
"name" : "MAGIC-derived InterventionOnlyEvidence: Body weight in SGLT2 inhibitors Group in Adults with type 2 diabetes",
"description" : "This Evidence Resource is referenced in an example for the EBMonFHIR Implementation Guide.",
"isExample" : true,
"profile" : [
"http://hl7.org/fhir/uv/ebm/StructureDefinition/intervention-only-evidence"
]
},
{
"extension" : [
{
"url" : "http://hl7.org/fhir/tools/StructureDefinition/resource-information",
"valueString" : "Evidence"
}
],
"reference" : {
"reference" : "Evidence/293981"
},
"name" : "MAGIC-derived InterventionOnlyEvidence: Cardiovascular mortality in SGLT2 inhibitors Group in Adults with type 2 diabetes",
"description" : "This Evidence Resource is referenced in an example for the EBMonFHIR Implementation Guide.",
"isExample" : true,
"profile" : [
"http://hl7.org/fhir/uv/ebm/StructureDefinition/intervention-only-evidence"
]
},
{
"extension" : [
{
"url" : "http://hl7.org/fhir/tools/StructureDefinition/resource-information",
"valueString" : "Evidence"
}
],
"reference" : {
"reference" : "Evidence/293986"
},
"name" : "MAGIC-derived InterventionOnlyEvidence: Diabetic ketoacidosis in SGLT2 inhibitors Group in Adults with type 2 diabetes",
"description" : "This Evidence Resource is referenced in an example for the EBMonFHIR Implementation Guide.",
"isExample" : true,
"profile" : [
"http://hl7.org/fhir/uv/ebm/StructureDefinition/intervention-only-evidence"
]
},
{
"extension" : [
{
"url" : "http://hl7.org/fhir/tools/StructureDefinition/resource-information",
"valueString" : "Evidence"
}
],
"reference" : {
"reference" : "Evidence/293984"
},
"name" : "MAGIC-derived InterventionOnlyEvidence: End-stage kidney disease in SGLT2 inhibitors Group in Adults with type 2 diabetes",
"description" : "This Evidence Resource is referenced in an example for the EBMonFHIR Implementation Guide.",
"isExample" : true,
"profile" : [
"http://hl7.org/fhir/uv/ebm/StructureDefinition/intervention-only-evidence"
]
},
{
"extension" : [
{
"url" : "http://hl7.org/fhir/tools/StructureDefinition/resource-information",
"valueString" : "Evidence"
}
],
"reference" : {
"reference" : "Evidence/293988"
},
"name" : "MAGIC-derived InterventionOnlyEvidence: Genital infection in SGLT2 inhibitors Group in Adults with type 2 diabetes",
"description" : "This Evidence Resource is referenced in an example for the EBMonFHIR Implementation Guide.",
"isExample" : true,
"profile" : [
"http://hl7.org/fhir/uv/ebm/StructureDefinition/intervention-only-evidence"
]
},
{
"extension" : [
{
"url" : "http://hl7.org/fhir/tools/StructureDefinition/resource-information",
"valueString" : "Evidence"
}
],
"reference" : {
"reference" : "Evidence/293990"
},
"name" : "MAGIC-derived InterventionOnlyEvidence: Health-related quality of life in SGLT2 inhibitors Group in Adults with type 2 diabetes",
"description" : "This Evidence Resource is referenced in an example for the EBMonFHIR Implementation Guide.",
"isExample" : true,
"profile" : [
"http://hl7.org/fhir/uv/ebm/StructureDefinition/intervention-only-evidence"
]
},
{
"extension" : [
{
"url" : "http://hl7.org/fhir/tools/StructureDefinition/resource-information",
"valueString" : "Evidence"
}
],
"reference" : {
"reference" : "Evidence/293985"
},
"name" : "MAGIC-derived InterventionOnlyEvidence: Heart failure in SGLT2 inhibitors Group in Adults with type 2 diabetes",
"description" : "This Evidence Resource is referenced in an example for the EBMonFHIR Implementation Guide.",
"isExample" : true,
"profile" : [
"http://hl7.org/fhir/uv/ebm/StructureDefinition/intervention-only-evidence"
]
},
{
"extension" : [
{
"url" : "http://hl7.org/fhir/tools/StructureDefinition/resource-information",
"valueString" : "Evidence"
}
],
"reference" : {
"reference" : "Evidence/293982"
},
"name" : "MAGIC-derived InterventionOnlyEvidence: Nonfatal myocardial infarction in SGLT2 inhibitors Group in Adults with type 2 diabetes",
"description" : "This Evidence Resource is referenced in an example for the EBMonFHIR Implementation Guide.",
"isExample" : true,
"profile" : [
"http://hl7.org/fhir/uv/ebm/StructureDefinition/intervention-only-evidence"
]
},
{
"extension" : [
{
"url" : "http://hl7.org/fhir/tools/StructureDefinition/resource-information",
"valueString" : "Evidence"
}
],
"reference" : {
"reference" : "Evidence/293983"
},
"name" : "MAGIC-derived InterventionOnlyEvidence: Nonfatal stroke in SGLT2 inhibitors Group in Adults with type 2 diabetes",
"description" : "This Evidence Resource is referenced in an example for the EBMonFHIR Implementation Guide.",
"isExample" : true,
"profile" : [
"http://hl7.org/fhir/uv/ebm/StructureDefinition/intervention-only-evidence"
]
},
{
"extension" : [
{
"url" : "http://hl7.org/fhir/tools/StructureDefinition/resource-information",
"valueString" : "Evidence"
}
],
"reference" : {
"reference" : "Evidence/293987"
},
"name" : "MAGIC-derived InterventionOnlyEvidence: Serious hyperglycaemia in SGLT2 inhibitors Group in Adults with type 2 diabetes",
"description" : "This Evidence Resource is referenced in an example for the EBMonFHIR Implementation Guide.",
"isExample" : true,
"profile" : [
"http://hl7.org/fhir/uv/ebm/StructureDefinition/intervention-only-evidence"
]
},
{
"extension" : [
{
"url" : "http://hl7.org/fhir/tools/StructureDefinition/resource-information",
"valueString" : "Evidence"
}
],
"reference" : {
"reference" : "Evidence/293989"
},
"name" : "MAGIC-derived InterventionOnlyEvidence: Severe gastrointestinal events in SGLT2 inhibitors Group in Adults with type 2 diabetes",
"description" : "This Evidence Resource is referenced in an example for the EBMonFHIR Implementation Guide.",
"isExample" : true,
"profile" : [
"http://hl7.org/fhir/uv/ebm/StructureDefinition/intervention-only-evidence"
]
},
{
"extension" : [
{
"url" : "http://hl7.org/fhir/tools/StructureDefinition/resource-information",
"valueString" : "StructureDefinition:resource"
}
],
"reference" : {
"reference" : "StructureDefinition/metaanalysis-eligibility-criteria"
},
"name" : "MetaanalysisEligibilityCriteria",
"description" : "Profile of Group for Evidence Based Medicine IG. The MetaanalysisEligibilityCriteria Profile is used to describe inclusion and exclusion criteria for a meta-analysis.",
"isExample" : false
},
{
"extension" : [
{
"url" : "http://hl7.org/fhir/tools/StructureDefinition/resource-information",
"valueString" : "Group"
}
],
"reference" : {
"reference" : "Group/175766"
},
"name" : "MetaanalysisEligibilityCriteria: Mean difference in HbA1c effect of bariatric surgery in type 2 diabetes and elevated BMI in 2016 meta-analysis",
"description" : "Study population includes type 2 diabetes and BMI > 25 kg/m2; study design includes randomized assignment; exposure is bariatric surgery vs. no bariatric surgery; outcome measured is mean difference in HbA1c comparing bariatric surgery vs. no bariatric surgery",
"isExample" : true,
"profile" : [
"http://hl7.org/fhir/uv/ebm/StructureDefinition/metaanalysis-eligibility-criteria"
]
},
{
"extension" : [
{
"url" : "http://hl7.org/fhir/tools/StructureDefinition/resource-information",
"valueString" : "StructureDefinition:resource"
}
],
"reference" : {
"reference" : "StructureDefinition/metaanalysis-outcome-definition"
},
"name" : "MetaanalysisOutcomeDefinition",
"description" : "Profile of Group for Evidence Based Medicine IG. The MetaanalysisOutcomeDefinition Profile is used to express the criteria defining an evidence variable in the role of outcome where the population (dataset) is a set of Evidence Resources. Characteristics define the characteristics of the Evidence Resource to be eligible to be used for this outcome.",
"isExample" : false
},
{
"extension" : [
{
"url" : "http://hl7.org/fhir/tools/StructureDefinition/resource-information",
"valueString" : "Group"
}
],
"reference" : {
"reference" : "Group/175765"
},
"name" : "MetaanalysisOutcomeDefinition: Mean difference in HbA1c between Surgery and Medical/Lifestyle groups at end of follow-up",
"description" : "Mean difference in HbA1c between Surgery and Medical/Lifestyle groups at end of follow-up. As a MetaanalysisOutcomeDefinition, the type of object that has the characteristics in the definition is an Evidence Resource.",
"isExample" : true,
"profile" : [
"http://hl7.org/fhir/uv/ebm/StructureDefinition/metaanalysis-outcome-definition"
]
},
{
"extension" : [
{
"url" : "http://hl7.org/fhir/tools/StructureDefinition/resource-information",
"valueString" : "StructureDefinition:resource"
}
],
"reference" : {
"reference" : "StructureDefinition/metaanalysis-study-group"
},
"name" : "MetaanalysisStudyGroup",
"description" : "Profile of Group for Evidence Based Medicine IG. The MetaanalysisStudyGroup Profile is used to represent an enumerated group of participants in a meta-analysis where the participants are Evidence Resources.",
"isExample" : false
},
{
"extension" : [
{
"url" : "http://hl7.org/fhir/tools/StructureDefinition/resource-information",
"valueString" : "Group"
}
],
"reference" : {
"reference" : "Group/179799"
},
"name" : "MetaanalysisStudyGroup: Effect Estimates for Mortality at 14 days from COVID19 Remdesivir vs. Placebo RCTs",
"description" : "Effect Estimates for Mortality at 14 days from COVID19 Remdesivir vs. Placebo RCTs (Biegel 2020 data 35/541 vs. 61/521) (Wang 2020 data 15/153 vs. 7/78) (SOLIDARITY data 219/2743 vs. 219/2708)",
"isExample" : true,
"profile" : [
"http://hl7.org/fhir/uv/ebm/StructureDefinition/metaanalysis-study-group"
]
},
{
"extension" : [
{
"url" : "http://hl7.org/fhir/tools/StructureDefinition/resource-information",
"valueString" : "Group"
}
],
"reference" : {
"reference" : "Group/33395"
},
"name" : "MetaanalysisStudyGroup: Study results included in Mean difference in HbA1c effect of bariatric surgery in 2016 meta-analysis",
"description" : "Study results (Evidence Resources) included in Mean difference in HbA1c effect of bariatric surgery in 2016 meta-analysis",
"isExample" : true,
"profile" : [
"http://hl7.org/fhir/uv/ebm/StructureDefinition/metaanalysis-study-group"
]
},
{
"extension" : [
{
"url" : "http://hl7.org/fhir/tools/StructureDefinition/resource-information",
"valueString" : "EvidenceVariable"
}
],
"reference" : {
"reference" : "EvidenceVariable/12719"
},
"name" : "Mortality at 14 days",
"description" : "mortality at 14 days",
"isExample" : true
},
{
"extension" : [
{
"url" : "http://hl7.org/fhir/tools/StructureDefinition/resource-information",
"valueString" : "StructureDefinition:resource"
}
],
"reference" : {
"reference" : "StructureDefinition/net-effect-contribution"
},
"name" : "NetEffectContribution",
"description" : "Profile of Evidence for Evidence Based Medicine IG. The NetEffectContribution Profile is used for evidence in which the effect estimates, expressed as risk differences, is multiplied by a relative importance rating of the outcomes.",
"isExample" : false
},
{
"extension" : [
{
"url" : "http://hl7.org/fhir/tools/StructureDefinition/resource-information",
"valueString" : "Evidence"
}
],
"reference" : {
"reference" : "Evidence/179591"
},
"name" : "NetEffectContribution: Additional GI surgical procedure for Example for GIN 2022",
"description" : "-1.24 (-1.74 to -0.87)",
"isExample" : true,
"profile" : [
"http://hl7.org/fhir/uv/ebm/StructureDefinition/net-effect-contribution"
]
},
{
"extension" : [
{
"url" : "http://hl7.org/fhir/tools/StructureDefinition/resource-information",
"valueString" : "Evidence"
}
],
"reference" : {
"reference" : "Evidence/179586"
},
"name" : "NetEffectContribution: All-cause mortality for Example for GIN 2022",
"description" : "2.14 (1.8 to 2.42)",
"isExample" : true,
"profile" : [
"http://hl7.org/fhir/uv/ebm/StructureDefinition/net-effect-contribution"
]
},
{
"extension" : [
{
"url" : "http://hl7.org/fhir/tools/StructureDefinition/resource-information",
"valueString" : "Evidence"
}
],
"reference" : {
"reference" : "Evidence/179589"
},
"name" : "NetEffectContribution: New onset depression for Example for GIN 2022",
"description" : "-0.16 (-0.23 to -0.13)",
"isExample" : true,
"profile" : [
"http://hl7.org/fhir/uv/ebm/StructureDefinition/net-effect-contribution"
]
},
{
"extension" : [
{
"url" : "http://hl7.org/fhir/tools/StructureDefinition/resource-information",
"valueString" : "Evidence"
}
],
"reference" : {
"reference" : "Evidence/179587"
},
"name" : "NetEffectContribution: Nonfatal myocardial infarction or stroke for Example for GIN 2022",
"description" : "0.91 (0.47 to 1.27)",
"isExample" : true,
"profile" : [
"http://hl7.org/fhir/uv/ebm/StructureDefinition/net-effect-contribution"
]
},
{
"extension" : [
{
"url" : "http://hl7.org/fhir/tools/StructureDefinition/resource-information",
"valueString" : "Evidence"
}
],
"reference" : {
"reference" : "Evidence/179588"
},
"name" : "NetEffectContribution: Remission of diabetes for Example for GIN 2022",
"description" : "2.15 (1.33 to 3.26) - example showing statistic.extension:modelExpression",
"isExample" : true,
"profile" : [
"http://hl7.org/fhir/uv/ebm/StructureDefinition/net-effect-contribution"
]
},
{
"extension" : [
{
"url" : "http://hl7.org/fhir/tools/StructureDefinition/resource-information",
"valueString" : "Evidence"
}
],
"reference" : {
"reference" : "Evidence/179590"
},
"name" : "NetEffectContribution: Treatment with opioids for Example for GIN 2022",
"description" : "-0.24 (-0.32 to -0.16)",
"isExample" : true,
"profile" : [
"http://hl7.org/fhir/uv/ebm/StructureDefinition/net-effect-contribution"
]
},
{
"extension" : [
{
"url" : "http://hl7.org/fhir/tools/StructureDefinition/resource-information",
"valueString" : "StructureDefinition:resource"
}
],
"reference" : {
"reference" : "StructureDefinition/net-effect-contribution-list"
},
"name" : "NetEffectContributionList",
"description" : "Profile of List for Evidence Based Medicine IG. The NetEffectContributionList Profile is used to provide a list of Evidence Resources (NetEffectContribution Profile). The NetEffectContributionList Profile is used to represent a Group of Evidence for the population for a NetEffectEstimate (Profile of Evidence) using a net effect analysis approach and is referenced from a NetEffectContributions (Profile of Group).",
"isExample" : false
},
{
"extension" : [
{
"url" : "http://hl7.org/fhir/tools/StructureDefinition/resource-information",
"valueString" : "List"
}
],
"reference" : {
"reference" : "List/179585"
},
"name" : "NetEffectContributionList: Bariatric Surgery Example for GIN 2022",
"description" : "A list of Evidence Resources (NetEffectContribution Profile) used to provide the group members for a NetEffectContributions Profile.",
"isExample" : true,
"profile" : [
"http://hl7.org/fhir/uv/ebm/StructureDefinition/net-effect-contribution-list"
]
},
{
"extension" : [
{
"url" : "http://hl7.org/fhir/tools/StructureDefinition/resource-information",
"valueString" : "StructureDefinition:resource"
}
],
"reference" : {
"reference" : "StructureDefinition/net-effect-contributions"
},
"name" : "NetEffectContributions",
"description" : "Profile of Group for Evidence Based Medicine IG. The NetEffectContributions Profile is used to represent an enumerated group of participants in a net effect analysis where the participants are Evidence Resources (NetEffectContribution Profile).",
"isExample" : false
},
{
"extension" : [
{
"url" : "http://hl7.org/fhir/tools/StructureDefinition/resource-information",
"valueString" : "Group"
}
],
"reference" : {
"reference" : "Group/179584"
},
"name" : "NetEffectContributions: Bariatric Surgery Example for GIN 2022",
"description" : "This is an example of a NetEffectContributions Profile of a Group Resource. This is a conceptual group (membership = 'conceptual') where the type of group member is an Evidence Resource (NetEffectContribution Profile) and this type is not supported in the type element so the type element is not used. The characteristic is defined by reference to a NetEffectContributionList Profile of List Resource where the 'group members' can be found.",
"isExample" : true,
"profile" : [
"http://hl7.org/fhir/uv/ebm/StructureDefinition/net-effect-contributions"
]
},
{
"extension" : [
{
"url" : "http://hl7.org/fhir/tools/StructureDefinition/resource-information",
"valueString" : "StructureDefinition:resource"
}
],
"reference" : {
"reference" : "StructureDefinition/net-effect-estimate"
},
"name" : "NetEffectEstimate",
"description" : "Profile of Evidence for Evidence Based Medicine IG. The NetEffectEstimate Profile is used for evidence in which the observed data is net effect contributions (effect estimates expressed as risk differences, multiplied by relative importance ratings of outcomes).",
"isExample" : false
},
{
"extension" : [
{
"url" : "http://hl7.org/fhir/tools/StructureDefinition/resource-information",
"valueString" : "Evidence"
}
],
"reference" : {
"reference" : "Evidence/179583"
},
"name" : "NetEffectEstimate: Bariatric Surgery Example for GIN 2022",
"description" : "Net Effect Estimate = 3.55 (2.38 to 4.73)",
"isExample" : true,
"profile" : [
"http://hl7.org/fhir/uv/ebm/StructureDefinition/net-effect-estimate"
]
},
{
"extension" : [
{
"url" : "http://hl7.org/fhir/tools/StructureDefinition/resource-information",
"valueString" : "EvidenceVariable"
}
],
"reference" : {
"reference" : "EvidenceVariable/282897"
},
"name" : "NHANES LBDGLUSI: Fasting Glucose (mmol/L)",
"description" : "This variable definition is used for an NHANES data dictionary.",
"isExample" : true,
"profile" : [
"http://hl7.org/fhir/uv/ebm/StructureDefinition/variable-definition"
]
},
{
"extension" : [
{
"url" : "http://hl7.org/fhir/tools/StructureDefinition/resource-information",
"valueString" : "Group"
}
],
"reference" : {
"reference" : "Group/282891"
},
"name" : "NHANES LBDGLUSI: Fasting Glucose (mmol/L) Variable Definition",
"description" : "This Group Resource is referenced in an example for the EBMonFHIR Implementation Guide.",
"isExample" : true
},
{
"extension" : [
{
"url" : "http://hl7.org/fhir/tools/StructureDefinition/resource-information",
"valueString" : "EvidenceVariable"
}
],
"reference" : {
"reference" : "EvidenceVariable/282881"
},
"name" : "NHANES LBXGLU: Fasting Glucose (mg/dL)",
"description" : "This variable definition is used for an NHANES data dictionary.",
"isExample" : true,
"profile" : [
"http://hl7.org/fhir/uv/ebm/StructureDefinition/variable-definition"
]
},
{
"extension" : [
{
"url" : "http://hl7.org/fhir/tools/StructureDefinition/resource-information",
"valueString" : "Group"
}
],
"reference" : {
"reference" : "Group/282882"
},
"name" : "NHANES LBXGLU: Fasting Glucose (mg/dL) Variable Definition",
"description" : "This Group Resource is referenced in an example for the EBMonFHIR Implementation Guide.",
"isExample" : true
},
{
"extension" : [
{
"url" : "http://hl7.org/fhir/tools/StructureDefinition/resource-information",
"valueString" : "Composition"
}
],
"reference" : {
"reference" : "Composition/282931"
},
"name" : "NHANES Plasma Fasting Glucose (GLU_J) Data Dictionary",
"description" : "This Composition summarizes the code key for understanding a research study dataset, including references to EvidenceVariable Resources (VariableDefinition Profile) for each of the data elements (variables) in the dataset.",
"isExample" : true,
"profile" : [
"http://hl7.org/fhir/uv/ebm/StructureDefinition/research-study-data-dictionary"
]
},
{
"extension" : [
{
"url" : "http://hl7.org/fhir/tools/StructureDefinition/resource-information",
"valueString" : "EvidenceVariable"
}
],
"reference" : {
"reference" : "EvidenceVariable/282880"
},
"name" : "NHANES SEQN Respondent Sequence Number",
"description" : "This variable definition for NHANES data dictionaries is for the research subject (respondent) identifier used to coordinate data across datasets.",
"isExample" : true,
"profile" : [
"http://hl7.org/fhir/uv/ebm/StructureDefinition/variable-definition"
]
},
{
"extension" : [
{
"url" : "http://hl7.org/fhir/tools/StructureDefinition/resource-information",
"valueString" : "EvidenceVariable"
}
],
"reference" : {
"reference" : "EvidenceVariable/282898"
},
"name" : "NHANES WTSAF2YR: Fasting Subsample 2 Year MEC Weight",
"description" : "This variable definition is used for an NHANES data dictionary.",
"isExample" : true,
"profile" : [
"http://hl7.org/fhir/uv/ebm/StructureDefinition/variable-definition"
]
},
{
"extension" : [
{
"url" : "http://hl7.org/fhir/tools/StructureDefinition/resource-information",
"valueString" : "Group"
}
],
"reference" : {
"reference" : "Group/282899"
},
"name" : "NHANES WTSAF2YR: Fasting Subsample 2 Year MEC Weight) Variable Definition",
"description" : "This Group Resource is referenced in an example for the EBMonFHIR Implementation Guide.",
"isExample" : true
},
{
"extension" : [
{
"url" : "http://hl7.org/fhir/tools/StructureDefinition/resource-information",
"valueString" : "StructureDefinition:resource"
}
],
"reference" : {
"reference" : "StructureDefinition/non-comparative-evidence"
},
"name" : "NonComparativeEvidence",
"description" : "Profile of Evidence for Evidence Based Medicine IG. The NonComparativeEvidence Profile is used for evidence about a single group with no comparisons between groups.",
"isExample" : false
},
{
"extension" : [
{
"url" : "http://hl7.org/fhir/tools/StructureDefinition/resource-information",
"valueString" : "ResearchStudy"
}
],
"reference" : {
"reference" : "ResearchStudy/208285"
},
"name" : "Norwegian Cohort Study Comparing Bariatric Surgery vs Medical Obesity Treatment for Long-term Medical Complications and Obesity-Related Comorbidities",
"description" : "The main purpose of this study is, in combination with data from the Register and Biobank study and follow-up data from the Norwegian Prescription Database, to compare the long-term effects (4-10 years) of surgical and non-surgical treatment of morbid obesity on obesity\nrelated comorbidities by studying changes in medicine usage after treatment.\n\nHypotheses\n1. Primary hypothesis: As compared to non-surgical treatment, bariatric surgery will be associated with higher rates of remission, and lower rates of new-onset drug treated hypertension during a follow-up period of ≤ 10 years.\n2. Secondary hypotheses: Changes in the usage of other drugs, particularly drugs related to obesity related comorbidities, will differ significantly between patients undergoing bariatric surgery or non-surgical treatment during the follow-up period.",
"isExample" : true
},
{
"extension" : [
{
"url" : "http://hl7.org/fhir/tools/StructureDefinition/resource-information",
"valueString" : "EvidenceVariable"
}
],
"reference" : {
"reference" : "EvidenceVariable/7753"
},
"name" : "Organ support-free days",
"description" : "The primary outcome was organ support–free days, evaluated on an ordinal scale that combined in-hospital death and the number of days free of cardiovascular or respiratory organ support up to day 21 among patients who survived to hospital discharge. Patients who were discharged from the hospital before day 21 were assumed to be alive and free of organ support through day 21. Any death during the index hospitalization through 90 days was assigned the worst score on the outcome scale (–1). This end point reflects both the use of ICU-level interventions and survival, with higher values indicating better outcomes.",
"isExample" : true
},
{
"extension" : [
{
"url" : "http://hl7.org/fhir/tools/StructureDefinition/resource-information",
"valueString" : "ArtifactAssessment"
}
],
"reference" : {
"reference" : "ArtifactAssessment/104064"
},
"name" : "Outcome Importance Rating 100 of All-cause mortality",
"description" : "This example expresses the outcome desirability with a CodeableConcept datatype and the relative outcome importance (100%) with a Quantity datatype.",
"isExample" : true,
"profile" : [
"http://hl7.org/fhir/uv/ebm/StructureDefinition/rating"
]
},
{
"extension" : [
{
"url" : "http://hl7.org/fhir/tools/StructureDefinition/resource-information",
"valueString" : "ArtifactAssessment"
}
],
"reference" : {
"reference" : "ArtifactAssessment/104192"
},
"name" : "Outcome Importance Rating 30 of Nonfatal myocardial infarction or stroke",
"description" : "This example expresses the outcome desirability with a CodeableConcept datatype and the relative outcome importance (30%) with a Quantity datatype.",
"isExample" : true,
"profile" : [
"http://hl7.org/fhir/uv/ebm/StructureDefinition/outcome-importance"
]
},
{
"extension" : [
{
"url" : "http://hl7.org/fhir/tools/StructureDefinition/resource-information",
"valueString" : "ArtifactAssessment"
}
],
"reference" : {
"reference" : "ArtifactAssessment/104194"
},
"name" : "Outcome Importance Rating 5 of New onset depression",
"description" : "This example expresses the outcome desirability with a CodeableConcept datatype and the relative outcome importance (5%) with a Quantity datatype.",
"isExample" : true,
"profile" : [
"http://hl7.org/fhir/uv/ebm/StructureDefinition/rating"
]
},
{
"extension" : [
{
"url" : "http://hl7.org/fhir/tools/StructureDefinition/resource-information",
"valueString" : "ArtifactAssessment"
}
],
"reference" : {
"reference" : "ArtifactAssessment/104193"
},
"name" : "Outcome Importance Rating 5 of Remission of diabetes",
"description" : "This example expresses the outcome desirability with a CodeableConcept datatype and the relative outcome importance (5%) with a Quantity datatype",
"isExample" : true,
"profile" : [
"http://hl7.org/fhir/uv/ebm/StructureDefinition/outcome-importance"
]
},
{
"extension" : [
{
"url" : "http://hl7.org/fhir/tools/StructureDefinition/resource-information",
"valueString" : "ArtifactAssessment"
}
],
"reference" : {
"reference" : "ArtifactAssessment/104195"
},
"name" : "Outcome Importance Rating 5 of Treatment with opioids",
"description" : "This example expresses the outcome desirability with a CodeableConcept datatype and the relative outcome importance (5%) with a Quantity datatype.",
"isExample" : true,
"profile" : [
"http://hl7.org/fhir/uv/ebm/StructureDefinition/outcome-importance"
]
},
{
"extension" : [
{
"url" : "http://hl7.org/fhir/tools/StructureDefinition/resource-information",
"valueString" : "ArtifactAssessment"
}
],
"reference" : {
"reference" : "ArtifactAssessment/104196"
},
"name" : "Outcome Importance Rating 8 of Additional GI surgical procedure",
"description" : "This example expresses the outcome desirability with a CodeableConcept datatype and the relative outcome importance (8%) with a Quantity datatype.",
"isExample" : true,
"profile" : [
"http://hl7.org/fhir/uv/ebm/StructureDefinition/outcome-importance"
]
},
{
"extension" : [
{
"url" : "http://hl7.org/fhir/tools/StructureDefinition/resource-information",
"valueString" : "Composition"
}
],
"reference" : {
"reference" : "Composition/247500"
},
"name" : "Outcome Measure Report: Association of Bariatric Surgery vs Medical Obesity Treatment With Long-term Medical Complications and Obesity-Related Comorbidities (2018 Norwegian Cohort)",
"description" : "This example of an OutcomeMeasureReport Profile shows a report from a single observational study with 4 outcome measures.",
"isExample" : true,
"profile" : [
"http://hl7.org/fhir/uv/ebm/StructureDefinition/outcome-measure-report"
]
},
{
"extension" : [
{
"url" : "http://hl7.org/fhir/tools/StructureDefinition/resource-information",
"valueString" : "StructureDefinition:resource"
}
],
"reference" : {
"reference" : "StructureDefinition/outcome-definition"
},
"name" : "OutcomeDefinition",
"description" : "Profile of Group for Evidence Based Medicine IG. The OutcomeDefinition Profile is used to express the criteria defining an evidence variable (or categorical value for a variable) in the role of outcome.",
"isExample" : false
},
{
"extension" : [
{
"url" : "http://hl7.org/fhir/tools/StructureDefinition/resource-information",
"valueString" : "EvidenceVariable"
}
],
"reference" : {
"reference" : "EvidenceVariable/236953"
},
"name" : "OutcomeDefinition: All-cause mortality",
"description" : "All-cause mortality",
"isExample" : true
},
{
"extension" : [
{
"url" : "http://hl7.org/fhir/tools/StructureDefinition/resource-information",
"valueString" : "Group"
}
],
"reference" : {
"reference" : "Group/172480"
},
"name" : "OutcomeDefinition: American Diabetes Association composite triple end point for metabolic control",
"description" : "The American Diabetes Association composite triple end point of hemoglobin A1c less than 7.0%, low-density lipoprotein cholesterol less than 100 mg/dL, and systolic blood pressure less than 130 mm Hg at 5 years",
"isExample" : true,
"profile" : [
"http://hl7.org/fhir/uv/ebm/StructureDefinition/outcome-definition"
]
},
{
"extension" : [
{
"url" : "http://hl7.org/fhir/tools/StructureDefinition/resource-information",
"valueString" : "EvidenceVariable"
}
],
"reference" : {
"reference" : "EvidenceVariable/236986"
},
"name" : "OutcomeDefinition: Body weight",
"description" : "Body weight",
"isExample" : true
},
{
"extension" : [
{
"url" : "http://hl7.org/fhir/tools/StructureDefinition/resource-information",
"valueString" : "EvidenceVariable"
}
],
"reference" : {
"reference" : "EvidenceVariable/236956"
},
"name" : "OutcomeDefinition: Cardiovascular mortality",
"description" : "Cardiovascular mortality",
"isExample" : true
},
{
"extension" : [
{
"url" : "http://hl7.org/fhir/tools/StructureDefinition/resource-information",
"valueString" : "Group"
}
],
"reference" : {
"reference" : "Group/173252"
},
"name" : "OutcomeDefinition: Diabetes in remission",
"description" : "Diabetes in remission",
"isExample" : true,
"profile" : [
"http://hl7.org/fhir/uv/ebm/StructureDefinition/outcome-definition"
]
},
{
"extension" : [
{
"url" : "http://hl7.org/fhir/tools/StructureDefinition/resource-information",
"valueString" : "EvidenceVariable"
}
],
"reference" : {
"reference" : "EvidenceVariable/236971"
},
"name" : "OutcomeDefinition: Diabetic ketoacidosis",
"description" : "Diabetic ketoacidosis",
"isExample" : true
},
{
"extension" : [
{
"url" : "http://hl7.org/fhir/tools/StructureDefinition/resource-information",
"valueString" : "EvidenceVariable"
}
],
"reference" : {
"reference" : "EvidenceVariable/236965"
},
"name" : "OutcomeDefinition: End-stage kidney disease",
"description" : "End-stage kidney disease",
"isExample" : true
},
{
"extension" : [
{
"url" : "http://hl7.org/fhir/tools/StructureDefinition/resource-information",
"valueString" : "EvidenceVariable"
}
],
"reference" : {
"reference" : "EvidenceVariable/236977"
},
"name" : "OutcomeDefinition: Genital infection",
"description" : "Genital infection",
"isExample" : true
},
{
"extension" : [
{
"url" : "http://hl7.org/fhir/tools/StructureDefinition/resource-information",
"valueString" : "Group"
}
],
"reference" : {
"reference" : "Group/172484"
},
"name" : "OutcomeDefinition: HbA1c at 12 months",
"description" : "HbA1c at 12 months",
"isExample" : true,
"profile" : [
"http://hl7.org/fhir/uv/ebm/StructureDefinition/outcome-definition"
]
},
{
"extension" : [
{
"url" : "http://hl7.org/fhir/tools/StructureDefinition/resource-information",
"valueString" : "Group"
}
],
"reference" : {
"reference" : "Group/172477"
},
"name" : "OutcomeDefinition: HbA1c at 24 months",
"description" : "HbA1c at 24 months",
"isExample" : true,
"profile" : [
"http://hl7.org/fhir/uv/ebm/StructureDefinition/outcome-definition"
]
},
{
"extension" : [
{
"url" : "http://hl7.org/fhir/tools/StructureDefinition/resource-information",
"valueString" : "Group"
}
],
"reference" : {
"reference" : "Group/173245"
},
"name" : "OutcomeDefinition: HbA1c at 36 months",
"description" : "HbA1c at 36 months",
"isExample" : true,
"profile" : [
"http://hl7.org/fhir/uv/ebm/StructureDefinition/outcome-definition"
]
},
{
"extension" : [
{
"url" : "http://hl7.org/fhir/tools/StructureDefinition/resource-information",
"valueString" : "Group"
}
],
"reference" : {
"reference" : "Group/175762"
},
"name" : "OutcomeDefinition: HbA1c at 6 months",
"description" : "HbA1c at 6 months",
"isExample" : true,
"profile" : [
"http://hl7.org/fhir/uv/ebm/StructureDefinition/outcome-definition"
]
},
{
"extension" : [
{
"url" : "http://hl7.org/fhir/tools/StructureDefinition/resource-information",
"valueString" : "Group"
}
],
"reference" : {
"reference" : "Group/172476"
},
"name" : "OutcomeDefinition: HbA1c at 60 months",
"description" : "HbA1c at 60 months",
"isExample" : true,
"profile" : [
"http://hl7.org/fhir/uv/ebm/StructureDefinition/outcome-definition"
]
},
{
"extension" : [
{
"url" : "http://hl7.org/fhir/tools/StructureDefinition/resource-information",
"valueString" : "EvidenceVariable"
}
],
"reference" : {
"reference" : "EvidenceVariable/236983"
},
"name" : "OutcomeDefinition: Health-related quality of life",
"description" : "Health-related quality of life",
"isExample" : true
},
{
"extension" : [
{
"url" : "http://hl7.org/fhir/tools/StructureDefinition/resource-information",
"valueString" : "EvidenceVariable"
}
],
"reference" : {
"reference" : "EvidenceVariable/236968"
},
"name" : "OutcomeDefinition: Heart failure",
"description" : "Hospital admission for heart failure",
"isExample" : true
},
{
"extension" : [
{
"url" : "http://hl7.org/fhir/tools/StructureDefinition/resource-information",
"valueString" : "Group"
}
],
"reference" : {
"reference" : "Group/291368"
},
"name" : "OutcomeDefinition: Mortality at 14 days",
"description" : "This Group Resource is referenced in an example for the EBMonFHIR Implementation Guide.",
"isExample" : true,
"profile" : [
"http://hl7.org/fhir/uv/ebm/StructureDefinition/outcome-definition"
]
},
{
"extension" : [
{
"url" : "http://hl7.org/fhir/tools/StructureDefinition/resource-information",
"valueString" : "Group"
}
],
"reference" : {
"reference" : "Group/173251"
},
"name" : "OutcomeDefinition: New onset depression",
"description" : "New onset depression",
"isExample" : true
},
{
"extension" : [
{
"url" : "http://hl7.org/fhir/tools/StructureDefinition/resource-information",
"valueString" : "EvidenceVariable"
}
],
"reference" : {
"reference" : "EvidenceVariable/236959"
},
"name" : "OutcomeDefinition: Nonfatal myocardial infarction",
"description" : "Nonfatal myocardial infarction",
"isExample" : true
},
{
"extension" : [
{
"url" : "http://hl7.org/fhir/tools/StructureDefinition/resource-information",
"valueString" : "Group"
}
],
"reference" : {
"reference" : "Group/173248"
},
"name" : "OutcomeDefinition: Nonfatal myocardial infarction or stroke",
"description" : "Nonfatal myocardial infarction or stroke",
"isExample" : true,
"profile" : [
"http://hl7.org/fhir/uv/ebm/StructureDefinition/outcome-definition"
]
},
{
"extension" : [
{
"url" : "http://hl7.org/fhir/tools/StructureDefinition/resource-information",
"valueString" : "EvidenceVariable"
}
],
"reference" : {
"reference" : "EvidenceVariable/236962"
},
"name" : "OutcomeDefinition: Nonfatal stroke",
"description" : "Nonfatal stroke",
"isExample" : true
},
{
"extension" : [
{
"url" : "http://hl7.org/fhir/tools/StructureDefinition/resource-information",
"valueString" : "EvidenceVariable"
}
],
"reference" : {
"reference" : "EvidenceVariable/236974"
},
"name" : "OutcomeDefinition: Serious hyperglycaemia",
"description" : "Serious hyperglycaemia",
"isExample" : true
},
{
"extension" : [
{
"url" : "http://hl7.org/fhir/tools/StructureDefinition/resource-information",
"valueString" : "EvidenceVariable"
}
],
"reference" : {
"reference" : "EvidenceVariable/236980"
},
"name" : "OutcomeDefinition: Severe gastrointestinal events",
"description" : "Severe gastrointestinal events",
"isExample" : true
},
{
"extension" : [
{
"url" : "http://hl7.org/fhir/tools/StructureDefinition/resource-information",
"valueString" : "StructureDefinition:resource"
}
],
"reference" : {
"reference" : "StructureDefinition/outcome-importance"
},
"name" : "OutcomeImportance",
"description" : "Profile of ArtifactAssessment for Evidence Based Medicine IG. The OutcomeImportance Profile is used for expression of the relative importance of an outcome. The outcome is typically expressed with an EvidenceVariable Resource and may use the VariableDefinition Profile of EvidenceVariable (or OutcomeDefinition Profile of Group).",
"isExample" : false
},
{
"extension" : [
{
"url" : "http://hl7.org/fhir/tools/StructureDefinition/resource-information",
"valueString" : "StructureDefinition:resource"
}
],
"reference" : {
"reference" : "StructureDefinition/outcome-list"
},
"name" : "OutcomeList",
"description" : "Profile of List for Evidence Based Medicine IG. The OutcomeList Profile is used to provide a list of outcomes. The OutcomeList Profile is referenced in the EvidenceReportSubject Profile as a way to define the set of outcomes that an EvidenceReport is about.",
"isExample" : false
},
{
"extension" : [
{
"url" : "http://hl7.org/fhir/tools/StructureDefinition/resource-information",
"valueString" : "List"
}
],
"reference" : {
"reference" : "List/179579"
},
"name" : "OutcomeList: Clinical Outcomes for Effects of Bariatric Surgery",
"description" : "A list of EvidenceVariable Resources (OutcomeVariable Profile) used to provide the value of a characteristic for a ComparativeEvidenceReportSubject Profile.",
"isExample" : true,
"profile" : [
"http://hl7.org/fhir/uv/ebm/StructureDefinition/outcome-list"
]
},
{
"extension" : [
{
"url" : "http://hl7.org/fhir/tools/StructureDefinition/resource-information",
"valueString" : "StructureDefinition:resource"
}
],
"reference" : {
"reference" : "StructureDefinition/outcome-measure-report"
},
"name" : "OutcomeMeasureReport",
"description" : "Profile of Composition for Evidence Based Medicine IG. The OutcomeMeasureReport Profile is used for an evidence report including the findings for any number of outcome measures in a research study.",
"isExample" : false
},
{
"extension" : [
{
"url" : "http://hl7.org/fhir/tools/StructureDefinition/resource-information",
"valueString" : "StructureDefinition:resource"
}
],
"reference" : {
"reference" : "StructureDefinition/outcome-measure-synthesis-report"
},
"name" : "OutcomeMeasureSynthesisReport",
"description" : "Profile of Composition for Evidence Based Medicine IG. The OutcomeMeasureSynthesisReport Profile is used for an evidence report including the findings for any number of outcomes in a synthesis of research studies, where there may be a unique observed study group, observed exposure group, and observed comparator group for each outcome.",
"isExample" : false
},
{
"extension" : [
{
"url" : "http://hl7.org/fhir/tools/StructureDefinition/resource-information",
"valueString" : "EvidenceVariable"
}
],
"reference" : {
"reference" : "EvidenceVariable/32143"
},
"name" : "OutcomeVariable: American Diabetes Association composite triple end point for metabolic control at 5 years",
"description" : "The American Diabetes Association composite triple end point of hemoglobin A1c less than 7.0%, low-density lipoprotein cholesterol less than 100 mg/dL, and systolic blood pressure less than 130 mm Hg at 5 years",
"isExample" : true,
"profile" : [
"http://hl7.org/fhir/uv/ebm/StructureDefinition/variable-definition"
]
},
{
"extension" : [
{
"url" : "http://hl7.org/fhir/tools/StructureDefinition/resource-information",
"valueString" : "EvidenceVariable"
}
],
"reference" : {
"reference" : "EvidenceVariable/173243"
},
"name" : "OutcomeVariable: HbA1c at 12 months",
"description" : "HbA1c at 12 months",
"isExample" : true,
"profile" : [
"http://hl7.org/fhir/uv/ebm/StructureDefinition/variable-definition"
]
},
{
"extension" : [
{
"url" : "http://hl7.org/fhir/tools/StructureDefinition/resource-information",
"valueString" : "EvidenceVariable"
}
],
"reference" : {
"reference" : "EvidenceVariable/173246"
},
"name" : "OutcomeVariable: HbA1c at 24 months",
"description" : "HbA1c at 24 months",
"isExample" : true,
"profile" : [
"http://hl7.org/fhir/uv/ebm/StructureDefinition/variable-definition"
]
},
{
"extension" : [
{
"url" : "http://hl7.org/fhir/tools/StructureDefinition/resource-information",
"valueString" : "EvidenceVariable"
}
],
"reference" : {
"reference" : "EvidenceVariable/173244"
},
"name" : "OutcomeVariable: HbA1c at 36 months",
"description" : "HbA1c at 36 months",
"isExample" : true,
"profile" : [
"http://hl7.org/fhir/uv/ebm/StructureDefinition/variable-definition"
]
},
{
"extension" : [
{
"url" : "http://hl7.org/fhir/tools/StructureDefinition/resource-information",
"valueString" : "EvidenceVariable"
}
],
"reference" : {
"reference" : "EvidenceVariable/175763"
},
"name" : "OutcomeVariable: HbA1c at 6 months",
"description" : "HbA1c at 6 months",
"isExample" : true,
"profile" : [
"http://hl7.org/fhir/uv/ebm/StructureDefinition/variable-definition"
]
},
{
"extension" : [
{
"url" : "http://hl7.org/fhir/tools/StructureDefinition/resource-information",
"valueString" : "EvidenceVariable"
}
],
"reference" : {
"reference" : "EvidenceVariable/173247"
},
"name" : "OutcomeVariable: HbA1c at 60 months",
"description" : "HbA1c at 60 months",
"isExample" : true,
"profile" : [
"http://hl7.org/fhir/uv/ebm/StructureDefinition/variable-definition"
]
},
{
"extension" : [
{
"url" : "http://hl7.org/fhir/tools/StructureDefinition/resource-information",
"valueString" : "EvidenceVariable"
}
],
"reference" : {
"reference" : "EvidenceVariable/46025"
},
"name" : "OutcomeVariable: Mean difference in HbA1c between Surgery and Medical/Lifestyle groups at end of follow-up",
"description" : "Mean difference in HbA1c between Surgery and Medical/Lifestyle groups at end of follow-up for HbA1c end point",
"isExample" : true,
"profile" : [
"http://hl7.org/fhir/uv/ebm/StructureDefinition/variable-definition"
]
},
{
"extension" : [
{
"url" : "http://hl7.org/fhir/tools/StructureDefinition/resource-information",
"valueString" : "EvidenceVariable"
}
],
"reference" : {
"reference" : "EvidenceVariable/104118"
},
"name" : "OutcomeVariable: New onset depression",
"description" : "This example expresses the variable 'New onset depression' as a dichotomous variable with a definition using definition.reference which references an OutcomeDefinition Profile of Group Resource.",
"isExample" : true,
"profile" : [
"http://hl7.org/fhir/uv/ebm/StructureDefinition/variable-definition"
]
},
{
"extension" : [
{
"url" : "http://hl7.org/fhir/tools/StructureDefinition/resource-information",
"valueString" : "EvidenceVariable"
}
],
"reference" : {
"reference" : "EvidenceVariable/104097"
},
"name" : "OutcomeVariable: Nonfatal myocardial infarction or stroke",
"description" : "Nonfatal myocardial infarction or stroke",
"isExample" : true,
"profile" : [
"http://hl7.org/fhir/uv/ebm/StructureDefinition/variable-definition"
]
},
{
"extension" : [
{
"url" : "http://hl7.org/fhir/tools/StructureDefinition/resource-information",
"valueString" : "EvidenceVariable"
}
],
"reference" : {
"reference" : "EvidenceVariable/104117"
},
"name" : "OutcomeVariable: Remission of diabetes",
"description" : "This example expresses the variable 'Remission of diabetes' as a dichotomous variable with a definition using both definition.concept (for a SNOMED CT term) and definition.reference which references an OutcomeDefinition Profile of Group Resource.",
"isExample" : true,
"profile" : [
"http://hl7.org/fhir/uv/ebm/StructureDefinition/variable-definition"
]
},
{
"extension" : [
{
"url" : "http://hl7.org/fhir/tools/StructureDefinition/resource-information",
"valueString" : "EvidenceVariable"
}
],
"reference" : {
"reference" : "EvidenceVariable/104120"
},
"name" : "OutcomeVariable_Additional_GI_surgical_procedure",
"description" : "This example expresses the variable 'Additional GI surgical procedure' as a dichotomous variable with a simple definition using definition.concept.text",
"isExample" : true,
"profile" : [
"http://hl7.org/fhir/uv/ebm/StructureDefinition/variable-definition"
]
},
{
"extension" : [
{
"url" : "http://hl7.org/fhir/tools/StructureDefinition/resource-information",
"valueString" : "EvidenceVariable"
}
],
"reference" : {
"reference" : "EvidenceVariable/49217"
},
"name" : "OutcomeVariable_All_cause_mortality",
"description" : "A dichotomous variable (outcome measure) defined by CodeableConcept.",
"isExample" : true,
"profile" : [
"http://hl7.org/fhir/uv/ebm/StructureDefinition/variable-definition"
]
},
{
"extension" : [
{
"url" : "http://hl7.org/fhir/tools/StructureDefinition/resource-information",
"valueString" : "EvidenceVariable"
}
],
"reference" : {
"reference" : "EvidenceVariable/104119"
},
"name" : "OutcomeVariable_Treatment_with_opioids",
"description" : "This example expresses the variable 'Treatment with opioids' as a dichotomous variable with a simple definition using definition.concept.text",
"isExample" : true,
"profile" : [
"http://hl7.org/fhir/uv/ebm/StructureDefinition/variable-definition"
]
},
{
"extension" : [
{
"url" : "http://hl7.org/fhir/tools/StructureDefinition/resource-information",
"valueString" : "Composition"
}
],
"reference" : {
"reference" : "Composition/247499"
},
"name" : "Participant Flow Report: Association of Bariatric Surgery vs Medical Obesity Treatment With Long-term Medical Complications and Obesity-Related Comorbidities (2018 Norwegian Cohort)",
"description" : "This example of a ParticipantFlowReport Profile shows a report from a single observational study with 2 participant flow measures.",
"isExample" : true,
"profile" : [
"http://hl7.org/fhir/uv/ebm/StructureDefinition/participant-flow-report"
]
},
{
"extension" : [
{
"url" : "http://hl7.org/fhir/tools/StructureDefinition/resource-information",
"valueString" : "Evidence"
}
],
"reference" : {
"reference" : "Evidence/179462"
},
"name" : "ParticipantFlow: 2018 Norwegian Cohort Included in Analysis",
"description" : "1888 included in analysis",
"isExample" : true,
"profile" : [
"http://hl7.org/fhir/uv/ebm/StructureDefinition/participant-flow-evidence"
]
},
{
"extension" : [
{
"url" : "http://hl7.org/fhir/tools/StructureDefinition/resource-information",
"valueString" : "Evidence"
}
],
"reference" : {
"reference" : "Evidence/179464"
},
"name" : "ParticipantFlow: 2018 Norwegian Cohort Medical Group Included in Analysis",
"description" : "956 included in analysis",
"isExample" : true,
"profile" : [
"http://hl7.org/fhir/uv/ebm/StructureDefinition/participant-flow-evidence"
]
},
{
"extension" : [
{
"url" : "http://hl7.org/fhir/tools/StructureDefinition/resource-information",
"valueString" : "Evidence"
}
],
"reference" : {
"reference" : "Evidence/179463"
},
"name" : "ParticipantFlow: 2018 Norwegian Cohort Surgical Group Included in Analysis",
"description" : "932 included in analysis",
"isExample" : true,
"profile" : [
"http://hl7.org/fhir/uv/ebm/StructureDefinition/participant-flow-evidence"
]
},
{
"extension" : [
{
"url" : "http://hl7.org/fhir/tools/StructureDefinition/resource-information",
"valueString" : "StructureDefinition:resource"
}
],
"reference" : {
"reference" : "StructureDefinition/participant-flow-evidence"
},
"name" : "ParticipantFlowEvidence",
"description" : "Profile of Evidence for Evidence Based Medicine IG. The ParticipantFlowEvidence Profile is used for counts of completion and reasons for non-completion of participation in a research study.",
"isExample" : false
},
{
"extension" : [
{
"url" : "http://hl7.org/fhir/tools/StructureDefinition/resource-information",
"valueString" : "Evidence"
}
],
"reference" : {
"reference" : "Evidence/179460"
},
"name" : "ParticipantFlowEvidence: 2018 Norwegian Cohort Excluded from Analysis",
"description" : "221 excluded from analysis",
"isExample" : true,
"profile" : [
"http://hl7.org/fhir/uv/ebm/StructureDefinition/participant-flow-evidence"
]
},
{
"extension" : [
{
"url" : "http://hl7.org/fhir/tools/StructureDefinition/resource-information",
"valueString" : "StructureDefinition:resource"
}
],
"reference" : {
"reference" : "StructureDefinition/participant-flow-evidence-variable"
},
"name" : "ParticipantFlowEvidenceVariable",
"description" : "Profile of EvidenceVariable for Evidence Based Medicine IG. The ParticipantFlowEvidenceVariable Profile is used to describe outcome measures for completion and reasons for non-completion of participation in a research study.",
"isExample" : false
},
{
"extension" : [
{
"url" : "http://hl7.org/fhir/tools/StructureDefinition/resource-information",
"valueString" : "EvidenceVariable"
}
],
"reference" : {
"reference" : "EvidenceVariable/179636"
},
"name" : "ParticipantFlowMeasure: Dropout due to stopping intervention",
"description" : "Dropout due to stopping intervention",
"isExample" : true,
"profile" : [
"http://hl7.org/fhir/uv/ebm/StructureDefinition/participant-flow-evidence-variable"
]
},
{
"extension" : [
{
"url" : "http://hl7.org/fhir/tools/StructureDefinition/resource-information",
"valueString" : "EvidenceVariable"
}
],
"reference" : {
"reference" : "EvidenceVariable/179459"
},
"name" : "ParticipantFlowMeasure: Exclusion from analysis",
"description" : "This example expresses the variable 'Excluded from analysis' as a dichotomous variable with a simple definition using definition.concept.text and is used with the ParticipantFlow Profile of Evidence in the Evidence.variableDefinition with variableRole='outcome'",
"isExample" : true,
"profile" : [
"http://hl7.org/fhir/uv/ebm/StructureDefinition/participant-flow-evidence-variable"
]
},
{
"extension" : [
{
"url" : "http://hl7.org/fhir/tools/StructureDefinition/resource-information",
"valueString" : "EvidenceVariable"
}
],
"reference" : {
"reference" : "EvidenceVariable/179461"
},
"name" : "ParticipantFlowMeasure: Inclusion in analysis",
"description" : "This example expresses the variable 'Inclusion in analysis' as a dichotomous variable with a simple definition using definition.concept.text and is used with the ParticipantFlow Profile of Evidence in the Evidence.variableDefinition with variableRole='outcome'",
"isExample" : true,
"profile" : [
"http://hl7.org/fhir/uv/ebm/StructureDefinition/participant-flow-evidence-variable"
]
},
{
"extension" : [
{
"url" : "http://hl7.org/fhir/tools/StructureDefinition/resource-information",
"valueString" : "StructureDefinition:resource"
}
],
"reference" : {
"reference" : "StructureDefinition/participant-flow-report"
},
"name" : "ParticipantFlowReport",
"description" : "Profile of Composition for Evidence Based Medicine IG. The ParticipantFlowReport Profile is used for an evidence report including the counts (and proportions) for any number of participant flow measures in a research study. For example, the ParticipantFlowReport may include the data for a CONSORT Participant Flow Diagram reported with a randomized controlled trial.",
"isExample" : false
},
{
"extension" : [
{
"url" : "http://hl7.org/fhir/tools/StructureDefinition/resource-information",
"valueString" : "Group"
}
],
"reference" : {
"reference" : "Group/7750"
},
"name" : "Participants_in_Anticoagulation_for_COVID_19_Combined_ATTACC_ACTIV_4a_and_REMAP_CAP_RCT_hospitalized_not_critically_ill",
"description" : "An enumerated group participating in a randomized trial.",
"isExample" : true
},
{
"extension" : [
{
"url" : "http://hl7.org/fhir/tools/StructureDefinition/resource-information",
"valueString" : "Group"
}
],
"reference" : {
"reference" : "Group/7749"
},
"name" : "Patients_who_are_hospitalized_for_COVID_19_and_who_are_not_critically_ill",
"description" : "An definitional group used to support the 'intended' element in Evidence.varaibleDefinition with variableRole = 'population'.",
"isExample" : true
},
{
"extension" : [
{
"url" : "http://hl7.org/fhir/tools/StructureDefinition/resource-information",
"valueString" : "EvidenceVariable"
}
],
"reference" : {
"reference" : "EvidenceVariable/12718"
},
"name" : "Placebo",
"description" : "Placebo",
"isExample" : true
},
{
"extension" : [
{
"url" : "http://hl7.org/fhir/tools/StructureDefinition/resource-information",
"valueString" : "PlanDefinition"
}
],
"reference" : {
"reference" : "PlanDefinition/179468"
},
"name" : "PlanDefinition for Recommendation: ADA Obesity Management Recommendation 8.16",
"description" : "8.16 Metabolic surgery should be a recommended option to treat type 2 diabetes in screened surgical candidates with BMI ≥40 kg/m2 (BMI ≥37.5 kg/m2 in Asian Americans) and in adults with BMI 35.0–39.9 kg/m2 (32.5–37.4 kg/m2 in Asian Americans) who do not achieve durable weight loss and improvement in comorbidities (including hyperglycemia) with nonsurgical methods. A",
"isExample" : true,
"profile" : [
"http://hl7.org/fhir/uv/ebm/StructureDefinition/recommendation-plan"
]
},
{
"extension" : [
{
"url" : "http://hl7.org/fhir/tools/StructureDefinition/resource-information",
"valueString" : "PlanDefinition"
}
],
"reference" : {
"reference" : "PlanDefinition/179554"
},
"name" : "PlanDefinition for Recommendation: ADA Obesity Management Recommendation 8.17",
"description" : "8.17 Metabolic surgery may be considered as an option to treat type 2 diabetes in adults with BMI 30.0–34.9 kg/m2 (27.5–32.4 kg/m2 in Asian Americans) who do not achieve durable weight loss and improvement in comorbidities (including hyperglycemia) with nonsurgical methods. A",
"isExample" : true,
"profile" : [
"http://hl7.org/fhir/uv/ebm/StructureDefinition/recommendation-plan"
]
},
{
"extension" : [
{
"url" : "http://hl7.org/fhir/tools/StructureDefinition/resource-information",
"valueString" : "StructureDefinition:resource"
}
],
"reference" : {
"reference" : "StructureDefinition/preprint-citation"
},
"name" : "PreprintCitation",
"description" : "Profile of Citation for Evidence Based Medicine IG. The PreprintCitation Profile is used for citations of an article published in a form prior to peer-reviewed publication in a journal, book, or other permanent record.",
"isExample" : false
},
{
"extension" : [
{
"url" : "http://hl7.org/fhir/tools/StructureDefinition/resource-information",
"valueString" : "Citation"
}
],
"reference" : {
"reference" : "Citation/5296"
},
"name" : "PreprintCitation: Nigella Sativa for COVID-19 OSF Preprint",
"description" : "A preprint that has only an abstract and data is different than CT.gov results",
"isExample" : true,
"profile" : [
"http://hl7.org/fhir/uv/ebm/StructureDefinition/preprint-citation"
]
},
{
"extension" : [
{
"url" : "http://hl7.org/fhir/tools/StructureDefinition/resource-information",
"valueString" : "StructureDefinition:resource"
}
],
"reference" : {
"reference" : "StructureDefinition/rating"
},
"name" : "Rating",
"description" : "Profile of ArtifactAssessment for Evidence Based Medicine IG. The Rating Profile is used for classifier tags that may include quantitative ratings and may be created independently from Resource creators.",
"isExample" : false
},
{
"extension" : [
{
"url" : "http://hl7.org/fhir/tools/StructureDefinition/resource-information",
"valueString" : "StructureDefinition:resource"
}
],
"reference" : {
"reference" : "StructureDefinition/recommendation"
},
"name" : "Recommendation",
"description" : "Profile of Composition for Evidence Based Medicine IG. The Recommendation Profile is used for the composition of a recommendation (such as that from a clinical practice guideline) and may be tightly related to a RecommendationPlan Profile of PlanDefinition and a RecommendationJustification Profile of ArtifactAssessment.",
"isExample" : false
},
{
"extension" : [
{
"url" : "http://hl7.org/fhir/tools/StructureDefinition/resource-information",
"valueString" : "ValueSet"
}
],
"reference" : {
"reference" : "ValueSet/recommendation-justification-classifier"
},
"name" : "Recommendation Justification Classifier Codes Value Set",
"description" : "Codes for use with the Classifier drop-down menu for FEvIR(R): Recommendation Justification Builder.",
"isExample" : false
},
{
"extension" : [
{
"url" : "http://hl7.org/fhir/tools/StructureDefinition/resource-information",
"valueString" : "CodeSystem"
}
],
"reference" : {
"reference" : "CodeSystem/27834"
},
"name" : "Recommendation Justification Code System",
"description" : "This resource (this entire set of content) is being used for active development of a code system to support a RecommendationJustification Profile of ArtifactAssessment Resource. This code system is not yet released for expected use and may not be stable. This resource may be used for the continuous development of the code system, and published versions of the code system (when ready) may be published as separate resources with stable identifiers.",
"isExample" : true
},
{
"extension" : [
{
"url" : "http://hl7.org/fhir/tools/StructureDefinition/resource-information",
"valueString" : "Composition"
}
],
"reference" : {
"reference" : "Composition/179466"
},
"name" : "Recommendation: ADA Obesity Management Recommendation 8.16",
"description" : "Example of Recommendation Profile of Composition Resource.",
"isExample" : true,
"profile" : [
"http://hl7.org/fhir/uv/ebm/StructureDefinition/recommendation"
]
},
{
"extension" : [
{
"url" : "http://hl7.org/fhir/tools/StructureDefinition/resource-information",
"valueString" : "Composition"
}
],
"reference" : {
"reference" : "Composition/179699"
},
"name" : "Recommendation: ADA Obesity Management Recommendation 8.16-adapted",
"description" : "This example of adapting a Recommendation (removing the A from the end of the Recommendation Statement) shows the use of an Adaptation Profile of ArtifactAssessment and the use of the extensions: artifact-approvalDate, arifact-lastReviewDate, and artifact-effectivePeriod.",
"isExample" : true,
"profile" : [
"http://hl7.org/fhir/uv/ebm/StructureDefinition/recommendation"
]
},
{
"extension" : [
{
"url" : "http://hl7.org/fhir/tools/StructureDefinition/resource-information",
"valueString" : "Composition"
}
],
"reference" : {
"reference" : "Composition/179467"
},
"name" : "Recommendation: ADA Obesity Management Recommendation 8.17",
"description" : "Example of Recommendation Profile of Composition Resource.",
"isExample" : true,
"profile" : [
"http://hl7.org/fhir/uv/ebm/StructureDefinition/recommendation"
]
},
{
"extension" : [
{
"url" : "http://hl7.org/fhir/tools/StructureDefinition/resource-information",
"valueString" : "StructureDefinition:resource"
}
],
"reference" : {
"reference" : "StructureDefinition/recommendation-action"
},
"name" : "RecommendationAction",
"description" : "Profile of ActivityDefinition for Evidence Based Medicine IG. The RecommendationAction Profile is used for a recommendation from a clinical practice guideline.",
"isExample" : false
},
{
"extension" : [
{
"url" : "http://hl7.org/fhir/tools/StructureDefinition/resource-information",
"valueString" : "StructureDefinition:resource"
}
],
"reference" : {
"reference" : "StructureDefinition/recommendation-eligibility-criteria"
},
"name" : "RecommendationEligibilityCriteria",
"description" : "Profile of Group for Evidence Based Medicine IG. The RecommendationEligibilityCriteria Profile is used to express the criteria defining a group for whom a recommendation applies.",
"isExample" : false
},
{
"extension" : [
{
"url" : "http://hl7.org/fhir/tools/StructureDefinition/resource-information",
"valueString" : "Group"
}
],
"reference" : {
"reference" : "Group/32139"
},
"name" : "RecommendationEligibilityCriteria: Eligibility Criteria for Bariatric Surgery (ADA Recommendation 8.16)",
"description" : "Inclusion Criteria: [[1]] Adults. [[2]] Diagnosed with type 2 diabetes. [[3]] Body Mass Index (BMI) ≥ 40.0 kg/m2 (BMI ≥ 37.5 kg/m2 in Asian Americans), or BMI ≥ 35.0 kg/m2 and ≤ 39.9 kg/m2 (BMI 32.5-37.4 kg/m2 in Asian Americans) who do not achieve durable weight loss and improvement in comorbidities (including hyperglycemia) with nonsurgical methods. [[4]] Screened surgical candidates.",
"isExample" : true,
"profile" : [
"http://hl7.org/fhir/uv/ebm/StructureDefinition/recommendation-eligibility-criteria"
]
},
{
"extension" : [
{
"url" : "http://hl7.org/fhir/tools/StructureDefinition/resource-information",
"valueString" : "Group"
}
],
"reference" : {
"reference" : "Group/179511"
},
"name" : "RecommendationEligibilityCriteria: Eligibility Criteria for Bariatric Surgery (ADA Recommendation 8.17)",
"description" : "Inclusion Criteria: [[1]] Adults. [[2]] Diagnosed with type 2 diabetes. [[3]] Body Mass Index (BMI) ≥ 30.0 kg/m2 and ≤ 34.9 kg/m2 (BMI 27.5-32.4 kg/m2 in Asian Americans) who do not achieve durable weight loss and improvement in comorbidities (including hyperglycemia) with nonsurgical methods. [[4]] Screened surgical candidates.",
"isExample" : true,
"profile" : [
"http://hl7.org/fhir/uv/ebm/StructureDefinition/recommendation-eligibility-criteria"
]
},
{
"extension" : [
{
"url" : "http://hl7.org/fhir/tools/StructureDefinition/resource-information",
"valueString" : "StructureDefinition:resource"
}
],
"reference" : {
"reference" : "StructureDefinition/recommendation-justification"
},
"name" : "RecommendationJustification",
"description" : "Profile of ArtifactAssessment for Evidence Based Medicine IG. The RecommendationJustification Profile is used for expressing the rationale, evidence, and judgments supporting a recommendation, such as from a clinical practice guideline.",
"isExample" : false
},
{
"extension" : [
{
"url" : "http://hl7.org/fhir/tools/StructureDefinition/resource-information",
"valueString" : "StructureDefinition:resource"
}
],
"reference" : {
"reference" : "StructureDefinition/recommendation-plan"
},
"name" : "RecommendationPlan",
"description" : "Profile of PlanDefinition for Evidence Based Medicine IG. The RecommendationPlan Profile is used for the implementable representation of a recommendation (such as that from a clinical practice guideline).",
"isExample" : false
},
{
"extension" : [
{
"url" : "http://hl7.org/fhir/tools/StructureDefinition/resource-information",
"valueString" : "EvidenceVariable"
}
],
"reference" : {
"reference" : "EvidenceVariable/12717"
},
"name" : "Remdesivir",
"description" : "Remdesivir",
"isExample" : true
},
{
"extension" : [
{
"url" : "http://hl7.org/fhir/tools/StructureDefinition/resource-information",
"valueString" : "Group"
}
],
"reference" : {
"reference" : "Group/179783"
},
"name" : "Remdesivir IV 200 mg once then 100 mg once daily for 9 days",
"description" : "Remdesivir IV 200 mg once then 100 mg once daily for 9 days",
"isExample" : true,
"profile" : [
"http://hl7.org/fhir/uv/ebm/StructureDefinition/exposure-definition"
]
},
{
"extension" : [
{
"url" : "http://hl7.org/fhir/tools/StructureDefinition/resource-information",
"valueString" : "StructureDefinition:resource"
}
],
"reference" : {
"reference" : "StructureDefinition/research-study-data-dictionary"
},
"name" : "ResearchStudyDataDictionary",
"description" : "Profile of Composition for Evidence Based Medicine IG. The ResearchStudyDataDictionary Profile is used for a code key for variable names in a dataset containing the observations collected in a research study. Each variable is included in a section.entry instance which references a VariableDefinition Profile of EvidenceVariable.",
"isExample" : false
},
{
"extension" : [
{
"url" : "http://hl7.org/fhir/tools/StructureDefinition/resource-information",
"valueString" : "StructureDefinition:extension"
}
],
"reference" : {
"reference" : "StructureDefinition/research-study-estimand"
},
"name" : "ResearchStudyEstimand",
"description" : "An outcome measure described with the estimand framework.",
"isExample" : false
},
{
"extension" : [
{
"url" : "http://hl7.org/fhir/tools/StructureDefinition/resource-information",
"valueString" : "StructureDefinition:extension"
}
],
"reference" : {
"reference" : "StructureDefinition/research-study-excluded-study"
},
"name" : "ResearchStudyExcludedStudy",
"description" : "Link to a research study excluded from the systematic review.",
"isExample" : false
},
{
"extension" : [
{
"url" : "http://hl7.org/fhir/tools/StructureDefinition/resource-information",
"valueString" : "StructureDefinition:extension"
}
],
"reference" : {
"reference" : "StructureDefinition/research-study-included-study"
},
"name" : "ResearchStudyIncludedStudy",
"description" : "Link to a research study included in the systematic review.",
"isExample" : false
},
{
"extension" : [
{
"url" : "http://hl7.org/fhir/tools/StructureDefinition/resource-information",
"valueString" : "StructureDefinition:extension"
}
],
"reference" : {
"reference" : "StructureDefinition/research-study-number-of-studies-identified"
},
"name" : "ResearchStudyNumberOfStudiesIdentified",
"description" : "Number of studies found on search to be evaluated for inclusion.",
"isExample" : false
},
{
"extension" : [
{
"url" : "http://hl7.org/fhir/tools/StructureDefinition/resource-information",
"valueString" : "StructureDefinition:extension"
}
],
"reference" : {
"reference" : "StructureDefinition/research-study-number-of-studies-included"
},
"name" : "ResearchStudyNumberOfStudiesIncluded",
"description" : "Number of studies selected for inclusion.",
"isExample" : false
},
{
"extension" : [
{
"url" : "http://hl7.org/fhir/tools/StructureDefinition/resource-information",
"valueString" : "StructureDefinition:extension"
}
],
"reference" : {
"reference" : "StructureDefinition/research-study-result-as-composition"
},
"name" : "ResearchStudyResultAsComposition",
"description" : "Link to results generated by the study, using a Composition Resource.",
"isExample" : false
},
{
"extension" : [
{
"url" : "http://hl7.org/fhir/tools/StructureDefinition/resource-information",
"valueString" : "StructureDefinition:extension"
}
],
"reference" : {
"reference" : "StructureDefinition/research-study-sae-reporting-method"
},
"name" : "ResearchStudySaeReportingMethod",
"description" : "Method for reporting Serious Adverse Events.",
"isExample" : false
},
{
"extension" : [
{
"url" : "http://hl7.org/fhir/tools/StructureDefinition/resource-information",
"valueString" : "StructureDefinition:extension"
}
],
"reference" : {
"reference" : "StructureDefinition/research-study-search-strategy"
},
"name" : "ResearchStudySearchStrategy",
"description" : "Link to search terms and sources for finding studies for inclusion.",
"isExample" : false
},
{
"extension" : [
{
"url" : "http://hl7.org/fhir/tools/StructureDefinition/resource-information",
"valueString" : "StructureDefinition:extension"
}
],
"reference" : {
"reference" : "StructureDefinition/research-study-sponsor-confidentiality-statement"
},
"name" : "ResearchStudySponsorConfidentialityStatement",
"description" : "Sponsor Confidentiality Statement.",
"isExample" : false
},
{
"extension" : [
{
"url" : "http://hl7.org/fhir/tools/StructureDefinition/resource-information",
"valueString" : "StructureDefinition:extension"
}
],
"reference" : {
"reference" : "StructureDefinition/research-study-study-amendment"
},
"name" : "ResearchStudyStudyAmendment",
"description" : "An amendment to a study protocol.",
"isExample" : false
},
{
"extension" : [
{
"url" : "http://hl7.org/fhir/tools/StructureDefinition/resource-information",
"valueString" : "StructureDefinition:extension"
}
],
"reference" : {
"reference" : "StructureDefinition/research-study-systematic-review-eligibility-criteria"
},
"name" : "ResearchStudySystematicReviewEligibilityCriteria",
"description" : "Link to criteria for inclusion of studies in the systematic review.",
"isExample" : false
},
{
"extension" : [
{
"url" : "http://hl7.org/fhir/tools/StructureDefinition/resource-information",
"valueString" : "ArtifactAssessment"
}
],
"reference" : {
"reference" : "ArtifactAssessment/179692"
},
"name" : "Risk of Bias Assessment of Critically appraised summary of primary outcome of multi-platform RCT of anticoagulation for non-critically ill patients with COVID-19",
"description" : "The ArtifactAssessment Resource is used here to show a complex risk of bias assessment with multiple recursive components.",
"isExample" : true,
"profile" : [
"http://hl7.org/fhir/uv/ebm/StructureDefinition/risk-of-bias"
]
},
{
"extension" : [
{
"url" : "http://hl7.org/fhir/tools/StructureDefinition/resource-information",
"valueString" : "ValueSet"
}
],
"reference" : {
"reference" : "ValueSet/181524"
},
"name" : "Risk Of Bias Type Value Set",
"description" : "Types of bias for use with risk of bias assessment. This is a snapshot version from a code system in development (original source at https://fevir.net/resources/CodeSystem/27270) and is provided for example support in the EBMonFHIR Implementation Guide.",
"isExample" : true
},
{
"extension" : [
{
"url" : "http://hl7.org/fhir/tools/StructureDefinition/resource-information",
"valueString" : "StructureDefinition:resource"
}
],
"reference" : {
"reference" : "StructureDefinition/risk-of-bias"
},
"name" : "RiskOfBias",
"description" : "Profile of ArtifactAssessment for Evidence Based Medicine IG. The RiskOfBias Profile is used for expression of the assessment of the threats to validity (or risk of bias) of an Evidence artifact or an artifact consisting of Evidence or the plan to create Evidence.",
"isExample" : false
},
{
"extension" : [
{
"url" : "http://hl7.org/fhir/tools/StructureDefinition/resource-information",
"valueString" : "CodeSystem"
}
],
"reference" : {
"reference" : "CodeSystem/181513"
},
"name" : "Scientific Evidence Code System (SEVCO) -- EXAMPLE VERSION for EBMonFHIR Implementation Guide",
"description" : "This code system was copied as a snapshot from the version being used for active development of the Scientific Evidence Code System (SEVCO). This code system is not yet released for expected use and may not be stable. This resource may be used for supporting the examples in the EBMonFHIR Implementation Guide, and published versions of the code system (when ready) will be published as separate resources with stable identifiers.",
"isExample" : true
},
{
"extension" : [
{
"url" : "http://hl7.org/fhir/tools/StructureDefinition/resource-information",
"valueString" : "Group"
}
],
"reference" : {
"reference" : "Group/264328"
},
"name" : "Search Strategy for NMA_Diabetes",
"description" : "An example of a search strategy for a systematic review.",
"isExample" : true,
"profile" : [
"http://hl7.org/fhir/uv/ebm/StructureDefinition/search-strategy"
]
},
{
"extension" : [
{
"url" : "http://hl7.org/fhir/tools/StructureDefinition/resource-information",
"valueString" : "StructureDefinition:resource"
}
],
"reference" : {
"reference" : "StructureDefinition/search-results"
},
"name" : "SearchResults",
"description" : "Profile of Library for Evidence Based Medicine IG. The SearchResults Profile is used to represent search results, such as for a systematic review.",
"isExample" : false
},
{
"extension" : [
{
"url" : "http://hl7.org/fhir/tools/StructureDefinition/resource-information",
"valueString" : "Library"
}
],
"reference" : {
"reference" : "Library/179606"
},
"name" : "SearchResults: PubMed search for Wonder Woman",
"description" : "Example of searching for 'Wonder Woman' in titles and abstracts in PubMed",
"isExample" : true,
"profile" : [
"http://hl7.org/fhir/uv/ebm/StructureDefinition/search-results"
]
},
{
"extension" : [
{
"url" : "http://hl7.org/fhir/tools/StructureDefinition/resource-information",
"valueString" : "StructureDefinition:resource"
}
],
"reference" : {
"reference" : "StructureDefinition/search-strategy"
},
"name" : "SearchStrategy",
"description" : "Profile of Group for Evidence Based Medicine IG. The SearchStrategy Profile is used to express the criteria defining a search strategy, such as for a systematic review.",
"isExample" : false
},
{
"extension" : [
{
"url" : "http://hl7.org/fhir/tools/StructureDefinition/resource-information",
"valueString" : "Group"
}
],
"reference" : {
"reference" : "Group/179592"
},
"name" : "SearchStrategy: PubMed and Embase search for van Veldhuisen 2022 systematic review",
"description" : "We conducted a search in Pubmed and Embase databases from inception to 28 August 2021. The search strategy composed the PICO method: patients of interest were obese, adult (age ≥18 years old) patients, Intervention was bariatric surgery, Controls were obese patients who did not undergo bariatric surgery, and Outcomes were defined as all-cause mortality, CV mortality, and incidence of CV disease, i.e. incident AF, incident HF, incident myocardial infarction, incident stroke, and incident aortic stenosis. Further, for clarity reasons we investigated myocardial infarction, and not incident coronary artery disease, because it is very difficult if not impossible to define its onset, also this was not uniform across the studies. Somewhat similarly, we investigated stroke and not incident cerebrovascular disease. A few studies, however, further differentiated between ischaemic vs. haemorrhagic stroke, and thus we also separately investigated the effect on ischaemic stroke.",
"isExample" : true,
"profile" : [
"http://hl7.org/fhir/uv/ebm/StructureDefinition/search-strategy"
]
},
{
"extension" : [
{
"url" : "http://hl7.org/fhir/tools/StructureDefinition/resource-information",
"valueString" : "Group"
}
],
"reference" : {
"reference" : "Group/179593"
},
"name" : "SearchStrategy: PubMed search for Wonder Woman",
"description" : "Example of searching for \"Wonder Woman\" in titles and abstracts in PubMed",
"isExample" : true,
"profile" : [
"http://hl7.org/fhir/uv/ebm/StructureDefinition/search-strategy"
]
},
{
"extension" : [
{
"url" : "http://hl7.org/fhir/tools/StructureDefinition/resource-information",
"valueString" : "ValueSet"
}
],
"reference" : {
"reference" : "ValueSet/265087"
},
"name" : "SearchStrategyCharacteristicCode Value Set",
"description" : "This value set is a temporary workspace while drafting the Evidence Based Medicine Implementation Guide. It may not be stable and may not be persistent.",
"isExample" : true
},
{
"extension" : [
{
"url" : "http://hl7.org/fhir/tools/StructureDefinition/resource-information",
"valueString" : "Group"
}
],
"reference" : {
"reference" : "Group/236949"
},
"name" : "SGLT2 inhibitors Group in Adults with type 2 diabetes",
"description" : "Sodium-Glucose Transport Protein 2 (SGLT2) inhibitors",
"isExample" : true,
"profile" : [
"http://hl7.org/fhir/uv/ebm/StructureDefinition/exposure-group"
]
},
{
"extension" : [
{
"url" : "http://hl7.org/fhir/tools/StructureDefinition/resource-information",
"valueString" : "StructureDefinition:resource"
}
],
"reference" : {
"reference" : "StructureDefinition/single-study-evidence"
},
"name" : "SingleStudyEvidence",
"description" : "Profile of Evidence for Evidence Based Medicine IG. The SingleStudyEvidence Profile is used for evidence from single studies, explicitly expressing that no studies were synthesized.",
"isExample" : false
},
{
"extension" : [
{
"url" : "http://hl7.org/fhir/tools/StructureDefinition/resource-information",
"valueString" : "StructureDefinition:resource"
}
],
"reference" : {
"reference" : "StructureDefinition/soa-plandefinition"
},
"name" : "SoaPlanDefinition",
"description" : "Profile of PlanDefinition for temporary testing to coordination with M11 use.",
"isExample" : false
},
{
"extension" : [
{
"url" : "http://hl7.org/fhir/tools/StructureDefinition/resource-information",
"valueString" : "PlanDefinition"
}
],
"reference" : {
"reference" : "PlanDefinition/181450"
},
"name" : "SoaPlanDefinition: Follow-up assessment 3 months after study start",
"description" : "Example of Schedule of Activities with follow-up assessment 3 months after study start",
"isExample" : true,
"profile" : [
"http://hl7.org/fhir/uv/ebm/StructureDefinition/soa-plandefinition"
]
},
{
"extension" : [
{
"url" : "http://hl7.org/fhir/tools/StructureDefinition/resource-information",
"valueString" : "StructureDefinition:resource"
}
],
"reference" : {
"reference" : "StructureDefinition/software-citation"
},
"name" : "SoftwareCitation",
"description" : "Profile of Citation for Evidence Based Medicine IG. The SoftwareCitation Profile is used for citations of executable code.",
"isExample" : false
},
{
"extension" : [
{
"url" : "http://hl7.org/fhir/tools/StructureDefinition/resource-information",
"valueString" : "Citation"
}
],
"reference" : {
"reference" : "Citation/179560"
},
"name" : "SoftwareCitation: Computable Publishing®: ClinicalTrials.gov-to-FEvIR Converter",
"description" : "This Citation Resource is referenced in an example for the EBMonFHIR Implementation Guide.",
"isExample" : true,
"profile" : [
"http://hl7.org/fhir/uv/ebm/StructureDefinition/software-citation"
]
},
{
"extension" : [
{
"url" : "http://hl7.org/fhir/tools/StructureDefinition/resource-information",
"valueString" : "StructureDefinition:resource"
}
],
"reference" : {
"reference" : "StructureDefinition/statistic-model"
},
"name" : "StatisticModel",
"description" : "Profile of Evidence for Evidence Based Medicine IG. The StatisticModel Profile is used to add extensions to Evidence for complex expressions for the statistical model or endpoint analysis plan.",
"isExample" : false
},
{
"extension" : [
{
"url" : "http://hl7.org/fhir/tools/StructureDefinition/resource-information",
"valueString" : "StructureDefinition:extension"
}
],
"reference" : {
"reference" : "StructureDefinition/statistic-model-expression"
},
"name" : "StatisticModelExpression",
"description" : "An expression that defines the statistical analysis.",
"isExample" : false
},
{
"extension" : [
{
"url" : "http://hl7.org/fhir/tools/StructureDefinition/resource-information",
"valueString" : "StructureDefinition:extension"
}
],
"reference" : {
"reference" : "StructureDefinition/statistic-model-include-if"
},
"name" : "StatisticModelIncludeIf",
"description" : "The condition under which the variable (or modelCharacteristic) will be included.",
"isExample" : false
},
{
"extension" : [
{
"url" : "http://hl7.org/fhir/tools/StructureDefinition/resource-information",
"valueString" : "Citation"
}
],
"reference" : {
"reference" : "Citation/33400"
},
"name" : "StudyCitation: 2022 Systematic Review of bariatric surgery mortality effect 35243488",
"description" : "This Citation Resource is referenced in an example for the EBMonFHIR Implementation Guide.",
"isExample" : true
},
{
"extension" : [
{
"url" : "http://hl7.org/fhir/tools/StructureDefinition/resource-information",
"valueString" : "StructureDefinition:resource"
}
],
"reference" : {
"reference" : "StructureDefinition/study-eligibility-criteria"
},
"name" : "StudyEligibilityCriteria",
"description" : "Profile of Group for Evidence Based Medicine IG. The StudyEligibilityCriteria Profile is used to describe inclusion and exclusion criteria for a clinical trial or other research study.",
"isExample" : false
},
{
"extension" : [
{
"url" : "http://hl7.org/fhir/tools/StructureDefinition/resource-information",
"valueString" : "Group"
}
],
"reference" : {
"reference" : "Group/172461"
},
"name" : "StudyEligibilityCriteria: Eligibility Criteria for DIBASY Trial",
"description" : "Patients aged 30-60 years with a body-mass index of 35 kg/m(2) or more and a history of type 2 diabetes lasting at least 5 years",
"isExample" : true,
"profile" : [
"http://hl7.org/fhir/uv/ebm/StructureDefinition/study-eligibility-criteria"
]
},
{
"extension" : [
{
"url" : "http://hl7.org/fhir/tools/StructureDefinition/resource-information",
"valueString" : "Group"
}
],
"reference" : {
"reference" : "Group/171819"
},
"name" : "StudyEligibilityCriteria: Obese patients ≥ 18 years old",
"description" : "obese, adult (age ≥18 years old) patients",
"isExample" : true,
"profile" : [
"http://hl7.org/fhir/uv/ebm/StructureDefinition/study-eligibility-criteria"
]
},
{
"extension" : [
{
"url" : "http://hl7.org/fhir/tools/StructureDefinition/resource-information",
"valueString" : "Group"
}
],
"reference" : {
"reference" : "Group/33398"
},
"name" : "StudyEligibilityCriteria: Type 2 diabetes and elevated BMI in 2016 meta-analysis",
"description" : "A conceptual group with 2 characteristics for study participant eligibility criteria that were used for a meta-analysis.",
"isExample" : true,
"profile" : [
"http://hl7.org/fhir/uv/ebm/StructureDefinition/metaanalysis-eligibility-criteria"
]
},
{
"extension" : [
{
"url" : "http://hl7.org/fhir/tools/StructureDefinition/resource-information",
"valueString" : "Group"
}
],
"reference" : {
"reference" : "Group/170443"
},
"name" : "StudyEligibilityCriteria_Eligibility_Criteria_for_Bariatric_Surgery_Randomized_Trial_Diabetes_Surgery_Study",
"description" : "Inclusion Criteria: Age 30 to 67 years at eligibility visit. Diagnosed with T2DM at least 6 months prior to enrollment, under the active care of a doctor for at least the six months prior to enrollment, and HbA1c ≥ 8.0%. Body Mass Index (BMI) ≥ 30.0 kg/m2 and ≤ 39.9 kg/m2 at eligibility visit. Willingness to accept random assignment to either treatment group. Expect to live or work within approximately one hour's traveling time from the study clinic for the duration of the two-year trial. Willingness to comply with the follow-up protocol and successful completion of the run-in. Written informed consent. ///// Exclusion Criteria: Cardiovascular event (myocardial infarction, acute coronary syndrome, coronary artery angioplasty or bypass, stroke) in the past six months. Current evidence of congestive heart failure, angina pectoris, or symptomatic peripheral vascular disease. Cardiac stress test indicating that surgery or IMM would not be safe. Pulmonary embolus or thrombophlebitis in the past six months. Cancer of any kind (except basal cell skin cancer or cancer in situ) unless documented to be disease-free for five years. Significant anemia (hemoglobin 1.0 g or more below normal range) or history of coagulopathy. Serum creatinine ≥ 1.5 mg/dl. HbA1c > 14.0%.",
"isExample" : true,
"profile" : [
"http://hl7.org/fhir/uv/ebm/StructureDefinition/study-eligibility-criteria"
]
},
{
"extension" : [
{
"url" : "http://hl7.org/fhir/tools/StructureDefinition/resource-information",
"valueString" : "StructureDefinition:resource"
}
],
"reference" : {
"reference" : "StructureDefinition/study-group"
},
"name" : "StudyGroup",
"description" : "Profile of Group for Evidence Based Medicine IG. The StudyGroup Profile is used to represent an enumerated group of participants in a research study.",
"isExample" : false
},
{
"extension" : [
{
"url" : "http://hl7.org/fhir/tools/StructureDefinition/resource-information",
"valueString" : "Group"
}
],
"reference" : {
"reference" : "Group/32145"
},
"name" : "StudyGroup: Diabetes Surgery Study Trial Enrollment Group",
"description" : "An enumerated group with a single characteristic referencing the StudyEligibilityCriteria.",
"isExample" : true,
"profile" : [
"http://hl7.org/fhir/uv/ebm/StructureDefinition/study-group"
]
},
{
"extension" : [
{
"url" : "http://hl7.org/fhir/tools/StructureDefinition/resource-information",
"valueString" : "Group"
}
],
"reference" : {
"reference" : "Group/178427"
},
"name" : "StudyGroup: Severely Obese Adults 2018 Norwegian Cohort",
"description" : "Cohort study with baseline data of exposures from November 2005 through July 2010 and follow-up data from 2006 until death or through December 2015 at a tertiary care outpatient center, Vestfold Hospital Trust, Norway. Consecutive treatment-seeking adult patients (n\t=\t2109) with severe obesity assessed (221 patients excluded and 1888 patients included).",
"isExample" : true,
"profile" : [
"http://hl7.org/fhir/uv/ebm/StructureDefinition/study-group"
]
},
{
"extension" : [
{
"url" : "http://hl7.org/fhir/tools/StructureDefinition/resource-information",
"valueString" : "Group"
}
],
"reference" : {
"reference" : "Group/46117"
},
"name" : "StudyGroup_DIBASY_Trial_Enrollment_Group",
"description" : "An enumerated group with a single characteristic referencing the StudyEligibilityCriteria.",
"isExample" : true,
"profile" : [
"http://hl7.org/fhir/uv/ebm/StructureDefinition/study-group"
]
},
{
"extension" : [
{
"url" : "http://hl7.org/fhir/tools/StructureDefinition/resource-information",
"valueString" : "StructureDefinition:resource"
}
],
"reference" : {
"reference" : "StructureDefinition/summary-of-findings"
},
"name" : "SummaryOfFindings",
"description" : "Profile of Composition for Evidence Based Medicine IG. The SummaryOfFindings Profile is used for an evidence report combining Evidence and EvidenceVariable Resources, organized around VariableDefinition (Profile of EvidenceVariable), to represent the summary of findings of comparative evidence.",
"isExample" : false
},
{
"extension" : [
{
"url" : "http://hl7.org/fhir/tools/StructureDefinition/resource-information",
"valueString" : "Composition"
}
],
"reference" : {
"reference" : "Composition/104215"
},
"name" : "SummaryOfFindings: Bariatric Surgery Summary of Findings Example for GIN 2022",
"description" : "Example of SummaryOfFindings Profile of Composition Resource.",
"isExample" : true,
"profile" : [
"http://hl7.org/fhir/uv/ebm/StructureDefinition/summary-of-findings"
]
},
{
"extension" : [
{
"url" : "http://hl7.org/fhir/tools/StructureDefinition/resource-information",
"valueString" : "Composition"
}
],
"reference" : {
"reference" : "Composition/236951"
},
"name" : "SummaryOfFindings: SGLT2 inhibitors vs. GLP-1 RA in Adults with type 2 diabetes",
"description" : "This is an example of the SummaryOfFindings Profile of Composition.",
"isExample" : true,
"profile" : [
"http://hl7.org/fhir/uv/ebm/StructureDefinition/summary-of-findings"
]
},
{
"extension" : [
{
"url" : "http://hl7.org/fhir/tools/StructureDefinition/resource-information",
"valueString" : "StructureDefinition:resource"
}
],
"reference" : {
"reference" : "StructureDefinition/summary-of-net-effect"
},
"name" : "SummaryOfNetEffect",
"description" : "Profile of Composition for Evidence Based Medicine IG. The SummaryOfNetEffect Profile is used for an evidence report combining ArtifactAssessment and Evidence and EvidenceVariable Resources, organized around VariableDefinition (Profile of EvidenceVariable), to represent the summary of net effect contributions of comparative evidence, adjusted for the relative importance of outcomes.",
"isExample" : false
},
{
"extension" : [
{
"url" : "http://hl7.org/fhir/tools/StructureDefinition/resource-information",
"valueString" : "Composition"
}
],
"reference" : {
"reference" : "Composition/104383"
},
"name" : "SummaryOfNetEffect: Bariatric Surgery Summary of Net Effect Contributions Example for GIN 2022",
"description" : "Example of SummaryOfNetEffect Profile of Composition Resource.",
"isExample" : true,
"profile" : [
"http://hl7.org/fhir/uv/ebm/StructureDefinition/summary-of-net-effect"
]
},
{
"extension" : [
{
"url" : "http://hl7.org/fhir/tools/StructureDefinition/resource-information",
"valueString" : "StructureDefinition:resource"
}
],
"reference" : {
"reference" : "StructureDefinition/systematic-review"
},
"name" : "SystematicReview",
"description" : "Profile of ResearchStudy for Evidence Based Medicine IG. The SystematicReview Profile is used for a scientific study based on a protocol that includes search and selection of eligible studies, study quality assessment, data extraction, and synthesis.",
"isExample" : false
},
{
"extension" : [
{
"url" : "http://hl7.org/fhir/tools/StructureDefinition/resource-information",
"valueString" : "StructureDefinition:resource"
}
],
"reference" : {
"reference" : "StructureDefinition/systematic-review-eligibility-criteria"
},
"name" : "SystematicReviewEligibilityCriteria",
"description" : "Profile of Group for Evidence Based Medicine IG. The SystematicReviewEligibilityCriteria Profile is used to describe inclusion and exclusion criteria for a systematic review.",
"isExample" : false
},
{
"extension" : [
{
"url" : "http://hl7.org/fhir/tools/StructureDefinition/resource-information",
"valueString" : "Group"
}
],
"reference" : {
"reference" : "Group/179619"
},
"name" : "SystematicReviewEligibilityCriteria: ADT and Docetaxel vs. ADT alone for metastatic hormone-naive prostate cancer",
"description" : "**Study selection criteria**\nTypes of Studies.\nRandomized controlled clinical trials (RCTs) with parallel design that compared the association of ADT and chemotherapy (docetaxel), versus ADT alone.\n\nTypes of participants.\nPatients aged ≥18 years with cytological or histological diagnosis of mHNPC.",
"isExample" : true,
"profile" : [
"http://hl7.org/fhir/uv/ebm/StructureDefinition/systematic-review-eligibility-criteria"
]
},
{
"extension" : [
{
"url" : "http://hl7.org/fhir/tools/StructureDefinition/resource-information",
"valueString" : "StructureDefinition:resource"
}
],
"reference" : {
"reference" : "StructureDefinition/systematic-review-excluded-studies"
},
"name" : "SystematicReviewExcludedStudies",
"description" : "Profile of Library for Evidence Based Medicine IG. The SystematicReviewExcludedStudies Profile is used to represent the subset of search results of a systematic review which did not meet the inclusion criteria.",
"isExample" : false
},
{
"extension" : [
{
"url" : "http://hl7.org/fhir/tools/StructureDefinition/resource-information",
"valueString" : "Library"
}
],
"reference" : {
"reference" : "Library/179632"
},
"name" : "SystematicReviewExcludedStudies: ADT and Docetaxel vs. ADT alone for metastatic hormone-naive prostate cancer",
"description" : "11 excluded studies",
"isExample" : true,
"profile" : [
"http://hl7.org/fhir/uv/ebm/StructureDefinition/systematic-review-excluded-studies"
]
},
{
"extension" : [
{
"url" : "http://hl7.org/fhir/tools/StructureDefinition/resource-information",
"valueString" : "StructureDefinition:resource"
}
],
"reference" : {
"reference" : "StructureDefinition/systematic-review-included-studies"
},
"name" : "SystematicReviewIncludedStudies",
"description" : "Profile of Library for Evidence Based Medicine IG. The SystematicReviewIncludedStudies Profile is used to represent the subset of search results of a systematic review which meet the inclusion criteria.",
"isExample" : false
},
{
"extension" : [
{
"url" : "http://hl7.org/fhir/tools/StructureDefinition/resource-information",
"valueString" : "Library"
}
],
"reference" : {
"reference" : "Library/179618"
},
"name" : "SystematicReviewIncludedStudies: ADT and Docetaxel vs. ADT alone for metastatic hormone-naive prostate cancer",
"description" : "3 included studies",
"isExample" : true,
"profile" : [
"http://hl7.org/fhir/uv/ebm/StructureDefinition/systematic-review-included-studies"
]
},
{
"extension" : [
{
"url" : "http://hl7.org/fhir/tools/StructureDefinition/resource-information",
"valueString" : "EvidenceVariable"
}
],
"reference" : {
"reference" : "EvidenceVariable/7751"
},
"name" : "Therapeutic-dose anticoagulation with heparin",
"description" : "Therapeutic-dose anticoagulation with unfractionated or low-molecular-weight heparin was administered according to local protocols for the treatment of acute venous thromboembolism for up to 14 days or until recovery; the latter was defined as hospital discharge or a discontinuation of supplemental oxygen for at least 24 hours.",
"isExample" : true
},
{
"extension" : [
{
"url" : "http://hl7.org/fhir/tools/StructureDefinition/resource-information",
"valueString" : "StructureDefinition:resource"
}
],
"reference" : {
"reference" : "StructureDefinition/variable-definition"
},
"name" : "VariableDefinition",
"description" : "Profile of EvidenceVariable for Evidence Based Medicine IG. The VariableDefinition Profile uses a CodeableReference Datatype to provide a concept (e.g. coding in a code system) and/or a reference to a Group Resource for structured data to define the variable.",
"isExample" : false
},
{
"extension" : [
{
"url" : "http://hl7.org/fhir/tools/StructureDefinition/resource-information",
"valueString" : "StructureDefinition:resource"
}
],
"reference" : {
"reference" : "StructureDefinition/web-page-citation"
},
"name" : "WebPageCitation",
"description" : "Profile of Citation for Evidence Based Medicine IG. The WebPageCitation Profile is used for citations of a web page or website, typically when there is not another type being used to classify the cited artifact.",
"isExample" : false
},
{
"extension" : [
{
"url" : "http://hl7.org/fhir/tools/StructureDefinition/resource-information",
"valueString" : "Citation"
}
],
"reference" : {
"reference" : "Citation/179561"
},
"name" : "WebPageCitation: A HEvKA Update Summary",
"description" : "This Citation Resource is referenced in an example for the EBMonFHIR Implementation Guide.",
"isExample" : true,
"profile" : [
"http://hl7.org/fhir/uv/ebm/StructureDefinition/web-page-citation"
]
}
],
"page" : {
"sourceUrl" : "toc.html",
"name" : "toc.html",
"title" : "Table of Contents",
"generation" : "html",
"page" : [
{
"sourceUrl" : "index.html",
"name" : "index.html",
"title" : "Introduction",
"generation" : "markdown"
},
{
"sourceUrl" : "evidence.html",
"name" : "evidence.html",
"title" : "Evidence Profiles",
"generation" : "markdown"
},
{
"sourceUrl" : "evidencevariable.html",
"name" : "evidencevariable.html",
"title" : "EvidenceVariable Profiles",
"generation" : "markdown"
},
{
"sourceUrl" : "group.html",
"name" : "group.html",
"title" : "Group Profiles",
"generation" : "markdown"
},
{
"sourceUrl" : "citation.html",
"name" : "citation.html",
"title" : "Citation Profiles",
"generation" : "markdown"
},
{
"sourceUrl" : "artifactassessment.html",
"name" : "artifactassessment.html",
"title" : "ArtifactAssessment Profiles",
"generation" : "markdown"
},
{
"sourceUrl" : "composition.html",
"name" : "composition.html",
"title" : "Composition Profiles",
"generation" : "markdown"
},
{
"sourceUrl" : "otherprofiles.html",
"name" : "otherprofiles.html",
"title" : "Other Profiles",
"generation" : "markdown"
},
{
"sourceUrl" : "profiles.html",
"name" : "profiles.html",
"title" : "Profiles",
"generation" : "markdown"
},
{
"sourceUrl" : "extensions.html",
"name" : "extensions.html",
"title" : "Extensions",
"generation" : "markdown"
},
{
"sourceUrl" : "terminologies.html",
"name" : "terminologies.html",
"title" : "Terminologies",
"generation" : "markdown"
},
{
"sourceUrl" : "examples.html",
"name" : "examples.html",
"title" : "Examples",
"generation" : "markdown"
},
{
"sourceUrl" : "downloads.html",
"name" : "downloads.html",
"title" : "Downloads",
"generation" : "markdown"
}
]
},
"parameter" : [
{
"code" : {
"system" : "http://hl7.org/fhir/tools/CodeSystem/ig-parameters",
"code" : "copyrightyear"
},
"value" : "2024+"
},
{
"code" : {
"system" : "http://hl7.org/fhir/tools/CodeSystem/ig-parameters",
"code" : "releaselabel"
},
"value" : "ballot"
},
{
"code" : {
"system" : "http://hl7.org/fhir/tools/CodeSystem/ig-parameters",
"code" : "auto-oid-root"
},
"value" : "2.16.840.1.113883.4.642.40.44"
},
{
"code" : {
"system" : "http://hl7.org/fhir/tools/CodeSystem/ig-parameters",
"code" : "path-history"
},
"value" : "http://hl7.org/fhir/uv/ebm/history.html"
},
{
"code" : {
"system" : "http://hl7.org/fhir/tools/CodeSystem/ig-parameters",
"code" : "autoload-resources"
},
"value" : "true"
},
{
"code" : {
"system" : "http://hl7.org/fhir/guide-parameter-code",
"code" : "path-resource"
},
"value" : "input/capabilities"
},
{
"code" : {
"system" : "http://hl7.org/fhir/guide-parameter-code",
"code" : "path-resource"
},
"value" : "input/examples"
},
{
"code" : {
"system" : "http://hl7.org/fhir/guide-parameter-code",
"code" : "path-resource"
},
"value" : "input/extensions"
},
{
"code" : {
"system" : "http://hl7.org/fhir/guide-parameter-code",
"code" : "path-resource"
},
"value" : "input/models"
},
{
"code" : {
"system" : "http://hl7.org/fhir/guide-parameter-code",
"code" : "path-resource"
},
"value" : "input/operations"
},
{
"code" : {
"system" : "http://hl7.org/fhir/guide-parameter-code",
"code" : "path-resource"
},
"value" : "input/profiles"
},
{
"code" : {
"system" : "http://hl7.org/fhir/guide-parameter-code",
"code" : "path-resource"
},
"value" : "input/resources"
},
{
"code" : {
"system" : "http://hl7.org/fhir/guide-parameter-code",
"code" : "path-resource"
},
"value" : "input/vocabulary"
},
{
"code" : {
"system" : "http://hl7.org/fhir/guide-parameter-code",
"code" : "path-resource"
},
"value" : "input/maps"
},
{
"code" : {
"system" : "http://hl7.org/fhir/guide-parameter-code",
"code" : "path-resource"
},
"value" : "input/testing"
},
{
"code" : {
"system" : "http://hl7.org/fhir/guide-parameter-code",
"code" : "path-resource"
},
"value" : "input/history"
},
{
"code" : {
"system" : "http://hl7.org/fhir/guide-parameter-code",
"code" : "path-resource"
},
"value" : "fsh-generated/resources"
},
{
"code" : {
"system" : "http://hl7.org/fhir/guide-parameter-code",
"code" : "path-pages"
},
"value" : "template/config"
},
{
"code" : {
"system" : "http://hl7.org/fhir/guide-parameter-code",
"code" : "path-pages"
},
"value" : "input/images"
},
{
"code" : {
"system" : "http://hl7.org/fhir/tools/CodeSystem/ig-parameters",
"code" : "path-liquid"
},
"value" : "template/liquid"
},
{
"code" : {
"system" : "http://hl7.org/fhir/tools/CodeSystem/ig-parameters",
"code" : "path-liquid"
},
"value" : "input/liquid"
},
{
"code" : {
"system" : "http://hl7.org/fhir/tools/CodeSystem/ig-parameters",
"code" : "path-qa"
},
"value" : "temp/qa"
},
{
"code" : {
"system" : "http://hl7.org/fhir/tools/CodeSystem/ig-parameters",
"code" : "path-temp"
},
"value" : "temp/pages"
},
{
"code" : {
"system" : "http://hl7.org/fhir/tools/CodeSystem/ig-parameters",
"code" : "path-output"
},
"value" : "output"
},
{
"code" : {
"system" : "http://hl7.org/fhir/guide-parameter-code",
"code" : "path-tx-cache"
},
"value" : "input-cache/txcache"
},
{
"code" : {
"system" : "http://hl7.org/fhir/tools/CodeSystem/ig-parameters",
"code" : "path-suppressed-warnings"
},
"value" : "input/ignoreWarnings.txt"
},
{
"code" : {
"system" : "http://hl7.org/fhir/tools/CodeSystem/ig-parameters",
"code" : "template-html"
},
"value" : "template-page.html"
},
{
"code" : {
"system" : "http://hl7.org/fhir/tools/CodeSystem/ig-parameters",
"code" : "template-md"
},
"value" : "template-page-md.html"
},
{
"code" : {
"system" : "http://hl7.org/fhir/tools/CodeSystem/ig-parameters",
"code" : "apply-contact"
},
"value" : "true"
},
{
"code" : {
"system" : "http://hl7.org/fhir/tools/CodeSystem/ig-parameters",
"code" : "apply-context"
},
"value" : "true"
},
{
"code" : {
"system" : "http://hl7.org/fhir/tools/CodeSystem/ig-parameters",
"code" : "apply-copyright"
},
"value" : "true"
},
{
"code" : {
"system" : "http://hl7.org/fhir/tools/CodeSystem/ig-parameters",
"code" : "apply-jurisdiction"
},
"value" : "true"
},
{
"code" : {
"system" : "http://hl7.org/fhir/tools/CodeSystem/ig-parameters",
"code" : "apply-license"
},
"value" : "true"
},
{
"code" : {
"system" : "http://hl7.org/fhir/tools/CodeSystem/ig-parameters",
"code" : "apply-publisher"
},
"value" : "true"
},
{
"code" : {
"system" : "http://hl7.org/fhir/tools/CodeSystem/ig-parameters",
"code" : "apply-version"
},
"value" : "true"
},
{
"code" : {
"system" : "http://hl7.org/fhir/tools/CodeSystem/ig-parameters",
"code" : "apply-wg"
},
"value" : "true"
},
{
"code" : {
"system" : "http://hl7.org/fhir/tools/CodeSystem/ig-parameters",
"code" : "active-tables"
},
"value" : "true"
},
{
"code" : {
"system" : "http://hl7.org/fhir/tools/CodeSystem/ig-parameters",
"code" : "fmm-definition"
},
"value" : "http://hl7.org/fhir/versions.html#maturity"
},
{
"code" : {
"system" : "http://hl7.org/fhir/tools/CodeSystem/ig-parameters",
"code" : "propagate-status"
},
"value" : "true"
},
{
"code" : {
"system" : "http://hl7.org/fhir/tools/CodeSystem/ig-parameters",
"code" : "excludelogbinaryformat"
},
"value" : "true"
},
{
"code" : {
"system" : "http://hl7.org/fhir/tools/CodeSystem/ig-parameters",
"code" : "tabbed-snapshots"
},
"value" : "true"
}
]
}
}
XIG built as of ??metadata-date??. Found ??metadata-resources?? resources in ??metadata-packages?? packages.